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Abstract: 
Investigation of the Thermochemiluminescent (TCL) phenomenon as an 
innovative detection technique for  (bio)analytical applications: from the 
synthesis of new TCL candidates to the realization of TCL-based probes for 
immunoassays 
 
In the present PhD thesis, thermochemiluminescence (TCL) phenomenum as a new 
promising tool for development of innovative (bio)analytical detection methods has been 
investigated. The TCL process occurs when an increase in temperature triggers the 
decomposition of a thermolabile molecule (e.g. 1,2-dioxetane derivatives), generating a 
fragment in its electronic excited state, which relaxes to the ground state through the 
emission of a photon. The first part of this work was focused on the synthesis of new TCL 
candidates (acridin-based 1,2-dioxetanes), aiming the optimization of the TCL properties 
in terms of lower decomposition temperatures and higher fluorescence quantum yields of 
the generated excited fragments. Thus, a small library of acridin-based 1,2-dioxetanes 
were synthesized, introducing various electron withdrawing groups (EWG) on the acridin 
moiety. Then, more significant structural modifications were investigated, replacing the 
acridin portion with a different chromophoric unit. Moreover, through a chemometric 
approach, both the structural and electronic molecular descriptors for each molecule 
were analysed and used to elaborate a model able to predict the olefin photooxygenation 
outcome (a key step in the synthesis of 1,2-dioxetane derivative). Moving forward, the 
focus was shifted to the realization of TCL-based nanosensors for immunoassay 
applications. In particular, the fabrication of both molecular and nanometric-scale probes 
was performed, linking the TCL substrate (1,2-dioxetane) directly to universal biomarker 
or encapsulating it within a polymeric nanoshell.  
Concerning the molecular probe, acridin 1,2-dioxetane was functionalized with biotin in 
order to create a TCL sensor for detection of streptavidin-based targets. However, the 
final molecule did not show enough stability to be employed in (bio)analytical 
applications. TCL process was, then, combined with the semiconductive polymer dots 
(Pdots) technology to realize ultrabright thermo-responsive nanoparticles able to detect 
biotinylated compounds of interest. In particular, the FRET mechanism occurring between 
the polymeric matrix of Pdots (CN-PPV, ɸF = 60%) and TCL substrate (1,2-dioxetane, ɸF = 
11%), has been exploited to both enhance the light generation and shift the emission 
towards longer wavelengths (550 nm). Furthermore, TCL-Pdots were tested in a non-
competitive sandwich-type immunoassay for detection of Immunoglobuline G (IgG), 
revealing a TCL signal proportional to the concentration of analyte and a limit of detection 
(LOD) in the nanomolar range. The last part of this work was focused on the realization of 
an home-made portable device to combine TCL-based detection technique with 
smartphone technology. All the different items constituting the apparatus have been 
fabricated exploiting a 3D printing process and acrylonitrile-butadiene-styrene (ABS), as 
starting material. The device was tailored to the 41-megapixel camera of a Nokia Lumia 
1020 exploiting, thus, the performance of the complementary Metal Oxide 
Semiconductor (CMOS) sensor of the smartphone’s camera (used as detector). 
Preliminary measurements exhibited a good reproducibility and a low limit of detection 
(LOD = 2,58 x10-12 mol mm-2), for the TCL-based smartphone device, suggesting its 
suitability for development of point-of-need analytical test. 
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Chapter1
The role of 1,2-dioxetane compounds in the
luminescent processes
1.1 Introduction
The term luminescence was introduced for the first time in 1888 by the
physicist and historian Eilhardt Wiedemann to describe all those phenomena in
which the light production was not due to an increase in temperature. In this
terms, luminescence or cold light represents the opposite of incandescence or
hot light, which consists in the black-body radiation. During the luminescent
phenomenon, an electronically excited molecule relaxes to its electronic ground
state, releasing the excess of energy as an electromagnetic radiation (EMR). The
wavelength of such EMR will depend on the energy gap between the electronic
levels involved in the transition. The luminescence process can be distinguished
in two main categories, according to the different ways of triggering the emission
of photons:
Photoluminescence if the molecule is excited through a physical stimulus (i.e.
an electromagnetic radiation). Typical photoluminescent phenomena are
the Fluorescence and Phosphorescence processes;
Chemical luminescence if the excitation step does not require any interaction
between the molecule and the EMR. On the contrary, the excitation energy
is provided by a chemical reaction. The main luminescent processes of this
category are:
• Bioluminescence (BL)
• Chemiluminescence (CL)
• Electrochemiluminescence (ECL)
• Thermochemiluminescence (TCL)
• Meccanochemiluminescence (MCL)
1
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Figure 1.1: The Jablonski energy diagram. The radiative and non radiative process are
represented by solid and dashed lines respectively.
Regardless of the nature of the triggering process, an electronically excited
molecule will undergo the same fate. In fact, as soon as the molecule absorbs
energy from the external environment, the electrons will be promoted from the
ground state to an excited one. While the electronic ground-state is always a
singlet one (S0), the final state (just before the molecule relaxes emitting a photon)
can be either a singlet (S1, S2, S2. . . ) or a triplet (T1) one, depending on the energy
absorbed. Once the molecule is excited, it can relax back to the ground state
following two different intramolecular pathways, as depicted by the Jablonski
diagram [see Ref. 1] in Figure 1.1:
• Non-radiative relaxation if the excess of energy is dissipated as thermal
energy towards the environment. Examples of this process are the internal
conversion (IC) and the intersystem crossing (ISC). Both of them bring the
excited molecule to its lower state S1 or T1, respectively;
• Radiative relaxation if the excited molecule decays to its ground state
emitting a photon. Examples of this pathway are the Fluorescence (corre-
sponding to the transition S1 → S0) and the Phosphorescence (correspond-
ing to the transition T1 → S0) processes.
Usually, a fluorophore needs to be excited to its S1orT1 first, then it can
relax to the ground state emitting a photon. In fact, common fluorescent or
phosphorescent substrates have to absorb energy from an external source such as
a Uv-vis lamp, a laser etc., since they do not possess extra energy per se. However,
1,2-dioxetanes represent an uncommon class of fluorescent organic molecules,
which have gained a great interested among the scientific community due to
their peculiar properties. The endoperoxide unit, characteristic of 1,2-dioxetane
derivatives, can undergo a fast triggered decomposition generating two fragments,
2
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Scheme 1.1: The energy diagram relative to the thermal decomposition of TMDO.
one of which in its electronically excited state. The capacity of producing light,
without any excitation source, have made this class of organic compounds very
appealing for development of new (bio)analytical detection methods.
1.2 Exergonicity of the 1,2-dioxetane thermal decomposition
Using the proper trigger (e.g. a chemical reaction, an increase in temperature
etc.), the 1,2-dioxetane can decompose generating two carbonyl fragments, one
of which in its fundamental state (S0) and the other one in its excited state (S,
from which the corresponding triplet state T1 may be populated by ISC). The
latter, then, relaxes to the ground state, releasing a photon with energy equal to
the HOMO-LUMO gap. The generation of an electronic excited product can be
explained considering the thermodynamic of the whole decomposition process. In
particular, it could be helpful looking at the well-studied thermal decomposition
of the tetramethyl 1,2-dioxetane (TMDO) [see Ref. 2], depicted in Scheme 1.1.
TMDO undergoes a thermal decomposition, generating two molecules of acetone.
The energy of the transition state is remarkably high in respect to the energy of
final product (≈ 90 kcal mol−1 higher) and it can be calculated as the sum of
the activation enthalpy ∆H‡ (≈ +27 kcal mol−1) and the reaction enthalpy ∆H
(≈ −63 kcal mol−1). Therefore, the exothermicity of the reaction insures the
formation of the electronically excited fragment. Depending on the electronic
and structural features, the 1,2-dioxetane derivatives can release energies ranging
from 65 to 90 kcal mol−1.
−∆G ≥ hc
λex
=
28600
λex
(1.1)
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Scheme 1.2: Mechanism a) concerted and b) biradical, proposed for the decomposition
of 1,2-dioxetane.
Thus, using the formula for the free energy involved in the process (see Eq. 1.1),
the thermal decomposition can produce photons in the range 320 - 440 nm.
1.3 Mechanism for the 1,2-dioxetane chemiexcitation
Although the 1,2-dioxetanes have been known for a long time, the mechanism
of their decomposition is still under debate. In fact, several hypothesis have been
proposed to explain the process by which the endoperoxide group generates an
electronically excited fragment, but none of them can be taken as a comprehen-
sive theory for the chemiexcitation step. The first mechanism, known as the
synchronous or concerted process, consists in a symmetry forbidden pericyclic
rearrangement, and it was proposed by McCapra [see Ref. 3, 4] and Turro [see
Ref. 5–7] at the end of the ’60s (see Scheme 1.2 a). It suggests the simultaneous
homolytic scission of the bonds between both the oxygen atoms (O-O’) and the
carbon ones (C-C’). Besides the synchronous, concerted pathway, O’Neal [see
Ref. 8, 9] and Richardson [see Ref. 10] have described a stepwise mechanism
that proceeds via a biradical intermediate (see Scheme 1.2 b). They propose the
formation of a biradical compound, after the homolytic cleavage of the O-O’
bond, as supported by kinetic [see Ref. 11] and ab initio calculation [see Ref. 12]
results.
As depicted in Scheme 1.2, both the synchronous and the biradical mechanism
lead to the formation of two carbonyl fragments, one of which in an eletronically
excited state that can be either a S1 or a T1 state. The excited fragment, then,
relaxes, to its ground state emitting a photon. Quantum mechanic calculations
have suggested the dependence of the decomposition pathway on the specific
4
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1,2-dioxetane derivative: alyphatic compounds seem to follow the concerted
process [see Ref. 13, 14], while substrates bearing aromatic rings or heteroatoms
proceed along the biradical mechanism [see Ref. 12, 15–17]. A subsequent
computational study on 1,2-dioxetane decomposition has proposed an alternative
path for the chemiexcitation step. In particular, De Vico et al. [see Ref. 18] have
described the thermal decomposition of the parent 1,2-dioxetane as a sequence
of four different events: first, streatching of the O-O’ and C-C’ bonds, followed
by the torsion of the dihedral angle O-C-C’-O’ and the asymmetric stretching of
the O-C and O’-C’ bonds. Lastly, the asymmetric pyramidalization of the C/C’
atoms leads to the final products. According to this theory, the parent dioxetane
would decompose through an asynchronous but somehow concerted mechanism,
because, after the formation of the biradical intermediate, there is no energy
barrier left for futher fragmentation. Re-elaborating some previous theoretical
studies about the isoelectronic 1,4-tetramethylene biradical [see Ref. 19], De Vico
has proposed the existence of the so-called ”entropic trapping” effect even in the
deomposition mechanism of the 1,2-dioxetane. Basically, the potential energy
surface (PES) for the ground-state S0 of the parent dioxetane has been calculated,
using a multistate multiconfigurational second-order perturbation level of theory
and found a minimal energy path (MEP) that starts from the S0 transition state
and proceeds, almost flat, along the rotation of the dihedral angle O-C-C’-O’.
During the time spent in the MEP, the biradical intermediate can explore different
torsional configurations that are almost equivalent in energy. However, only
specific dihedral angles allow the trajectories to escape from the MEP back to
the ground-state PES, thus, the longer the intermediate remains in the entropic
trap (i.e the MEP) the longer it will take to dissociate into the products [see Ref.
20]. Furthermore, it was found that both the S1 and T1 become degenerate when
the dioxetane is in the vicinity of the transition state (O-O’ bond cleavage) and
they remain so along all the entropic trap region. This evidence seems to explain
the effect of substituents upon the chemiexcitation efficiency for the dioxetane
decomposition: increasing the number of substituents it will increase the degrees
of freedom and, therefore, the time passed within the entropic trap, where state
crossing is possible.
The influence of electron-donating substituents upon the chemiluminescence
yield was highlighted by Schaap and Gagnon [see Ref. 21] who synthesized a
phenol substitued dioxetane. Indeed, after removing the phenolic proton, they
measured a remarkable increase in the decomposition rate along with the pre-
dominant formation of the singlet excited state S1. From that moment on, several
chemically-triggered 1,2-dioxetanes have been synthesized, changing the nature
of the protected functional group, thus the deprotecting reagent used for the
5
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Scheme 1.3: a) CIEEL mechanism for the thermal decomposition of 1,2-dioxetane
derivatives and b) Numbering of odd and even positions for a generic naphtalen-based
1,2-dioxetane.
chemiluminescence reaction. Furthermore, a new decomposition mechanism was
proposed to explain this very efficient chemiexcitation: the chemically initiated
electron exchange luminescence (CIEEL) [see Ref. 22–28]. According to the
CIEEL mechanism (Scheme 1.3 a), the first step constists in a mono-electronic
transfer from a donor compound (D) to the dioxetane ring, which decomposes
generating a radical anion intermediate. The latter, then, reacts with the radi-
cal cation of the donor compound (D +) within a solvent cage and the charge
recombination process leads to the final excited product.
Another interesting result about triggerable 1,2-dioxetanes has been obtained
by Edwards and Bronstein [see Ref. 29, 30], who synthesized several naphtalen-
besed dioxetanes, bearing a silylated hydroxyl group on the aromatic system.
Exploiting different triggering reactions (e.g. base treatment or catalysis by
fluorine), they noticed a relationship between the position of the functional group
on the aromatic system, and the chemiluminescence yield. In particular, it was
demonstrated that substituents in ”odd” positions (i.e. 4, 5 or 7, as showed in
Scheme 1.3 b) lead to a much more efficient chemiexcitation than dioxetane with
a ”even” pattern (i.e. substituents in 3, 6 or 8 position, in Scheme 1.3 b).
1.4 1,2-dioxetane and analogues as the common ingredient in lumi-
nescent phenomena
Since the ’70s, the 1,2-dioxetane system has been attracting a great interest
among the scientific community, due to the astounding ability to emit photons
after its decomposition. An interesting aspect is the presence of this cyclic en-
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doperoxide group in a variety of luminescent processes (e.g. chemiluminescence,
bioluminescence etc. phenomena) where it can participate either as a reagent
or an intermediate. In the following sections, a brief overview of the multiple
analytical systems based on the 1,2-dioxetane unit will be provided.
1.4.1 1,2-dioxetanes and analogues in Chemiluminescence (CL)
The chemiluminescent phenomenon consists in the production of a EMR
triggered by a chemical reaction. The light signal generates after mixing two
or more reagents in the presence of a catalyst (usually an inorganic base or an
enzyme). The exergonic reaction produce an electronically exicited product which
can relax to the ground-state through a radiative or non-radiative process. Two
different types of chemiluminescent reactions can be distinguished: the type I (or
direct) CL process and the type II (or indirect) CL reaction. The latter differs from
the type I process since the product is not intrinsically fluorescent, thus, it has to
transfer the energy to a second molecule (energy acceptor, EA) which will relaxe
through the emission of a photon. A useful parameter to estimate the efficiency
of a chemiluminescent process is the CL quantum yield (ΦCL), defined as the
number of photons generated devided by the number of molecules (i.e. substrates)
reacted [see Ref. 31] (see Eq. 1.2).
ΦCL =
number of photons emitted
number of molecules reacted
(1.2)
The CL quantum yield can also be expressed as the product of three distinct
quantities (see Eq. 1.3): the quantum yield for the formation of the intermediate
ΦInt that depends on the efficiency of the chemical reaction; the quantum yield
for the production of electronically excited products ΦSE , correlated to the energy
transfer efficiency, and the emission quantum yield ΦEm.
ΦCL = ΦInt · ΦSE · ΦEm (1.3)
The 1,2-dioxetane has assumed a pivotal role in the field of chemiluminescence-
based analytical methods, since it represents the smallest CL active system and
the most versatile one (e.g. it can be functionalized quite easily, insuring the
tunability of CL properties). In particular, the dioxetane-based CL substrates can
be gathered in five different classes:
7
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Luminol and derivatives
The CL properties of 3-aminophthalhydrazide (luminol) have been described
for the first time in 1928 by the German chemist H. O. Albrecht, when he
noticed an enhancement of the luminescence of luminol dissolved in an alkaline
solution of hydrogen peroxide in precence of blood [see Ref. 32]. Looking at the
molecular structure of luminol (see Figure 1.2 for the structure of luminol and its
main derivatives), it is noticeable the presence of the hydrazide group which is
responsible for the chemiluminescent behaviour.
Figure 1.2: Molecular structure of a) luminol, and its derivatives b) isoluminol and c)
ABEN.
The typical reaction mechanism of these substrates occurs in a basic environ-
ment and involves a Peroxidase enzyme, that operates as catalyst, and a oxidizing
agent. The Horseradish peroxidase (HRP) and hydrogen peroxide (H2O2) are
the most common reagents used in the luminol-based CL systems. As depicted
in Scheme 1.4, the CL reaction starts with the deprotonation of the hydrazide
group, generating a dianion species. The keto-enol tautomerism promotes the
formation of the thermodinamically more stable intermediate which undergoes the
oxidation by H2O2 and HRP, generating the key-compound dioxetane. The latter
decomposes giving the final electronically excited product. Computational studies
have showed the dependence of the oxidation step on the reaction environment
[see Ref. 33]. In particular, aprotic solvents (DMSO or DMF) require strong
oxidizing agents [see Ref. 34] while, in protic solvents (H2O and alcohols), the
CL reaction occurs even using mild oxidants. However, in both cases the use of
an enzymatic and/or inorganic catalyst is required [see Ref. 35].
The main disadvantage of the luminol-based methods is the low fluorescence
quantum yield (Φf ) of the phtalhydrazide moiety, that is only 5% in DMSO [see
Ref. 36] and 1-1.5 % in H2O [see Ref. 34, 35]. For many years, several research
group have been introducing structural modifications on the luminol substrate,
aiming to enhance the chemiluminescent signal. A noticeable relationship be-
tween the position of substituents and Φf have been revealed, showing a retention
of chemiluminescence property, if the modifications affect the aromatic ring, or
a complete loss of light production, when structural changes interest the cyclic
8
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Scheme 1.4: Mechanism for the CL reaction of luminol.
Scheme 1.5: Mechanism for the oxidation of luminol, using phenol derivatives.
phtalhydrazide portion [see Ref. 35–37]. In addition to structural modifications,
the use of chemical enhancers can improve further the CL response modulating
the catalytic power of the used enzyme. For instance, Diaz et al. [see Ref. 38]
have reported the use of phenol derivatives in HRP/H2O2/luminol systems, to
enhance the HRP catalytic efficiency through a different reaction mechanism (see
Scheme 1.5).
The first step constits in the oxidation of HRP by H2O2 to give the intermediate
HRP-I; the latter, then, reacts with the dianion of luminol generating a partially
reduced complex HRP-II and the luminol radical. At this point, the original
oxidation state of HRP is restored after reacting with a second molecule of luminol.
However, not all the phenol compounds are able to act as chemical enhancer, but
only those which produce radicals with a similar or greater reduction potential
than luminol at pH 8.5 (0.8 V) can accelerate the CL reaction, thus increase the
light signal. Nowadays, luminol (and some of its derivatives) is one of the most
widely used compound in CL-based methods, thanks to its availability and low
cost. It has found applications in multiple fields of (bio)analytical chemistry. For
instance, it is used in food and environmental monitoring, in clinical analysis and
diagnostics, in forensic investigations etcetera [see Ref. 39, 40].
9
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Scheme 1.6: Mechanism for the CL reaction of a) Lucigenin and b) acridinium ester.
Lucigenin and Acridinium esters
The CL properties of acridinium salt and its derivatives have been known
since 1935, when Gleu and Petsch observed a blue (or green) light coming out
from the oxidation of bis(N-methylacridinium) nitrate (Lucigenin) [see Ref. 41].
The Lucigenin dication undergoes an oxidation reaction by hydrogen peroxide
in basic environment, generating the key-intermediate dioxetane, which decom-
poses instantaneously into the electronically excited 10-methyl-9(10H)-acridone
(see Scheme 1.6 a). Around Thirty years later, a new class of acridin-based CL
substrates were proposed, replacing one of the acrin moieties of Lucigenin with
an ester unit [see Ref. 4, 42, 43]. The CL reaction mechanism for a generic
acridinium ester is depicted in Scheme 1.6 b: firstly, the oxidation of the acri-
dinium unit occurs, followed by a deprotonation and intramolecular cyclization of
the hydroperoxide. Tha main difference between the decomposition mechanism
of Lucigenin and an acridinium ester consists in the formation of a new high-
energetic intermediate. In fact, rather than a 1,2-dioxetane, the intramolecular
cyclization leads to a dioxetanone compound, which releases carbon dioxide
(CO2) and the final excited product.
Looking at the molecular structure of acridinium salt, two distinct portiones
can be identified: the acridin moiety and the leaving group (-Lv). Both of them
play a crucial role in the modulation of CL properties. Indeed, introducing
electron-donating or -withdrawing groups onto the aromatic system, as well as
10
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Scheme 1.7: Mechanism for the CL decomposition of Alkaline Phosphatase substrate.
changing the -Lv nature, it is possible to modulate both the chemical stability and
the CL efficiency of these substrates [see Ref. 44]. Due to the strong interaction
with single-strand DNAs, acridinium derivatives are mainly used in the devel-
opment of CL-based probes for the analysis of pairing speed in hybridazation
processes, or to determine the thermodynamic affinity between oligonucleotidic
fragments and their target molecules [see Ref. 45–47].
1,2-dioxetane derivatives
The above-cited acridinium esters have to be oxidized in situ, since the dioxe-
tanone intermediate is quite unstable. However, introducing a proper stabilizing
moiety and a protected functional group, it is possible to create a triggerable
1,2-dioxetane derivative that results stable enough to be handled and even stored.
Therefore, the CL decomposition can be obtained using a chemical stimulus
which removes the protecting group and triggers the dioxetane fragmentation.
Among the myriad of chemically-triggered dioxetanes [see Ref. 48–51], the phos-
phoryl derivative represents the most common one, and it is used as substrate
for the Alkaline Phosphatase (AP) enzyme. The CL mechanism (Scheme 1.7)
expects a dephosphorylation of the substrate by the AP enzyme and the subse-
quent formation of a negative charge upon the aromatic ring. The latter causes a
destabilization of the dioxetane which decomposes generating an electronically-
excited methyl benzoate fragment. Due to the low Φf of the benzoate moiety, the
presence of a fluorescent energy acceptor (EA) is required, in order to develope
dioxetane-based analytical methods with high sensitivity.
Coelenterazine and oxalate esters
Coelenterazine is a light-emitting molecule (for the molecular structure see
Scheme 1.8 a) present in many coelenterate and represents the typical substrate
for luciferases, such as Renilla reniformis luciferase (Rluc), Gaussia luciferase
(Gluc), and some photoproteins like Aequorin. Coelenterazine was simultaneously
isolated by two groups during the characterization of the luminescent organisms
sea pansy (Renilla reniformis) and the coelenterate Aequorea victoria, respectively
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Scheme 1.8: a) Molecular structure of Coelenterazine and b) Mechanism for the CL
decomposition of diphenyl oxalate.
[see Ref. 52, 53]. The BL reaction followes the mechanism typical of acridinium
esters, but the intramolecular cyclization of hydroperoxide requires the presence
of both the enzyme and calcium cations [see Ref. 54–56]. Coelenterazine and its
derivatives have found several applications in the (bio)analytical field, especially
to detect the concentration of superoxide anions and metallic species (e.g. Calcium
and Barium) [see Ref. 57, 58].
A well-known class of dioxetane-based CL molecules are represented by the
oxalate esters. These compounds were proposed, for the first time, in 1967 by
Rauhut et al. [see Ref. 59], when he reported the chemiluminescent decompo-
sition of diphenyl oxalate, induced by hydrogen peroxide. Differently from the
compounds described so far, the oxidation of oxalate leads to a dioxetanedione in-
termediate (Scheme 1.8 b) which decomposes instantaneously into two molecules
of CO2 [see Ref. 60–62].
The three most famous oxalate derivatives are bis(2,4,6-trichlorophenyl)oxalate
(TCPO), Bis(2,4,5-trichlorophenyl-6-carbopentoxyphenyl)oxalate (CPPO) and
bis(2,4-dinitrophenyl) oxalate (DNPO), which are all used in glow sticks frab-
brications. Every oxalate-based system shows the presence of an EA, since the
dioxetanedione intermediate is not able to emit light per se. Moreover, the low
stability of oxalate esters has always represented the main disadvantage for this
class of CL substrates, and it has prompted researchers to investigate the effect
of different ester groups upon the oxalate stability [see Ref. 63–65]. Despite the
above-cited disadvantages, oxalate esters have found several applications as CL
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markers in immunoassay for hydrogen peroxide detection [see Ref. 66, 67].
1.4.2 1,2-dioxetanes in Bioluminescence (BL)
Bioluminescence is one of the most spectacular phenomena that occur in
nature and it has been observed and admired since the ancient times. It consists
in a particular form of chemiluminescence that occurs in living organisms, where
an enzyme (luciferase) catalyzes the oxidation of a luminescent substrate (lu-
ciferin), causing the emission of a bright light (mostly in the blue region of visible
spectrum).
Testimonies of BL manifestations have been reported by many academics
of the classical era such as Aristotle and Plyny the Elder, who described an
enchanting glow coming out from damp wood. Even the English naturalist
Charles Darwin reports an encounter with the BL phenomenon in his Journal and
remarks [see Ref. 68]:
While sailing in these latitudes on one very dark night, the sea presented
a wonderful and most beautiful spectacle. There was a fresh breeze, and
every part of the surface, which during the day is seen as foam, now glowed
with a pale light. The vessel drove before her bows two billows of liquid
phosphorus, and in her wake she was followed by a milky train. As far as
the eye reached, the crest of every wave was bright, and the sky above the
horizon, from the reflected glare of these livid flames, was not so utterly
obscure, as over the rest of the heavens.
In 1920, a monograph about the theme of bioluminescence (The Nature of Animal
Light) was published by the American zoologist E. Newton Harvey, who sum-
marized all the previous work conducted until then [see Ref. 69]. He was also
among the first to propose the causes for the evolution of BL systems, identifying
in respiratory chain proteins that hold fluorescent groups, the origin of BL phe-
nomenon [see Ref. 70]. Although his theory was disproven, Harvey prompted
many scientists to start working on the subject, and the two main hypotheses about
BL historical evolution, still prevailing today, were presented in 1993 and 1998
by Seliger and Rees et al., respectively [see Ref. 71, 72]. Both theories concern
the origin of marine bioluminescence but differ from each other in identifying
the reason that led natural evolution to develope BL systems. Seliger suggests
luciferases to be one of the oxygenase enzymes originally involved in the cleav-
age of pigment molecules. Therefore, when the early ancestors started moving
down to deeper and darker waters, an increase in eye sensitivity and enhancement
of visual signals occurred [se Ref. 73], provoking mutations in the oxygenase
enzymes (luciferases) and the appearance of external luminescence in tissues.
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On the other hand, Rees finds in the shift of luciferins functionality the origin
of BL phenomenon. Indeed, he supports that luciferin was initially protecting
marine organisms from deleterious reactive oxygen species (ROS), quenching
the radical compounds generated by environmental stress condition. However,
when early species moved down to the ocean depths, exposure to ROS decreased
significantly and luciferin underwent a functional change from antioxidant agent
to bioluminescent one.
Bioluminescence phenomena are widely diffused among both the animal and
vegetable kingdoms. In fact, it can be observed in several marine species, includ-
ing fish, jellyfish, algae, crustaceans and cephalopod molluscs, or in terrestrial
organisms, such as fireflies, glow-worms and fungi [see Ref. 74, 75]. Furthermore,
BL process can assume a moltitute of different functions, each one peculiar to
the specific taxa [see Ref. 74]. For instance, it can appear during the courting
phase to attract mates or repel contenders; it can participate in the hunting process
luring, stunning or confusing the prey or it can play a defensive function like
counterillumination camouflage, misdirection etc.
Regardless of the specific function or purpose of the BL event, the mechanism
[see Ref. 76] always involves an oxidant enzyme (generally named Luciferase)
and a substrate (known as Luciferin), which interact with each other forming
an enzyme-substrate complex (ES). The latter forms a peroxyluciferin-enzyme
system (ESO2) that undergoes an oxidation reaction, giving the complex product-
enzyme (EP). The final step consists in the EP breakdown and the generation of
the electronically excitet product (see Scheme 1.9 a).
The chemical nature of both luciferin and luciferase can be profoundly dif-
ferent depending on the BL system analyzed, and this variations usually result
in a different colour of the light emission. For instance, the substitution of a
single aminoacid along the peptide chain can strongly affect the wavelength of
EMR [see Ref. 77, 78]. Furthermore, the BL spectrum not always overlaps the
fluorescence one, since the species responsible for the light emission could be
different from the final product (i.e. it could be the ESO2 or the EP complex). The
three main bioluminescent systems are described below, and they can be found in
a moltitute of BL-based methodologies [see Ref. 79–82]:
Bioluminescent Bacteria
Among the bioluminescent organisms, BL bacteria are the most diffused ones,
expecially in the marine environment such as on the surface of decomposing
fish, in deep-water sediments and in the gut of aquatic animals. They can be
found in coastal waters near the outflow of river and in all those places known
as milky seas (such as Gulf of Trieste, coast of Africa and so on) [see Ref. 83].
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Scheme 1.9: a) General mechanism for the bioluminescent process and b) Mechanism
for the BL reaction occuring in bacteria.
Moreover, these BL creatures may live as indipendent organisms or in symbiosis
with others, assimilating nutrients from hosts and providing bioluminescence, for
camouflage, prey attraction etc., in exchange. Although bioluminescent bacteria
have been known and studied for centuries (folklores of ancient civilizationes
from Scandinavia, China and India are disseminated of encounters with ”magical”
luminescent small entities), the purpose for the light production is still under
debate. A plausible explanation for the occurring of BL phenomenon can be
found in the biochemistry of these organisms. Indeed, studies have suggested that
BL process may be activated in conditions of low oxygen concentration, as an
alternative pathway for electron flow [see Ref. 84]. Another hypothesis applies to
enteric bacteria, assuming the dispersal of their colonies as the reason for biolumi-
nescence [see Ref. 85]. In fact, once the bacteria have been digested and excreted
in fecal pellets, they can exploit the luminescence to lure other organisms eating
them, thus, they will insure a wider species distribution. An interesting aspect of
bacterial bioluminescence is the role played in quorum sensing, namely, the par-
ticular communication process between cells, which controlles and regulates gene
expression in response to cell density [see Ref. 86]. When the bacterial population
reaches high density levels, several extracellular signalling molecules (autoinduc-
ers) are released, which induce the over-expression of luciferase enzymes, thus,
the increase in light production.
A luciferase characteristic of BL bacterial species consists in a two-units
heterodimer enzyme. The subunit α (responsible for bioluminescence) is a 40
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kDa peptide chain, while the subunit β is a 35 kDa protein fragment. A typical
substrate (luciferin) is the flavin mononucleotide (FMN), which is produced from
riboflavin (vitamin B2) by the enzyme riboflavin kinase. Scheme 1.9 b shows
the reaction mechanism occurring in bioluminescent bacteria: firstly, FMN is
converted to its reduced form FMNH2 by the coenzyme Nicotinamide Adenine
Dinucleotide (NAD), followed by the formation of a luciferase-FMNH2 complex.
The latter reacts with molecular oxygen giving a quite stable peroxyde which
forms an oxyhemiacetal intermediate, in presence of fatty aldehydes. Finally, the
hydrolysis of hemiacetal leads to the hydroxyflavin-enzyme complex, responsible
for the light emission[see Ref. 87, 88].
Bioluminescent bacteria have been mainly exploited in the field of biotech-
nology and environmental microbiology. In particular, several BL bacteria-based
sensors have been developed for detection of contaminants in food or pollutants
released into the environment [see Ref. 89–92].
Fireflies and Cnidaria
The term Cnidaria indentifies a phylum containing over 10.000 species of
aquatic animals which can be found in almost every marine environment (fresh-
water and open ocean). Cnidaria members (sea anemones, true jellies, sea pens
etc.) along with the Ctenophora phylum (comb jellies) are grouped under the
Coelenterate class, since they all share the same physical characteristics. In fact,
the term originates from the greek words koilos and enteron which mean ”hollow”
and ”intestine” respectively, and it refers to the peculiar hollow body cavity that
is typical of the two phyla. The bioluminescence for these organisms follows the
above-described coelenterazine-based mechanism (see section 1.4.1), involving
the formation of a 1,2-dioxetanone species, as key intermediate, and the following
release of CO2 and generation of an electronically excited product.
Fireflies are a family of insect in the beetle order Coleoptera, which are known
for glowing during twilight to attract mates or to lure preies. These ”lightining
bugs” present specialized organs in the lower abdomen, where photons with
wavelengths ranging from 545 to 595 nm can be produced through a peculiar
bioluminescence reaction [see Ref. 93–95]. Luciferase from Photinus pyralis
species (a fireflies variety hailing from the North America areas) is one of the most
well-studied BL enzyme and it was the first employed in (bio)analytical applica-
tions. The mechanism for the bioluminescent reaction is depicted in Scheme 1.10,
showing the chemical transformations occuring upon the benzothyazolyl thiazole
derivative (D-Luciferin) [see Ref. 96, 97]. The first step consists in a condensation
of D-Luciferin with adenosine triphosphate (ATP), catalyzed by luciferase and
magnesium dication (Mg2+). In a second step, adenylate intermediate undergoes
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Scheme 1.10: Mechanism for the bioluminescent reaction occuring in Photinus pyralis.
an oxidation by molecular oxygen, generating a hydroperoxyde compound which
leads to the dioxetanone formation, after intramolecular cyclization. Lastly, the
unstable endoperoxide follows the same fate of dioxetanes, decomposing in a
electronically excited product.
Bioluminescence from fireflies have been widely exploited in a multitude of
analytical methodologies, due to the remarkable sensibility (high BL efficiency
and low matrix signal) and simplicity of the chemistry involved in this system. Se-
veral devices based on the Bioluminescence Resonance Energy Transfer (BRET)
phenomenon have been used for monitoring the protein-protein interaction as well
as to detect the presence of heavy metals or xenobiotics in cell cultures. Moreover,
BL-based sensors have been utilized for in vivo imaging [see Ref. 98], in tracking
tumoral cells or to determine the gene expression in living animals [see Ref. 99].
Other applications of fireflies-type BL systems can be found in drug-discovery,
expecially in the High Throughput Screeening (HTS) processes [see Ref. 100],
and environmental monitoring fields [see Ref. 101].
1.4.3 1,2-dioxetanes in Thermochemiluminescence (TCL)
Among the luminescence processes that involve decomposition of a 1,2-
dioxetane (or 1,2-dioxetanone) intermediate, Thermochemiluminescence (TCL)
phenomenon represents the less explored one. In fact, first attempts to apply TCL
as a detection method in (bio)analytical systems have been made in late ’80s, when
it was proposed for development of an immunoassay based on the adamantylidene
adamantane 1,2-dioxetane [see Ref. 102]. Raising the temperature above 200-250
◦C, the dioxetane decomposes into two identical fragments (2-adamantanone),
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Scheme 1.11: TCL decomposition of Adamantylidene adamantane 1,2-dioxetane.
one of which in its electronically excited state (see Scheme 1.11. The latter,
then, relaxes to its ground state emitting a high energy photon (with emission
wavelength at 420 nm).
The thermochemiluminescence quantum yield (ΦTCL) of the above-described
system is quite low, since the adamantanone fragment shows almost no singlet
relaxation [see Ref. 103–105]. Nevertheless, several research groups have tried
to perform dioxetane-based immunological analysis for detection of common
biomolecules of interest. For instance, in 1986 Luider et al. used an adamantyl-
dioxetane derivative to develope a TCL immunoassay for human chorionic go-
nadropin (hCG) [see Ref. 103]. Specifically, both a Thermochemiluminescence
ImmunoAssay method (TIA) and a Fluorescent Thermochemiluminescence Im-
munoassay system (FTIA), have tested, functionalizing the monoclonal anti-hCG
with the 1,2-dioxetane derivative alone or in the presence of the fluorescent en-
ergy acceptor 9,10-diphenylanthracene (DPA), respectively. TIA showed a larger
dynamic range than the classical enzyme-based assay but a lower precision and
detection limit. The latter was increased using the FTIA method, where several
EA molecules were conjugated to the monoclonal anti-hCG, insuring an higher
light response. Improvements of TCL-based immunoassay have reached by Hum-
melen et al., who described a Fluorescent Amplified Thermochemiluminescence
ImmunoAssay (FATIMA) system for detection of hIgG and carcinoembryonic
antigen (CEA) [see Ref. 106]. He functionalized Bovine Serum Albumine (BSA)
protein with up to 25 dioxetane derivatives and as much as energy acceptor DPA,
and he encaged the dioxetane moiety into a γ-cyclodextrin to improve both repro-
ducibility and linearity of TCL signal. Despite these first attempts made in late
’80s, TCL technique was subsequently abandoned because of the low sensibility
and high temperatures required for the decomposition of dioxetane derivative.
Recently, Roda et al. have proposed a new class of 1,2-dioxetane derivatives
suitable for analytical applications [see Ref. 107–111].
These innovative TCL substrates present two different portions: the adamantyl
moiety, required to insure stability to the dioxetane, and the acridin unit, re-
sponsible for the generation of the electronically excited product. The thermal
decomposition of acridin-based dioxetanes follows a CIEEL mechanism [see Ref.
112–114], where the lone pair of the endocyclic nitrogen plays a crucial role in the
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Scheme 1.12: CIEEL mechanism for the decomposition of acridin-based 1,2-
dioxetanes.
O-O’ breakdown (see Scheme 1.12). The first step consists in a electron transfer
from nitrogen to the endoperoxide system and simultaneous ring fragmentation.
Then, a back electron transfer occurs, leading to the formation of the electroni-
cally excited 9(10)-Acridanone. A small library of acridin-based dioxetanes have
been synthesized [see Ref. 110, 111], and the influence of substituents (different
electron withdrawing and donating groups on the aromatic system) upon TCL
properties have been investigated. Furthermore, in order to obtain sensibilities
comparable to those of classical CL methods, TCL-based nanometric probes have
been developed [see Ref. 107], doping silica nanoparticles with a high number of
both dioxetane derivatives and energy acceptors. The TCL probes have showed
high ΦF along with a quite low threshold for the decomposition temperature (emis-
sion start occurring when the temperature is raised above 100-120 ◦C) and good
water solubility, all properties that make this system suitable for immunoassay
applications.
1.4.4 1,2-dioxetanes in Mechanochemiluminescence (MCL)
Scheme 1.13: MCL process for the system dioxetane-poly methyl acrilate, occurring
after a mechanical stress .
Recently, the luminescence properties of 1,2-dioxetanes have been combined
with polymers technology, developing a rubber-like poly methyl acrilate system
that is able to produce a bright light emission, after applying a mechanical stress
upon the polymer chains [see Ref. 115]. Scheme 1.13 shows the mechanism
involved in the MCL process. Polymer chains functionalized with adamantylidene
19
CHAPTER 1. THE ROLE OF 1,2-DIOXETANE COMPOUNDS IN THE LUMINESCENT PROCESSES
adamantane 1,2-dioxetanes demonstrated to be potentially useful in mapping the
stress distribution in polymers, insuring high temporal resolution for real-time
monitoring of chain-scission events.
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Chapter2
Synthesis of 1,2-Dioxetanes as
Thermochemiluminescent Labels for
Ultrasensitive Bioassays: Rational Prediction of
Olefin Photooxygenation Outcome by Using a
Chemometric Approach
2.1 Introduction
From the 1970s to date, the 1,2-dioxetane system [see Ref. 116–121] has
continued to attract great interest due to its key role in chemiluminescence (CL)
and bioluminescence (BL) reactions [see Ref. 122–125]. Its peculiar proper-
ties have stimulated and enabled the development of a wide array of applica-
tions. For example, recently, 1,2-dioxetanes have been exploited as luminescent
mechanophores,namely, responsive units able to transduce mechanical stress into
an optical response [see Ref. 126, 127]. Primarily, dioxetane analogues have
proved to be potent tools in clinical diagnostics as chemiluminescent substrates
for enzymes, such as alkaline phosphatase, used as labels in immunoassays and
gene assays [see Ref. 128–138]. Indeed, CL, BL, and electrogenerated chemilumi-
nescence (ECL) detection techniques are particularly well suited in applications in
which high sensitivity is required, offering high detectability, even in low volumes,
a wide linear range of responses, and a high signal to noise ratio. Nevertheless,
CL, BL, and ECL detection requires the addition of reagents to induce light
emission, thus decreasing assay rapidity and simplicity, which are crucial for
on-field biosensor applications. The remarkable advantage of a thermochemilu-
minescence (TCL) label is that its light emission is simply produced by heating,
and nothing else. In fact, the TCL phenomenon originates from heating a suitable
thermodynamically relatively unstable molecule, which decomposes to yield a
product mainly in the singlet excited state that decays with photon emission
(see Scheme 2.1). Nowadays, TCL [see Ref. 139–149] offers challenging and
unexplored opportunities for the development of reagentless and ultrasensitive
detection methods exploitable, for example, in simple portable biosensors with
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Scheme 2.1: Acridan-containing 1,2-dioxetane 4a, which was employed by us as a
TCL label.
TCL molecules as labels, as either single molecules or included in functionalized
silica nanoparticles (SiNPs) [see Ref. 108, 109].
Thermochemiluminescent 1,2-dioxetanes, described for the first time in 1963,
were proposed for analytical applications in the late 1980s with limited success
due to the relatively high temperature of decomposition and very poor light
emission efficiency [see Ref. 150–152]. Over the last four years, we have reinves-
tigated acridan-based 1,2-dioxetanes (for example 4a;[see Ref. 153–158] Scheme
2.1) as TCL compounds. As an application, we incorporated 4a into SiNPs with
the aim of generating TCL probes for ultrasensitive immunoassays [see Ref. 107–
110]. SiNPs doped with our acridan-based 1,2-dioxetane displayed remarkable
advantages, compared to TCL labels proposed in the past, such as a lower trigger
temperature (below 100 °C) and highly improved detectability, comparable with
that obtained with enzyme-based CL detection.
In a preliminary stage, we studied the effect of weak electron-donating groups
(EDGs), such as methyl substituents, on the acridan moiety of 4a (4b-4g; see Fig-
ure 2.1). For example, we found that, with acridones as the emitting species, tri-
and tetramethyl-substituted acridones showed the highest fluorescence quantum
yields (ΦF ), in the range of 0.48-0.52. Accordingly, the corresponding 1,2-
dioxetanes 4f and 4g (Figure 2.1) presented limit of detection (LOD) values more
than one order of magnitude lower than that of the unsubstituted derivative 4a, as
determined by TCL imaging experiments. Moreover, we noticed that the impact
of the substituent was greater in the 2-position (and/or 7-position). Methyl groups
also caused a clear decrease in the activation energy (Ea) of the thermochemilu-
minescent reaction. Lastly, we observed that the rate of 1,2-dioxetane formation
through photooxygenation of the corresponding alkene strongly depended on the
substitution pattern of the acridan moiety.
Intrigued by the considerable effects of the acridan substituents on the proper-
ties of thermochemiluminescent 1,2-dioxetanes, we planned substantial structural
modifications to the fluorophore moiety of the dioxetane with the purpose of
1) improving and modulating the photophysical characteristics and activation
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Figure 2.1: Library of 1,2-dioxetanes studied herein.
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Scheme 2.2: Two-step synthetic approach to TCL 1,2-dioxetanes 4.
parameters of the TCL labels, and 2) studying the impact of several structural
features on a series of properties of the 1,2-dioxetanes, including the photooxy-
genation rate of the parent olefin with singlet oxygen (1O2). The complete list of
thermochemiluminescent 1,2-dioxetanes synthesized and investigated is shown in
Figure 2.1. All members of this library were fully characterized in terms of TCL
properties. The synthetic approach to thermochemiluminescent 1,2-dioxetanes
4 is depicted in Scheme 2.2. It consisted of two steps: a) reductive coupling of
two properly selected ketones (1 and 2) under McMurry conditions [see Ref. 159–
170], and b) photooxygenation [see Ref. 171–184] of the obtained tetrasubstituted
alkene 3 to provide the desired 1,2-dioxetane 4.
In a number of cases examined, however, photooxygenation did not occur.
Thus, we decided to perform a chemometric investigation with the aim of correlat-
ing selected representative structural and electronic features of the olefin reagent
with the success of the photooxygenation reaction.
2.2 Results and discussion
2.2.1 Synthesis
At the outset of this study, we optimized the reaction conditions of the two key
steps that led to parent 1,2-dioxetane 4a, which was selected as a model compound
(see Table 6.1 in the Supporting Information. The optimized procedure is detailed
in Table 2.1. The most relevant modifications concerning the photooxygenation
step were the replacement of polymer-bound Bengal Rose with Methylene Blue
as the sensitizer and an increased temperature; these conditions allowed us to
achieve better yields in a shorter time.
By using the optimized synthetic protocol, we accomplished a series of modi-
fications on the fluorophoric moiety of 4a (Table 2.1), preserving unaltered the
adamantyl unit that acts as a stabilizing framework [see Ref. 185, 186]. In fact,
among substituents employed as stabilizing subunits in 1,2-dioxetane[see Ref.
187, 188], the adamantyl group is widely recognized as a rigid and sterically
demanding framework able to significantly stabilize the endoperoxide unit.
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Table 2.1: Synthesis of differently substituted 1,2-dioxetane 4a, 4h-t.[a]
Entry Ketone 2 Olefin 3 (yield [%])[b] 1,2-Dioxetane 4 (time [h], yield [%])[b]
1 3a (94) 4a (2, 92)
2 3h (86)[c] 4h (2, 95)
3 3i (88) 4i (7, 55)[d]
4 3j (76) 4j (4, 89)
5 3h (48)[e] 4k (4, 89)
6 3l (89) 4l (2, 80)
7 3m (95)[c] 4m (12, 80)[f ]
8 3n (95) 4n (2, 91)[f ]
9 3o (92)[c] 4o (2, 85)
10 3p (93)[c] 4p (2, 87)[f ]
11 3q (91)[c] 4q (2, 92)
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12 3r (90) 4r (5, 91)
13 3s (77) 4s (7, 82)[f ]
14 3t (58) 4t (10, 50)
[a]Reaction conditions: a) McMurry coupling: adamantanone 1 (0.28 mmol), ketone 2 (1 equiv),
TiCl4 (6.1 equiv), Zn (13.5 equiv), THF (6 mL), reflux, 45 min; b) photooxygenation: Methy-
lene Blue (6.5 mol %), UV cutoff filter (λ = 550 nm), -20◦C, CH2Cl2 (1 mL for 10 mg of
olefin 3), 500 W halogen lamp, O2 (1 atm, balloon). [b]Determined after purification by flash
chromatography.[c]Ketone 2 (3.2 equiv), 1.5 h.[d]-30◦C.[e]Poor solubility of the starting ketone
2k.[f ]-40◦C.
Three different structural modifications were examined on parent molecule
4a. First, we decorated the acridone ring with fluorine substituents, as electron-
withdrawing groups (EWGs), to obtain difluoro- or tetrafluoroacridan derivatives,
as well as products containing both fluorine and a methyl substituent as EDG.
McMurry olefination proceeded smoothly on acridones 2h-l, regardless of the
substitution pattern, to provide the corresponding alkenes 3h-l in high yields (up
to 89%).
Also, the photooxygenation step provided, in most cases, good results, but the
reactivity of various olefins showed some differences. First, we observed that the
formal [2+2] cycloaddition of singlet oxygen to acridane-derived alkenes strongly
depended on steric hindrance. In fact, when a fluorine atom occupied the 1-
position on the aromatic system (Table 2.1, entry 3), the reaction was significantly
slower. On the other hand, the presence of EWGs (two or four fluorine atoms;
Table 2.1, entries 2-4 and 5, respectively) or a combination of an EWG and an
EDG (Table 2.1, entry 6) did not affect 1,2-dioxetane formation.
In the second stage, we replaced the ethyl acetate on the nitrogen with alkyl
or aryl substituents (Table 2.1, entries 7-11). The corresponding 1,2-dioxetanes
4m-q were always accessible, but when the electron-donating effect was more
pronounced (Table 2.1, entries 7, 8, and 10) we were forced to decrease the
photooxygenation temperature to -40 °C to obtain good results, since at -20
°C partial degradation of the dioxetane 4 to the corresponding ketones 1 and 2
occurred.
We also focused our attention on the nature of the endocyclic heteroatom
and replaced the nitrogen atom with oxygen (Table 2.1, entries 12 and 13). The
oxygen-bearing xanthyl derivatives 2r and 2s smoothly underwent McMurry
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olefination (3r,s) and subsequent photooxygenation; this allowed us to isolate
the corresponding 1,2-dioxetanes 4r and 4s in high yields after chromatographic
purification [see Ref. 189, 190]. The reaction with singlet oxygen was also
acceptable (Table 2.1, entry 14) when a direct linkage between the two aromatic
rings was created, as in fluorenone-derived olefin 3t [see Ref. 191, 192].
2.2.2 Photophysical and TCL properties
The TCL properties of this series of 1,2-dioxetanes 4h-t were investigated (Ta-
ble 2.2), together with the photophysical properties of the corresponding ketones
2h-t, which were the emitting species in the TCL process (Scheme 2.1). Specif-
ically, we confirmed the nature of the emitting species for methyl-substituted
acridan-1,2-dioxetanes ([see Ref. 110]) by comparing the TCL spectra of the
1,2-dioxetanes with the fluorescence spectra of the corresponding acridones. In all
cases, the TCL spectra closely matched the fluorescence spectra of the correspond-
ing acridones; thus demonstrating that the TCL emission was primarily due to
the singlet excited state of acridone. The singlet excited state of 2-adamantanone
could also be produced in the TCL process. However, its possible emission could
not be detected due to overlap with the fluorescence emission of acridones and
the weak intensity (for 2-adamantanone: ΦF=0.015 and λ= 425nm) [see Ref. 193,
194]. For comparison, we also show data for previously reported 1,2-dioxetane
4a and acridone 2a (Table 2.2, entry 1).
When we measured the fluorescence quantum yields (ΦF ) of ketones 2a and
2h-t (Table 2.2), it appeared clear that the emission performances of the acridones
(Table 2.2, entries 1-11) were strongly affected by the substitution pattern. In
particular, compared to reference compound 2a (Table 2.2, entry 1), fluorine atoms
on the acridone aromatic rings significantly decreased the ΦF values when present
in the 3- and/or 6-positions (Table 2.2, entry 2) or in the 1-position (Table 2.2,
entry 3). The ability of a para-fluorine to decrease the fluorescence quantum
yield of the corresponding acridanone was further confirmed by comparing 3-
F,6-Me derivative 2l (ΦF=0.04) with 3-Me derivative (ΦF=0.21). Conversely, the
insertion of fluorines in 2,7-positions enhanced the fluorescence quantum yield
(2j cf. 2a, 2k cf. 2h). These unexpected and intriguing results suggested that
the emitting performances of F-substituted acridane-based ketones were mostly
affected by the position rather than the electronic features of the substituents on
the aromatic rings. As a further confirmation, by replacing a fluorine atom (EWG)
in the 6-position with a methyl group (weak EDG), we obtained only a slight
increase in the ΦF value (2l, entry 6, cf. 2h, entry 2, Table 2.2). The observed
behavior also proved to be peculiar in comparison with the fluorescence quantum
yield trend previously recorded for (poly)methylated acridones [see Ref. 110]. In
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the presence of EDGs, the ΦF values showed an increase for substitution at both
the 2- and 3-positions. On the contrary, the insertion of fluorine atoms generated
the opposite effect, depending on their location on the aromatic system.
Previous studies have already demonstrated a significant dependence of the CL
quantum yield on the substitution pattern, for a specific class of 1,2-dioxetanes
(aryl-substituted derivatives). A new rule, known as the ”odd/even rationale”
was defined to explain the outcome from the chemically-triggered decomposi-
tion of such compounds, which yield phenolate-like emitting species (strong
EDG substitution). In particular, for chemically initiated electron exchange
luminescence (CIEEL)-active spiroadamantane 1,2-dioxetanes, such as acetoxy-
naphthyl spiroadamantyl dioxetanes, it was observed empirically that extended
conjugated (para substituted) carbonyl chromophores derived from dioxetanes
triggered decomposition gave rise to low chemiexcitation efficiencies, whereas
cross-conjugated (meta substituted) carbonyl compounds showed higher quantum
yields. The odd/even rationale was proposed to explain this phenomenon: charge
transfer from the donor (phenolate) to the acceptor (carbonyl group) occurs more
effectively when the two groups are cross-conjugated (odd number of carbons
between the interacting groups), and, presumably, the charge-transfer enhances
the excited-state formation and ensures high chemiexcitation efficiency. On the
contrary, extended conjugation (even number of carbons between the interacting
groups) stabilizes the ground state through dipolar resonance, which disfavors
excited-state formation and, consequently, provides low efficiency [see Ref. 195–
198]. However, since the different molecular structure, it is not possible to apply
the above-cited odd/even rationale to our 1,2-dioxetane derivatives (4a, 4h-t. Fur-
thermore, very few examples are present in the literature that describe the behavior
of EWG-substituted 1,2-dioxetanes [see Ref. 199–206], and no studies have been
reported on fluorine-bearing aryl dioxetanes or concerning the dependence of
1,2-dioxetanes properties on the EWG distribution on the acridan system. In
particular, opposite effects on fluorescence quantum yield as a function of the
substituent position have never been observed.
After examining the photophysical properties of ketones 2h-l, we turned
our attention to the activation parameters of the thermal decomposition of the
fluorinated 1,2-dioxetanes 4h-l. In particular, the activation parameters for the
thermal decomposition of 1,2-dioxetanes 4a and 4h-t were determined by a
standard isothermal kinetic method, which measured the emission decay kinetics
at different temperatures and gave the kinetic constants of the TCL process
(see the Supporting Information for details). The trend shown by acridane 1,2-
dioxetanes containing EDGs consists of lowered activation energies (Ea) and
pre-exponential coefficients (A) and increased fluorescence quantum yields ΦF
28
CHAPTER 2. SYNTHESIS OF 1,2-DIOXETANES AS THERMOCHEMILUMINESCENT LABELS FOR ULTRASENSITIVE
BIOASSAYS: RATIONAL PREDICTION OF OLEFIN PHOTOOXYGENATION OUTCOME BY USING A CHEMOMETRIC
APPROACH
Table 2.2: Photophysical properties of ketones 2a and 2h-t and activation parameters
for the thermal decomposition of the corresponding 1,2-dioxetanes 4a and 4h-t.
Entry 2 ΦF [a] 4 Ea (kcal mol−1)[b] lnA (s−1)[b] t1/2 (months)[c]
1 2a 0.11 4a 31.5 ± 0.8 35.6 ± 1.0 11
2 2h 0.01 4h 41.7 ± 4.4 48.0 ± 5.6 1400 (117 y)
3 2i 4 x 10−3 4i 36.1 ± 4.3 41.8 ± 5.6 55
4 2j 0.65 4j 27.9 ± 1.2 30.6 ± 1.5 3.9
5 2k 0.11 4k 25.8 ± 1.1 28.6 ± 1.4 1.0
6 2l 0.04 4l 35.1 ± 2.7 42.9 ± 3.5 3.4
7 2m 0.61 4m 30.9 ± 1.5 37.3 ± 2.0 0.76
8 2n 0.44 4n 23.7 ± 1.6 27.2 ± 2.2 0.097
9 2o 0.28 4o 27.7 ± 0.7 31.0 ± 0.9 1.9
10 2p 0.43 4p 26.2 ± 2.4 29.5 ± 3.3 0.66
11 2q 4 x 10−4 4q 32.0 ± 1.4 37.4 ± 1.9 4.4
12 2r 1 x 10−4 4r 46.4 ± 3.4 58.0 ± 4.7 180 (15 y)
13 2s 2 x 10−4 4s 27.0 ± 1.1 29.5 ± 1.5 2.6
14 2t 0.025 4t 33.8 ± 1.4 40.8 ± 1.9 3.1
[a]Determined in acetonitrile by using quinine sulfate as standard (ΦF = 0.53 in H2SO4 0.05 mol
L−1).[b]Mean ± SD of three independent measurements.[c]Calculated for the solid compound at
25◦C. Note: The variations of activation energy due to the presence of different substituents are
very often paralleled by an analogous change in the pre-exponential coefficient. As a result, the
trend in the activation energies often does not reflect the behavior of the kinetic rate constants of
the TCL reaction, and thus, the t1/2 values.
[see Ref. 110]. The significant increase in the fluorescence quantum yields
of acridones containing EDGs could be due to a decrease in the intersystem
crossing rate constant, and thus, to a lower efficiency of nonradiative deactivation
processes, as reported for aromatic compounds, such as anthracene [207]. We
reasoned that the introduction of fluorine atoms as EWGs should give more stable
and easy to handle 1,2-dioxetanes, without causing an excessive impairment of the
fluorescence quantum yield. The activation parameters recorded for the fluorinated
1,2-dioxetanes confirmed our hypothesis, but they also revealed some unexpected
results. The 3,6-difluorodioxetane 4h (Table 2.2, entry 2) was characterized by
the highest activation energy (Ea=41.7 kcal mol−1) and showed an outstanding
and unprecedented calculated half-life (t1/2) of 117 years, if stored as a solid
at 25°C [see Ref. 208–211]. Increased stability compared with unsubstituted
dioxetane 4a was also recorded for compound 4i (Table 2.2, entry 3; Ea=36.1
kcal mol−1, t1/2=55 months), whereas the remaining fluorinated dioxetanes 4j-l
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(Table 2.2, entries 4-6) proved to be less thermally stable. The results obtained
from this family of compounds confirmed that there was a correlation between
acridone fluorescence quantum yield and thermal stability of the corresponding
1,2-dioxetane. The substituents on the aromatic system that enhance the ΦF value,
such as fluorine atoms in the 2,7-positions (2j-k), facilitate dioxetane thermal
decomposition (4j-k) at the same time. Conversely, 3,6-difluoro- (2h) and 1,6-
difluoro-substituted (2i) acridones showed decreased fluorescence quantum yields,
but the corresponding dioxetanes 4h-i displayed significantly longer half-life
values. A comparison of these data with those recorded for methyl-substituted
acridan-based dioxetanes confirmed that the introduction of weak EDGs increased
the ketone fluorescence quantum yield and lowered the dioxetane activation
energy, regardless of the position on the aromatic ring. On the contrary, the
impact of fluorine atoms depended dramatically on the substituent position.
The second structural feature we studied was the nature of the substituent on
the acridan nitrogen (Table 2.2, entries 7-11). In fact, during the excitation step of
the acridone system, charge is transferred from the donor N atom to the carbonyl
group. The charge-transfer character of the excited acridone chromophore, as
expected for a vinylogous amide, is its main electronic characteristic. Thus, it is
reasonable that modifications on the nitrogen substituent affect the fluorescence
quantum yield much more than the introduction of substituents on the aromatic
rings. Furthermore, the position of the aromatic rings substituents perturbs
this charge-transfer transition significantly less in acridan-based systems than in
benzoate-based systems [see Ref. 212, 213].
Removing (2m, 4m) or elongating (2n, 4n) the ester group present in the
parent compounds (2a, 4a) provided the expected enhancement of ΦF and de-
crease in Ea values (Table 2.2, entries 7 and 8, respectively). This finding further
confirmed the stabilizing effect postulated for the acetate moiety, due to its
electron-withdrawing character. Then, we investigated N-aryl derivatives (2o-q,
4o-q; Table 2.2, entries 9-11) and observed, in general, a lower thermal stability
of the dioxetanes with respect to the reference compound 4a, even if the decrease
was more pronounced for the EDG-substituted compound 4p than that for the
para-fluorophenyl derivative 4q. The results obtained for N-aryl acridan 1,2-
dioxetanes are in agreement with the data reported by other authors [see Ref. 153–
158]. Considering the possible conformations of N-aryl acridan 1,2-dioxetanes,
a steric repulsion between the peri-hydrogen atoms of the acridan system and
the aryl group might be generated. Therefore, the two rings would not be able
to conjugate each other sufficiently and the electronic effects of the aryl group
would be largely reduced.
Thus, for acridane-based 1,2-dioxetanes, we conclude that 1) the introduction
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of fluorine atoms onto the aromatic rings represents a remarkable tool to stabilize
the dioxetane derivatives, in particular, when they are located at the 3- and/or
6- position, or to enhance their emitting performances, when located at the 2,7-
positions; 2) the acetate moiety proves to be the best performing N-substituent,
ensuring a good balance between ketone fluorescence quantum yield and dioxe-
tane stability. As far as the activation parameters for the thermal decomposition
of xanthyl-derived 1,2-dioxetanes (4r, s) and the photophysical properties of the
corresponding emitting species 2r and 2s are concerned, we observed that the
replacement of the endocyclic nitrogen with an oxygen provided a very stable
dioxetane (4r), but also strongly decreased the fluorescence quantum yield (cf. Ta-
ble 2.2, entries 1 and 12). Moreover, EDGs on the xanthyl scaffold (3,6-positions)
dramatically decreased the activation parameters without a perceptible benefit
in the ΦF value (cf. Table 2.2, entries 12 and 13). Lastly, fluorenyl dioxetane
4t, which featured a direct linkage between the aromatic rings, afforded accept-
able emitting properties (ΦF=0.025) accompanied by moderate thermal stability
(Table 2.2, entry 14).
2.2.3 Chemometric analyses
To widen our library of TCL 1,2-dioxetanes and to learn more about the
structure–property relationships of this class of compounds, we also synthesized
a series of olefins that, unexpectedly, did not undergo the photooxygenation step
(Figure 2.2).
Previously investigated acridane-based alkenes 3u-x [see Ref. 110] and the
1-Me, 6-F derivative 3y are all characterized by the presence of a methyl group at
the 1-position of the aromatic system. Such results suggest that steric crowding in
this region disfavors the addition of singlet oxygen. The slow photooxygenation
rate observed for 1,6-difluoro compound 3i (Table 2.1, entry 3) supports this
hypothesis.
The sulfur-containing olefins 3z-B did not react with singlet oxygen, regard-
less of the sulfur oxidation state [see Ref. 214–217]. We tested other reaction
temperatures (namely, 0 and -20◦C) and extended the reaction times up to 7 h,
but only the starting olefin was recovered. Finally, when we replaced the en-
docyclic heteroatom with a sp3- or sp2-hybridized carbon (3C-E), in all cases,
photooxygenation did not occur.
These findings reveal that the reactivity of an olefin in the photooxygenation
process strongly depends on its substitution pattern. It is known that the formal
[2+2] cycloaddition of singlet oxygen to alkenes takes place efficiently on elec-
tronrich systems [see Ref. 218–225]. However, the mechanism of this process has
been extensively debated in the literature (Scheme 2.3) [see Ref. 226–237], and
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Figure 2.2: Differently substituted alkenes unreactive under photooxygenation condi-
tions (the yields of olefin formation are given in parentheses; for synthetic details, see the
Supporting Information).
the most reliable one can vary case by case, depending on the molecular structure
of the substrate, the solvation energy, and also the sensitizer employed. As a con-
sequence, the nature of the olefin substituents (electron-donating ability, presence
of hydrogen-bond acceptors and/or donors, geometry, and steric hindrance) not
only affects the success of singlet oxygen addition, but it also determines the
reaction pathway.
The mechanism of singlet oxygen addition to double bonds has been studied
computationally several times, but the rigorous approach to this diradical system
requires expensive treatments of multireference states and it has been applied
exclusively on very simple systems [see Ref. 238–240]. Moreover, the prediction
of the mechanism of singlet oxygen reactions has proven a challenging task for
many reasons [see Ref. 241, 242], including because different possible reaction
pathways (Scheme 2.3) are often predicted depending on the level of theory
employed [see Ref. 243].
To rationalize all of our results, we decided to avoid an extremely demanding
and time-consuming quantum mechanical approach, considering that both excited
and radical states are involved in the reaction. Rather, we envisioned a chemomet-
ric approach as a more practical tool to identify which structural and electronic
properties of starting olefins, or combination of them, determine the success of
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Scheme 2.3: A representation of the various hypothesized mechanisms for the forma-
tion of 1,2-dioxetanes through singlet oxygen addition to olefins.
the photooxygenation step.
At the outset, we adopted principal component analysis (PCA) [see Ref.
244–247] of the structural and electronic molecular descriptors obtained by DFT
optimizations of olefins 3 [see Ref. 248]. After an initial conformational screening
by using a molecular mechanics (MM) force field on the data set of molecules,
the conformers obtained in a 8 kcal mol−1 window were optimized by using
DFT at the B3LYP/6-31G(d) level of theory (see the Supporting Information for
details). Among the different calculated electronic descriptors, we selected the
energy of the HOMO, the energy of the LUMO, the Mulliken charges on the
olefin carbon terminals Ca-Mul and C9-Mul (Figure 2.3) and the coefficients of
the atomic contribution of the alkene carbon atoms to the HOMO and LUMO
orbitals, calculated by using the Mulliken decomposition method (Ca-HOMO,
Ca-LUMO, C9-HOMO, and C9-LUMO). Moreover, we selected a few structural
parameters that reflect the geometry of the molecules in close proximity to the
double-bond reaction site.
In particular, we chose the two dihedral angles, φ1 and φ2, which represent the
deviation from planarity of the aromatic rings with respect to the plane defined
by the carbon-carbon double bond, and the four interatomic distances d1-d4 as
an index of steric crowding of the aromatic ring substituents around the Ca-C9
double bond (Figure 2.3). Specifically, when a substituent was present in the C1
position of the aromatic system, d2 and d4 were taken as the interatomic distances
between the double-bond carbon atoms Ca and C9 and the closest atom of the
substituent group, as shown in Figure 2.3.
We analyzed first a set of 23 similar molecules that possessed a common
acridane skeleton (3a-q, 3u-y, and 3F; Figure 2.4), the molecular descriptors of
which are collected in Table 6.3 in the Supporting Information (see Chapter 6).
Data were meancentered before analysis and were autoscaled by dividing them by
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Figure 2.3: DFT-optimized structure of 3a and structural molecular descriptors em-
ployed in the PCA.
the standard deviation of each column sample variable. The first four eigenvalues
greater than 1 obtained by PCA of the 23x14 data matrix and the explained
variances relative to each component are reported in Table 2.3. The model
obtained is able to explain 84.9 % of the total variance by using only three PCs,
whereas two PCs explain 64.7 % of the variance.
Table 2.3: Eigenvalues and percentage of explained variance relative to the first four
principal components (PCs) of the model used for the description of olefins 3a-q, 3u-y,
and 3F.
PC Eigenvalue Variance (%) Cumulative
Eigenvalue
Cumulative
Variance (%)
PC1 5.96 42.5 5.96 42.5
PC2 3.11 22.2 9.07 64.7
PC3 2.82 20.1 11.89 84.9
PC4 1.16 8.3 13.05 93.1
The score plot representing the projections of the data points in the plane
defined by the two first PCs is reported in Figure 2.5 A. A clustering of data is
apparent, with the alkenes that undergo photooxygenation grouped in the right
side of the plot (blue triangles) and the unreactive molecules clustered on the left
(red dots), mainly discriminated by the first PC. The loading plot, reported in
Figure 2.5 B with the variables colored by relative contributions, shows that the
variables mainly composing the first PC are the Mulliken charge C9-Mul (cos2
= 0.834), the dihedral angles φ1 and φ2 (cos2 = 0.808 and 0.807, respectively),
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Figure 2.4: Initial set of acridan-containing alkenes analyzed with the chemometric
approach.
the interatomic distances d2 and d4 (cos2 = 0.815 and 0.669, respectively), and,
to a lesser extent, the interatomic distance d1 (cos2 = 0.541) and the Mulliken
charge Ca-Mul (cos2 = 0.582). The only variables significantly contributing to
the second PC are the interatomic distance d3 (cos2 = 0.641) and, to a lesser
extent, the interatomic distance d1 cos2 = 0.413) and the energies of the HOMO
and LUMO orbitals (cos2 = 0.461 and 0.483, respectively). PCA results seem to
suggest that the difference in reactivity in the photooxygenation reaction between
the two groups of alkenes is mainly due to steric effects and not to electronic ones.
In particular, the presence of a bulky methyl group in the 1-position of the acridan
skeleton results in a significantly larger deviation from planarity for compounds
3u-y, with respect to all other reactive alkenes (see Table 6.3). This geometrical
distortion has the overall effect of making the Ca-C9 double bond more sterically
crowded and less accessible to singlet oxygen, as also evidenced by the shorter
interatomic distances d1 and d2 in the unreactive compounds.
The same analysis was repeated on the expanded data set comprising the
oxygen-bearing xanthyl derivatives 3r-s (XAN family), the sulfur-containing
olefins 3z, 3A, and 3B (THI family), and the anthrone-derived alkenes 3C-E
(ANT family), in addition to the previously analyzed acridane derivatives 3a-
q, 3u-y, and 3F (ACR family). The eigenvalues greater than 1 derived from
PCA of the as-obtained 31x14 data matrix are reported in Table 2.4, while the
corresponding molecular descriptors employed are collected in Table 6.4 in the
Supporting Information (see Chapter 6). By using the first three PCs, the model
can be used to explain 73.8 % of the total variance, whereas 56 % of the variance
is accounted for by using only the first two PCs.
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Figure 2.5: PCA results for the data matrix descriptors of olefins 3a-q, 3u-y, and 3F:
A) PCA score plot relative to the first two PCs (blue triangles: reactive compounds; red
dots: unreactive compounds). B) PCA loading plot relative to the first two PCs (variables
are colored according to their relative contribution).
Table 2.4: Eigenvalues and percentage of explained variance relative to the first five PCs
of the model used for the description of olefins 3a-s, 3u-z, and 3A-F.
PC Eigenvalue Variance (%) Cumulative
Eigenvalue
Cumulative
Variance (%)
PC1 4.45 31.8 4.45 31.8
PC2 3.39 24.2 7.84 56.0
PC3 2.49 17.8 10.33 73.8
PC4 1.42 10.1 11.75 83.9
PC5 1.09 7.8 12.84 91.6
The score plot representing the projections of the data points in the plane
defined by the two first PCs is reported in Figure 2.6 A and the corresponding
loading plot with the variables colored by relative contributions is shown in
Figure 2.6 B. Again, a quite marked separation in the score plot is apparent
between the reactive and unreactive olefins, which in this expanded data set is
discriminated by both the first and second PCs.
The relative loading plot (Figure 2.6 B) reveals that the variables contributing
to the first PC are mainly the steric parameters, similarly to what is obtained
for the previously analyzed ACR family. In particular, the highest contributing
variables are mainly the dihedral angles φ1 and φ2 (cos2 = 0.906 and 0.915,
respectively) and, to a lesser extent, the interatomic distances d2 and d4 (cos2 =
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Figure 2.6: PCA results for the data matrix descriptors of olefins 3a-s, 3u-z, and 3A-F:
A) PCA score plot relative to the first two PCs (blue triangles: reactive compounds; red
dots: unreactive compounds); B) PCA loading plot relative to the first two PCs (variables
are colored according to their relative contribution).
0.632 and 0.542, respectively) and the Mulliken charge Ca-Mul (cos2 = 0.654).
On the other hand, the variables significantly contributing to the second PC are
mainly electronic parameters, namely, the energies of the HOMO and LUMO
(cos2 = 0.592 and 0.759, respectively) and, to a lesser extent, the Mulliken charge
C9-Mul (cos2 = 0.475).
For this expanded data set, the PCA results suggest that both steric and
electronic effects play a role in determining the reactivity under photooxygenation
conditions; both factors are necessary, but not sufficient to trigger reactivity. The
score plot of the data projections (Figure 2.6 A) is apparently divided into four
quadrants, with the reactive olefins in the top-right sector, where both steric and
electronic parameters cooperate in the same positive direction. The acridane-
containing unreactive olefins (3u-y) are positioned in the top-left quadrant, in a
region where electronic effects alone would allow the photooxygention reaction,
which is hampered solely by steric hindrance around the Ca-C9 double bond
exerted by the methyl group present at the 1-position (121-124◦ versus 130◦ mean
φ1/φ2 values for all compounds). On the other hand, the anthrone- derived alkenes
3C-E are grouped in the bottom-right sector of the score plot, with the same
coordinates of the reactive olefins along the first PC. Although photooxygenation
should not be disallowed for steric reasons for these alkenes, the overall linear
combination of their electronic descriptors renders them unreactive. The sulfur-
containing olefins 3z and 3A are located in a borderline central region of the
plot, where both steric and electronic factors are not ideal for promoting the
photooxygention reaction, whereas the sulfone analogue 3B is projected farther
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Figure 2.7: PCA results for the data matrix descriptors of olefins 3a-q, 3u-y, and 3F
(ACR); 3r-s (XAN); 3z, 3A-B (THI); and 3C-E (ANT). PCA score plot relative to the
first two PCs, colored according to the structural features of the analyzed alkenes.
away along the negative PC2 axis. Finally, the reactive xanthyl derivatives 3r
and 3s are correctly projected in the same top-right quadrant of the previously
examined reactive acridane-based olefins, which possess both steric and electronic
properties that allow the photooxygenation reaction to proceed smoothly. The
score plot of the expanded data set relative to the first two PCs is again reported in
Figure 2.7, with the projected data points now colored according to the common
structural features of the employed alkenes (XAN: 3r,s; THI: 3z, 3A,B; ANT:
3C–E, and ACR: 3a–q, 3u–y, 3F). The marked clustering obtained in this plot
clearly shows the capability of the PCA model to discriminate between different
alkenes on the basis of their common structural features.
To further validate our chemometric approach, a supervised linear discrimi-
nant analysis (LDA) was performed on the expanded 31x14 data set. Using the
previously chosen parameters, we obtained a highly statistically significant model
(Wilks’ lambda = 0.0121, canonical correlation = 0.9939), showing perfect dis-
crimination between the two classes of reactive (mean of canonical variables=6.48)
and unreactive olefins (mean of canonical variables = -11.8). The correspond-
ing raw and standardized coefficients of the obtained linear discriminant are
reported in Table 2.5, whereas the canonical scores are plotted in Figure 2.8 for
all compounds.
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Table 2.5: Raw and standardized coefficients of the linear discriminant obtained in the
LDA model used for the description of olefins 3a-s, 3u-z, and 3A-F.
Variable Raw coefficient Standardized coefficient
HOMO 9.549 3.176
LUMO -4.564 -1.216
Ca-Mul 865.7 6.167
C9-Mul 83.51 1.631
φ1 0.8260 1.664
φ2 -1.319 -3.620
d1 -84.28 -2.000
d2 32.63 2.630
d3 -3.254 -0.05056
d4 -6.801 -0.3888
Ca-HOMO 31.76 1.629
C9-HOMO -40.83 -1.979
Ca-LUMO 23.65 0.7734
C9-LUMO 154.1 2.684
Constant -194.9 -
It is interesting to note that, when LDA was performed by using a stepwise
forward variable selection, only 8 of the 14 variables were used to obtain a
statistically significant model (Wilks’ lambda = 0.0191). Moreover, the most
contributing variables were almost exactly the same as those that composed
the main PCs of the corresponding PCA, namely, the dihedral angle φ1, the
interatomic distances d2 and d4, and the Mulliken charges Ca-Mul and C9-Mul.
To verify the capability of the LDA model to predict the reactivity of new
compounds with singlet oxygen, the fluorenyl alkene 3t (central five-membered
ring) and the specially designed new olefin 3G (central seven-membered ring;
Figure 2.9) were projected onto the linear discriminant.
The fluorenyl-derived alkene 3t was predicted to be reactive with a raw
canonical score of 30.8; a particularly high value due to an almost completely
planar arrangement of the aromatic rings with respect to the plane defined by
the carbon-carbon double bond (φ1, φ1 = 159.8◦). As already mentioned in
Table 2.1, entry 14, when 3t was subjected to the photooxygenation conditions,
the corresponding 1,2-dioxetane 4t was isolated in 50% yield overall. On the
contrary, 5-dibenzosuberenone-derived alkene 3G was predicted to be unreactive
with a raw canonical score of -39.9, again a particularly low value, mainly due
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Figure 2.8: Canonical scores relative to the LDA model for alkenes 3a-s, 3u-z and
3A-F.
to its significantly smaller dihedral angles φ1 and φ2 (113.3◦) and to the greater
negative Mulliken charge on C9 (-0.165 versus -0.09 mean C9-Mul charge). When
subjected to the photooxygenation conditions, olefin 3G did not react and only
the starting material was observed in the reaction mixture.
Figure 2.9: Olefins selected to verify the capability of the model to predict reactivity
with singlet oxygen.
The experimental findings obtained for the supplementary alkenes 3t and 3G
validate the developed chemometric model, which is able to anticipate the outcome
of a photooxygenation reaction carried out on structurally different tetrasubstituted
olefins, as characterized by an adamantyl unit coupled to a tricyclic aromatic
scaffold (regardless of the nature of the central ring).
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2.3 Conclusion
A small library of more than 30 olefins of general structure 3 have been sub-
jected to photooxygenation, with the aim of synthesizing new dioxetane-based
thermochemiluminescent labels with optimized light emission efficiency and
CL temperature triggering. Among them, 20 starting olefins provided the corre-
sponding 1,2-dioxetanes, whereas no traces of product were observed with the
other members of the series. To anticipate the feasibility of the photooxygenation
step leading to new potentially thermochemiluminescent dioxetanes, we sought a
rationale. A complete DFT analysis of the transition states for the formation of all
dioxetanes was not possible for us, given the heavy and time-consuming compu-
tational effort required by the multiconfigurational treatment of both closedshell
and free-radical excited states at a rigorous level. Thus, we adopted a chemo-
metric approach by exploiting PCA and LDA of the structural and electronic
molecular descriptors obtained by DFT optimizations of olefins 3. This approach
allowed us to determine steric and electronic parameters that govern dioxetane
formation. Great interest in new thermochemilumiscent molecules, for exam-
ple, in bioanalytical assays, was the driving force of this study, which allowed
us to discover that fluorine atoms on the acridan system remarkably stabilized
1,2-dioxetanes when located in the 3- and/or 6-position (4h and 4i). On the other
hand, 2,7-difluorinated acridane dioxetane 4j showed a significantly enhanced
fluorescence quantum yield with respect to the unsubstituted dioxetane 4a. Our
investigations for the development of original and enhanced dioxetane-based TCL
labels are still ongoing. For instance, flavone- and coumarin-containing [see Ref.
249–259] derivatives 4H and 4I (Scheme 2.4) are of interest.
Scheme 2.4: Preliminary results concerning flavone- (4H) and coumarin-based (4I)
1,2-dioxetanes.
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Indeed, even if their synthesis still requires some optimization, 1,2-dioxetanes
4H and 4I have been isolated and characterized as TCL compounds. Unexpectedly
high values of the activation parameters for thermal decomposition were recorded
for flavone-derived 1,2-dioxetane 4H, which resulted in a remarkable calculated
halflife at 25◦C (more than 6000 years); this offers the opportunity of useful
applications in diagnostics and bioanalysis. On the other hand, coumarin-based
1,2-dioxetane 4I showed limited thermal stability. An analogous chemometric
approach will be reported in due course for flavones and coumarins once a
significant number of compounds has been synthesized.
2.4 Experimental Section
2.4.1 Representative procedure for the synthesis of alkenes 3
Under a nitrogen atmosphere, TiCl4 (1 M in dichloromethane, 6.1 equiv)
was added to a suspension of zinc powder (13.5 equiv) in anhydrous THF (8
mL/0.5 mmol of 1) at 0◦C, and the suspension was stirred for 10 min under
reflux. A solution of ketone 2 (1 equiv) and 2-adamantanone 1 (1 equiv) in dry
THF (2 mL/0.5 mmol of 1) was added dropwise over a period of 30 min. The
reaction mixture was heated at reflux for 45 min. Then, it was cooled to room
temperature, quenched with water, and extracted with AcOEt (3x10 mL). The
combined organic layers were dried over sodium sulfate and evaporated under
vacuum. The crude product was purified by flash chromatography on silica gel.
2.4.2 Representative procedure for the synthesis of 1,2-dioxetanes 4
Alkene 3 (16 equiv) and Methylene Blue (1 equiv) were dissolved in CH2Cl2
(1 mL/10 mg of alkene 3). The solution was cooled (usually at -20 ◦C) and
subjected to an oxygen atmosphere (1 atm, balloon). The solution was stirred at
the same temperature under irradiation by using a 500W halogen lamp equipped
with an UV cutoff filter (0.5% transmission at λ = 550 nm). Irradiation was
continued until the starting material disappeared (usually 2 h of irradiation), and
the conversion was monitored by 1H NMR spectroscopy. Product 4 was purified
by rapid filtration on a 5 mm layer of silica gel, by using cooled (-40◦C) CH2Cl2
as the eluent, and the filtered solution was evaporated under vacuum at 0◦C.
For further details about the synthesis and characterization of all the substrates
above-reported see the corresponding Supporting Information (Chapte 6).
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Developement of a molecular probe based on
TCL phenomenon
3.1 Introduction
In a previous work, Roda et al. have reported the development of a new class
of TCL organically modified silica nanoparticles (TCL-ORMOSIL NPs), doping
the nanometric system with different acridin-based 1,2-dioxetanes [see Ref. 109].
Despite the enhanced emission efficiency (due to the high number of dioxetanes
physically entrapped in the silica matrix), and the ease of (bio)funtionalization,
TCL-ORMOSIL NPs have showed a poor stability in water solution. In particular,
it was observed a loss in TCL signal caused by the slow degradation of acridin-
dioxetanes during the synthesis. A plausible explanation lies on the capacity of
amino groups (necessary for the bioconjugation of NPs) to catalyze the decom-
position of cyclic endoperoxides through both an electron transfer mechanism
or nucleofilic attack [see Ref. 260, 261]. Furthermore, TCL compounds inside
NPs have showed different activation parameters for thermal decomposition, in
comparison with those of solid state. In fact, shorther half-life times have been
observed for the TCL signal generating from nanometric system, suggesting that
silica matrix may promote the decomposition of the endoperoxide unit [see Ref.
262]. In addition to the disadvantages above-cited, silica nanoparticles normally
require a great effort during the designing step, since their tendency to aggregate
in aqueous solution and give non-specific binding [see Ref. 263, 264]. In fact,
a proper and case-specific fuctionalization of nanoparticles surface proves to be
necessary in order to keep the colloidal sunspension stable in time. Moreover, the
optimization of surface concentrations for both inert and active functional groups
ensure high selectivity, reducing the non-specific binding [see Ref. 265, 266].
Aiming to develop a robust, universal and easy-to-handle TCL-based im-
munoassay, we investigated the possibility to create a molecular probe through
the direct derivatization of a 1,2-dioxetane substrate with a bioactive portion. The
molecular structure for the designed TCL-probe (8) is depicted in Figure 3.1.
The molecular probe consists of three different portions: the thermochemi-
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Figure 3.1: Molecular structure of TCL probe.
luminescent substrate, the biomarker unit and a connecting spacer. We chose
the parent dioxetane 4a (see Chapter 2) as TCL unit since it has been exten-
sively studied by our group and it possess good TCL properties, in terms of low
decomposition temperature and high fluorescence quantum yield. Concerning
the bioactive unit, we decided to exploit the Biotin-Streptavidin interaction for
enzyme recognition, functionalizing the TCL substrate with Biotin (Bt). In fact,
although a moltitude of ligand-binder systems have been described in literature
[see Ref. 267], the affinity between the small molecule Biotin and Streptavidin (St)
is known to be one of the highest among the enzyme-substrate non-covalent inter-
actions, with a dissociation constant in the femtomolar range [see Ref. 268] and it
can resist to very harsh experimental conditions (i.e. changes in pH values, high
temperatures and so on). Furthermore, the numerous streptavidinated enzymes
commercially available, along with the low cost of biotinilation reagents, make
the use of Bt-St technology suitable for development of universal immunoassays.
Regarding the spacer unit, a six-carbon atoms chain was chosen to preserve the
Biotin-Streptavidin interaction, since the binding site is pocket buried about 9
Angstrom beneath the surface of Streptavidin [see Ref. 269].
3.2 Results and discussion
The synthetic strategy followed to obtain the molecular TCL-probe 8 is
depicted in Scheme 3.1. Briefly, compound 1 [see Ref. 110], reacts with 2-
adamantanone through a McMurry reductive coupling, giving the intermediate 2,
which then hydrolyzes under basic conditions to generate the free carboxylic acid
3. The condensation reaction between 3 and the mono-protected amine derivative
4 leads to the formation of compound 5. The latter undergoes a deprotection step,
generating the intermediate 6, followed by the conjugation with the biomarker
Biotin to produce the corresponding olefin 7. Lastly, the alkene precursor 7 reacts
with singlet oxygen under irradiation, giving the final product 8.
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Scheme 3.1: Synthetic pathway followed to obtain compound 8.
Before starting the synthesis of 8, we insured about the stability of the olefin
precursor 7 under oxidative conditions (typical of the photo-oxygenation step). In
fact, the tendency of Biotin to generate the corresponding sulfone and sulfoxide
byproducts in presence of oxidative species, has been reported in literature [see
Ref. 270]. The unwanted oxidation of Biotin could disrupt the interaction with
Streptavidin, making the TCL-probe unusable for immunoassay applications.
Thus, a known amount of Biotin was tested under photo-oxygenation experimental
conditions (O2 atmosphere and irradiation) [see Ref. 110], and both 1H NMR
and HPLC-MS analyses of the crude have confirmed the stability of the bioactive
moiety.
During the synthesis of compound 8 we faced a few difficulties that eventually
prompted us to change synthetic strategy. In fact, the partial degradation of some
intermediates along with solubility-related issues during the purification steps,
caused a drop-down in the overall yield obtained for compound 6. Following,
a brief description of the main problems encountered in each synthetic step is
provided:
Synthesis of compound 3: While compound 2 was obtained in high yield (
around 90%), is was not possible to isolate intermediate 3 from its byproducts. In
fact, both 1H NMR and HPLC-MS analyses of the crude have showed the presence
of several degradation products such as, 9(10)-acridone, 2-adamantanone and a
few other unidentified compounds. Although we did not investigate the cause
for degradation of 3, the long reaction times (around three days) and the harsh
experimental conditions might be responsible for the low stability of substrate 3.
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Synthesis of compound 4: As showed in Scheme 3.1, we chose the 1,6-
hexanediamine to connect the TCL moiety to the biomarker. Although the
mono-protection reaction occurred in high yield, it was not possible to completely
purify compound 4 from its precursor. In fact, after testing several experimen-
tal parameters for the flash chromatography (i.e. different eluition phases and
amount of silica), we were not able to separate 4 from the starting material
1,6-hexanediamine, which kept co-eluiting with the former.
Synthesis of compound 5: Condensation between 3 and the mono-protected
1,6-hexanediamine was carried out under the classical peptide coupling conditions,
using 1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-
carbenium hexafluorophosphate (COMU) as the coupling agent. COMU repre-
sents the third generation of uronium-type coupling reagent [see Ref. 271], and
it has been recognized as one of the most efficient, especially for solution-phase
peptide synthesis, since its by-products are water soluble, and thus, easy to re-
move. Although the coupling reaction showed high conversion of 3 to 5, the final
yield did not exceed 44%. In fact, the low solubility of 5 in almost all the organic
solvents tested during the extraction phase, prevent us to recover it quantitatively.
Synthesis of compound 6: The deprotection of 5 was carried out under extreme
acid conditions, and the product was purified through multiple liquid-liquid
extractions, using basic aqueous solution to deprotonate the quaternary ammonium
cation, making it more organic-phase soluble. However, we were not able to
isolate 6 from the byproducts already formed in the previous step.
Following the synthetic procedure described in Scheme 3.1, it was not possible
to obtain compound 6 with overall yield higher than 30%. This result can be
ascribed to the low stability of compound 3 and the solubility-related problems
for the further intermediates. Thus, we designed an alternative synthetic strategy
depicted in Scheme 3.2.
In the second strategy, we avoided the formation of 3 (unstable), conducting
the hydrolysis of the ester unit upon the ketone 1, rather than the olefin 2. By this
way, we were able to obtain 9 quantitatively, shortening the reaction time from
three days down to two hours. Thus, we moved forward linking the acridin moiety
to the spacer hexanediamine to obtain compound 10 and, after a deprotection step,
intermediate 11. Then, a McMurry reaction between 2-adamantanone and the
already functionalized acridin portion yielded intermediate 6. From this point on,
the synthetic pathway was identical to the previous one.
Following the second strategy, we were not able to raise the yield for com-
pound 6 above 45%. In fact, some of the new intermediates still showed a very
low solubility in almost all the organic solvents (during the purification step
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through liquid-liquid extraction), preventing us to further optimize the synthetic
pathway. However, the second strategy was chosen as the best one, due to the
remarkable shorter reaction time and higher yield for the hydrolysis step.
Scheme 3.2: Alternative synthetic pathway followed to obtain compound 8.
After many synthetic efforts, we finally conducted the photo-oxygenation
of precursor 7 to give the final product 8. Following the classical procedure
[see Ref. 111] we noticed a slowing down in the kinetic of oxygen addition,
confirmed by 1H NMR analysis of crude. In fact, the NMR spectrum acquired
after 5 hours of irradiation, showed a very low conversion of starting material
(SM) into 8. We explained this result considering the low solubility of precursor
7 in the reaction environment (CH2Cl2). Thus, we added a few drops of methanol
to better solubilize the starting material, and acquired the 1H NMR after 5 hours
of further irradiation. The second NMR spectrum showed the presence of several
byproducts, which were identified through HPLC-MS analysis. In particular,
after 10 hours of irradiation we found the crude to be constituted by a mixture
of ketone 12, its sulfoxide derivative (13) and the oxidation by-products of 7
and 8 (compound 14 and 15 respectively) (see Figure 3.2). The oxidation of
Biotin moiety may be attributed to the enhanced solubility of 7 after methanol
addition. Furthermore, this hypothesis might explain why we did not see any
suolfoxide derivative during the preliminary test (Biotin dissolved in CH2Cl2
under irradiation), since the poor solubility of Biotin in organic solvents.
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Figure 3.2: Molecular structures of byproducts obtained after the photo-oxygenation of
7.
3.3 Conclusion
We investigated the development of a TCL-based molecular probe, link-
ing the parent acridin 1,2-dioxetane 4a to the biomarker Biotin through a 1,6-
hexanediamine as spacer. Aiming to synthesize of product 8 in high yield, we
explored two different synthetic approaches (see Scheme 3.1 and Scheme 3.2).
The main limitations were represented by the poor solubility of almost all the
intermediates in organic solvents. This prevented us to quantitatively recover
each compound during the purification step (through a liquid-liquid extraction
procedure). Moreover, we found product 8 to be unstable under the experimental
conditions typical for the photo-oxygenation step. In fact, we confirmed by 1H
NMR and HPLC-MS analyses the presence of both the correspoding degradation
products (2-adamantanone and ketone 12) and the sulfoxide derivatives of 7, 8
and 12 (see Figure 3.2). For the above-cited reasons, we decided to abandon
further investigations upon the molecular TCL probe 8.
More details about the experimental procedures followed for the synthesis of
compounds 1-11 can be found in the Supporting Information (see Chapter 7).
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Yellow-emitting thermochemiluminescent
Semiconducting Polymer Dots fuctionalized with
Streptavidin for immunoassay applications
4.1 Introduction
A definition for ”biosensor” was introduced by IUPAC in 1992, describing it
as an analytical device able to detect chemical compounds usually by electrical,
thermal or optical signals [see Ref. 272]. The first biosensor was proposed by
Clark and Lyons in 1962, who presented an electrochemical system for glucose
measuring in biological samples [see Ref. 273]. Since then, thousands of papers
have been published on the subject, describing an astonishing variety of biosen-
sors for many types of application: from quality-control in food industry and
environmental monitoring to clinical analysis, drug discovery and defence. In the
last 40 years, the world market for biosensors has witnessed an apparently endless
exponential growth, and predictions for the future estimate a turnover higher than
US$15 billions [see Ref. 274].
Classification of biosensor types can be made considering the different tras-
duction principle behind the generation of analytical signal, along with the specific
analyte determination mechanism. The response can be revealed either as an
optical (fluorescence, color-changing etc.) or (electro)chemical signal, and the
detection can rely on enzyme-substrate recognition, DNA-single strand pairing
and so on [see Ref. 275, 276].
Regardless the specific technology which is based on, a good biosensor must
possess some common charactheristics, in order to be suitable for (bio)analytical
applications. It should show high sensitivity and linearity within the operational
concentrations range, it should be selective towards one or a few target molecules
and it should display both a low limit of detection (LOD) and an almost absent
background signal [see Ref. 277]. From a practical perspective, a worthy biosensor
need to be both affordable and easy-to-handle, limiting the dependence of analysis
success on the operator expertise. Furthermore, it should guarantee short analysis
times along with automation compatibility, required for high-troughput screening.
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The majority of biosensors, currently employed worldwide both in research
laboratories and industries, is based on optical detection methods. In particular,
fluorescence-based (FL) sensors have been used for detection of small organic
molecules, enzymes and gas particles [see Ref. 278], in clinical analysis, diagnos-
tic and environmental control [see Ref. 279, 280]. Furthermore, a moltitude of
homogeneous and heterogeneous FL-immunoassays have been developed so far
[see Ref. 281, 282], exploiting FL-related phenomena such as light-polarization
[see Ref. 283], quenching effect and Flörster Resonance Energy Transfer (FRET)
process [see Ref. 284]. Encapsulation of fluorescent dyes within nanometric
biocompatible systems led to the realization of FL-sensors suitable for imaging
applications. Thus, silica nanoparticles [see Ref. 285], hydrogels, carbond dots,
semiconductive polymers etc., have represented a common matrix for FL-sensors
in bioimaging experiments [see Ref. 286]. Recent studies on FL sensors, have
proposed their application in cell-sorting process [see Ref. 287] and lateral flow
immunochromatography [see Ref. 288]. Despite its popularity, FL-based de-
tection method still suffers of several practical limitations, observable mainly
in biological fluids analysis [see Ref. 289]. The scattering of light as well as
self-quenching phenomena due to aggregation in solution [see Ref. 290], can
affect the outcome fluorescent signal. Besides, the presence of endogenous fluo-
rophores can interfere with either the absorption (inner filter effect) or emission
step. Improvements in FL sensors have been achieved through ”Time-resolved”
fluorescence technique, which relies on the long-lived luminescence exhibited by
lanthanide complexes to reduce background intereferences [see Ref. 291–293].
Alongside FL-based systems, a widespread class of luminescent sensors
involve a chemical reaction for the light generation step. Chemiluminescence
(CL) methods have been used for organic/inorganic molecules sensing [see Ref.
294], in determination of volatile species [see Ref. 295] and for bio-active agents
measurement. In particular, Chemiluminescent Immunoassay (CLIA) technique
have represented the direct descendent of Radio Immunoassay (RIA) method
[see Ref. 296], and CL-biosensors have gradually replaced radioactive probes
in biological and clinical analyses [see Ref. 297, 298]. Well-established CL
biosensors utilize Luminol or Acridinium salts as CL substrates either for direct
or indirect labelling, to reach very low limit of detection (down to attomoles
of analyte). However, the CL efficiency for both systems do not exceed a few
percentage points, due to the poor fluorescence of Luminol and derivatives or
the low CL reaction yield for Acridinium salts in neutral or basic solutions [see
Ref. 299]. The wide dynamic range, the high sensitivity (further increased by
the use of CL enhancers [see Ref. 300]) and specifity towards the target analyte
and the good compatibility with almost all the immunology assay protocols, have
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made CL-based sensors particularly suitable for automation [see Ref. 301] and
integration in on-site testing devices and microfluidic platforms [see Ref. 302,
303]. Although the many advantages of CLIA, the high cost and complexity of
CL- apparatus along with the not-always linear and easy-to-understand analytical
response still represent important limitations in CL-biosensors applicability.
Similarly to CL systems, Bioluminescent (BL) sensors exploit the emission
signal generated by an enzyme-catalized chemical reaction for analyte measuring.
BL-based methods have been largely employed in biochemistry and biotech-
nology fields to better understand the molecular mechanism behind a specific
physiological process [see Ref. 304]. Applications of BL phenomenum can be
found in assay for microbial viability [see Ref. 305–307] as well as bacterial
detection [see Ref. 308]. Furthermore, scientific literature is disseminated of
examples concerning in vivo experiments which rely on BL process for viral
pathogenesis investigation, tumor growth monitoring and studies about the inter-
action between cellular transmembrane receptors and new potential drugs [see
Ref. 309, 310]. Although many research groups have been trying to improve
the properties of both enzymes [see Ref. 311–314] and substrates [see Ref. 315]
involved in the biochemical reaction, BL-based detection techniques still present
drawbacks related to difficulty of method standardization, poor stability and
oxygen-sensitivity of the enzymatic catalyst and a limited number of Luciferase
and Luciferin commercially available [see Ref. 316].
Another main category of sensors for (bio)analyses exploits the Electro-
Chemiluinescent (ECL) phenomenum as trasduction principle [see Ref. 317,
318]. Electrogenerated chemiluminescence have represented a powerful analyt-
ical tool for both in vitro and in vivo applications. In fact, It has been used in
immuno- and DNA-assays development [see Ref. 319], for detection of peptides
and nucleic acids, pathogenic bacterial, single cells etc. [see Ref. 320, 321]. The
first class of ECL-based sensors used to employ polycyclic aromatic hydrocarbons
(PAHs) as electro-active species [see Ref. 322]. Although the very interesting
redox properties of PAHs, many of these organic molecules presented low sol-
ubility in aqueous solution along with a poor stability in presence of molecular
oxygen. Thus, a well-estabished class of ECL biosensors have been utilizing the
Ruthenium complex Ru(bpy)3
2+ as emitting specie, exploiting its electrochemical
and photopysical properties for high-sensitive analytical measuring [see Ref. 323,
324]. Further improvements of ECL-based tecnique have been achieved exploring
new electro-active luminescent nanomaterials such as semiconductor quantum
dots (QDs), metal nanocluster (MCs) and upconversion nanoparticles (UCNPs)
[see Ref. 325]. Despite the high sensitivity and robustness of electrochemilumi-
nescent biosensors, the applicability of ECL methods is still limited by the often
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prohibitive cost and complexity of apparatus [see Ref. 326].
In recent years, semiconducting polymer dots (Pdots) have affirmed them-
selves as a new class of highly fluorescent nanomaterials, which have found
application especially in bioimaging. Pdots-based probes have been successfully
used for in vivo dynamic monitoring of small molecules such as HNO and HClO
[see Ref. 327–329], in cell sorting [see Ref. 330] and for high-resolution flu-
orescence imaging [see Ref. 331–333]. In comparison with classical organic
fluorophores, Pdots are characterized by some remarkable photophysical proper-
ties which make them particularly suitable for biological and medical applications
[see Ref. 334, 335]. For instance, they possess enhanced photostability, high
fluorescence quantum yield, fast radiative rates and very narrow band emission.
Moreover, by changing the polymer matrix, it is possible to easily tune the wave-
length of emitted light, thus creating a wide panel of Pdots-based sensors able
to cover the entire visible spectrum (from blue light to NIR emission) [see Ref.
336–341].
Thermochemiluminescence (TCL) technique has been recently re-proposed
by our group, as innovative detection method for immunoassay applications [see
Ref. 107–109]. TCL process consists in the light production which occurs when a
thermally unstable substrate (tipically 1,2-dioxetane derivatives) is heated above
a threshold temperature. Indeed, the energy released during the thermal decom-
position of the endoperoxide unit [see Ref. 2] is high enough to bring one of the
two fragments to its electronically excited state, from which it can relax emitting
a photon (see Chapter 1). TCL-based methods benefit from several advantages
particularly related to the reagentless nature of the process itself, such as short
times of analyses and simplicity of the apparatus employed. Furthermore, the
absence of an excitation source strongly reduce the matrix effect (due to endoge-
nous fluorescent species or light scattering), allowing to reach high sensitivity and
reproducibility. In addition, by changing the molecular structure of 1,2-dioxetane
it is possible to finely tune the TCL properties in terms of higher fluorescence
quantum yiled and lower decomposition temperatures [see Ref. 110, 111].
Herein, we describe, for the first time, the synsthesis of a TCL-based Pdot
probe as innovative thermoresponsive biosensor for immunoassay applications.
Following a nanoscale co-precipitation technique [see REf. 342] we obtained
cyano-polyphenylene vinylene (CN-PPV)-based Pdots doped with acridin 1,2-
dioxetane derivative 1 (Scheme 4.1). The latter can undergo a fast thermal
decomposition at temperatures above 100 ◦C generating two fragments, one of
which (ketone 2) in its electronically excited state. Exploiting a FRET mechanism
occuring between the 1,2-dioxetane inside the nanoparticles (more precisely
the ketone derivative) and the surrounding polymer matrix (Scheme 4.1), these
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nanoprobes are able to emit yellow light (550 nm wavelength) after heating the
solution above the threshold temperature. Furthermore, the overall efficiency of
light generation has been enhanced thanks to the higher fluorescence quantum
yield (ΦF ) of CN-PPV [60%, see Ref. 343], in comparison with ΦF of ketone 2
[11%, see Ref. 107]. Besides, life-time measuraments for the excited ketone 2
have confirmed an efficiency for the FRET mechanism of 90%.
Scheme 4.1: Synthesis of 1,2-dioxetane 1-doped semiconductive polymer dots (TCL-
Pdots) through the nanoprecipitation method.
The synthetic procedure for TCL-Pdots was optimized in order to maximize
both the load of 1,2-dioxetane inside the NPs (i.e. the TCL signal) and the nanopar-
ticles size. Furthermore, TCL-Pdots have been conjugated with the biomarker
Streptavidin to make them suitable for detection of biotinylated analytical species.
The analysis of TCL-Pdots stability at 4 ◦C (storage conditions) and 37 ◦C (typical
temperature for the immunoassay incubation step) was assesed, revealing a loss
in TCL signal lower than 30 or 20 % after 20 days or 4 hours respectively. The
applicability of our nanoprobes as labelling agent was tested in a proof-of-concept
non-competitive immunoassay for detection of Immunoglobuline G (IgG), which
has shown a TCL signal proportional to the IgG concentration and a limit of
detection (LOD) for the enzyme in the nanomolar range.
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4.2 Results and discussion
4.2.1 Preparation of TCL-Pdots nanoprobes
The 1,2-dioxetane-doped Pdots were obtained following a nanoprecipitation
method (Scheme 4.1) [see Ref. 342] where CN-PPV, substrate 1 and carboxylic
acid functionalized polystyrene (PS-COOH) were blended together in anhydrous
THF and then quickly injected into Milli-Q water under sonication. We obtained
a quite monodispersed nanometric particles with an avarage diameter of 34 nm,
as calculated from dynamic light scattering (DLS) analysis . Differently from a
previously reported precedure [see Ref. 344], we chose PS-COOH polymer, rather
than PS-PEG-COOH, to cover the particles surface with carboxylic acid units. The
absence of the hydrophilic polyethylene glycol block should be able to limit the
swelling of Pdots during the heating phase, thus ensuring more temperature-stable
nanoparticles and preventing the potential leaking of 1 outiside the nanoshell at
high temperatures [see Ref. 345–347]. First attempts to make Pdots have shown a
dependence of both the particle size and the amount of entrapped 1,2-dioxetane
from the experimental conditions used in the nanoprecipitation step.
Thus, aiming at the optimization of Pdots dimension as well as their loading
capacity of 1, we conducted a stepwise screening of the three variables selected:
volume of THF injected, percentage of PS-COOH and amount of 1,2-dioxetane.
In particular, we investigated changes in the hydrodinamic diameter (by DLS
analyses) and TCL emission signal (using a CCD camera) of Pdots for each
optimization step (Table 4.1).
As reported in Table 4.1, the screening of both THF volumes and PS-COOH
% (v/v) have shown a similar trend in diameter changing, with an initial increase
in Pdots size and a subsequent reduction in particles dimensions for THF volume
higher than 9 mL and PS-COOH % (v/v) greater than 7 %. On the other hand, only
a slight increase in TCL signal was observed for bigger nanoparticles, suggesting
that the loading capacity of 1,2-dioxetane 1 might not be strongly influenced by
Pdots size. An opposite tendency in the variation of particles size was observed
during the screening of compound 1 % (v/v). Indeed, the diameter of Pdots was,
generally, inversely proportional to the amount of doping substrate. With the goal
to maximize the loading of 1,2-dioxetane 1, but still keeping particles dimensions
to realatively low values, we chose the best compromise among the variables
investigated, namely 7 mL of THF injected, 7.1 and 3.6 % (v/v) of PS-COOH
and 1,2-dioxetane respectively. The selected experimental conditions allowed us
to obtaine quite monodisperse nanoparticles with an avarage diameter of 42 nm,
as confirmed by both DLS experiments and TEM images (Figure 4.1 a and b,
respectively).
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Table 4.1: Diameter and loading capacity of Pdots obtained in each step of the optimiza-
tion screening.
Step I: screening of THF volume injected, keeping costant the amount
of compound 1, CN-PPV and PS-COOH.
Entry Volume of THF (mL) Diameter (nm) TCL signal ± SD (u.a)a,b
1 1 16,2 415,44 ± 141,70
2 3 13,1 461,82 ± 37,80
3 5 12,7 309,54 ± 20,14
4 7 21,1 522,13 ± 37,71
5 8 40,5 659,44 ± 54,88
6 9 52,3 610,29 ± 9,92
7 10 33,8 621,48 ± 4,32
Step II: screening of PS-COOH % (v/v), keeping costant the volume of
THF (7 mL) and the amount of compound 1 and CN-PPV.
Entry PS-COOH % (v/v) Diameter (nm) TCL signal (u.a)a
1 0.7 21.3 778,13 ± 43,62
2 1.4 21.1 558,73 ± 68,78
3 4.3 25.0 834,3 ± 8,34
4 7.1 32.4 1103,17 ± 50,4
5 10.0 20.2 972,94 ± 41,3
Step III: screening of compound 1 % (v/v), keeping costant
the volume of THF (7 mL) and the amount of PS-COOH and CN-PPV.
Entry Compound 1 % (v/v) Diameter (nm) TCL signal (u.a)a
1 1.4 43.5 829,46 ± 43,3
2 3.6 42.0 1103,17 ± 50,4
3 5.7 28.5 1046,78 ± 52,18
4 8.6 36.5 1086,1 ± 51,67
aTCL signal was measured through a CCD camera, acquiring images for 30 min at 110◦C.bTCL
emission as mean ± SD of three independent measurements.
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Figure 4.1: a) Dynamic light scattering analysis and b) TEM image of TCL-Pdots.
Then, TCL-Pdots were bioconjugated to Streptavidin (SA), following a pre-
viously reported procedure [see Ref. 339]. In particular, we performed a EDC-
catalyzed codensation reaction between the carboxylic units of PS-COOH chains
and amino groups of SA, to make a strong amide bond. In order to remove all the
free enzyme as well as EDC byproducts, TCL-Pdots-SA were filtered with a 100
Da cutoff centrifugal membrane first, then purified by size exclusion chromatog-
raphy. The absence of 1,2-dioxetane absorption in the UV-vis of filtrate, along
with the TCL emission from Pdots-SA after chhromatography (see Figure 8.1 of
Supporting Information) confirmed the successfull encapsulation of 1 inside the
polymer nanoparticles.
4.2.2 TCL-emission and FRET experiments
To the best of our knowledge, Pdots have been largely used either as direct
fluorescent sensors or as donor species in organic dye-coupled systems [see Ref.
348]. Here, we took advantage of the excellent light-harvesting ability of CN-
PPV to collect the light produced by decomposition of 1,2-dioxetane within the
polymeric nanoshell. Thus, the nanoparticle did not represent only a water-soluble
carrier for 1, but it actively participated in the light enhancement process.
Considering the extended overlap between the emission of dioxetane 1 (i.e.
ketone 2, which is the electronically excited fragment generated after thermal
decomposition of 1) and the absorption of CN-PPV-based Pdots (see Figure 8.2
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Figure 4.2: a) Lifetime measurements showing the fluorescence dacay of ketone 2 (red
line) and 2 in presence of quencher CN-PPV (black line); b) TCL emission spectrum for
a solution of dioxetane 1 and CN-PPV polymer in THF.
of Supporting Information), we were expecting 1,2-dioxetane 1 to be able to
efficently transfer its energy to the polymer chains through a Förster resonance
energy transfer. Therefore, we performed fluorescence life-time measurements of
nanoparticles containing either ketone 2 alone or blended with CN-PPV to esti-
mate the efficiency of FRET mechanism. Specifically, we conjugated compound
2 with amino-functionalized polystyrene (PS-NH2), and then, we synthesized two
different types of NPs according to the above-reported procedure (see Supporting
Information), injecting PS-NH2-2 in H2O with or without CN-PPV polymer.
The analysis of emission dacays (Figure 4.2 a) has shown a remarkable
decrease for the lifetime of excited ketone 2 in presence of CN-PPV. In fact, for
nanoparticles containing only acridanone 2 we measured a lifetime of 12.9 ns (τ0),
which droped down to 1.3 ns (τ1) when the semiconductive polymer was blended
together. Using the equation 4.1 [see Ref. 349], we calculated an efficiency for
the quanching process (φFRET ) of 90%.
φFRET = 1− τ1
τ0
(4.1)
Although the high efficiency of the FRET process, we noticed the fluorescence
of CN-PPV to be interestingly dependent on the temperature, in terms of both
the intensity and position of emission maximum (see Figure 8.5 of Supporting
Information). Raising the temperature from 25 to 110◦C (typically used during
TCL signal acquisition), we observed a decrease in emission intensity of about
45% along with a shift of λmax towards shorter wavelengths (from 600 to 550
nm). Assuming the same percentage decrease for φF of CN-PPV, Pdots system
still represented a valid enhancer of light emission, ensuring a TCL signal about
three times higher than 1,2-dioxetane 1 itself.
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The occurrence of FRET mechanism was further confirmed by TCL emission
experiment, in which compound 1 was thermally decomposed in presence of
CN-PPV polymer and the emission spectrum was recorded. We dissolved both
1,2-dioxetane and semiconductive polymer together in THF first, then we raised
the temperature up to 110 ◦C and started acquiring the emission. We did not
analyze a solution of TCL-Pdots directly because it was not possible to let the
solvent evaporate completely within the acquisition time. On the other hand, the
high temperature ensured a quick evaporation of THF, allowing us to observe the
TCL emission from a dry state sample, which is what we believe might be the
actual system during TCL signal acquisitions. As shown in Figure 4.2 b, heating
a solution of 1,2-dioxetane 1 and CN-PPV polymer above 100 ◦C generated a
strong emission at 550 nm, ascribing to the excited polymer chains against a poor
signal from ketone 2.
4.2.3 Activation parameters of 1 and TCL-Pdots-SA stability
The thermal decomposition of 1,2-dioxetane substrates is known to follow
a fist-order kinetic and it can be analyzed according to a standard Arrhenius
equation 8.1, to evaluate the activation parameters of the TCL reaction itself. k
represents the kinetic constant while A and Ea are the preexponential factor and
the activation energy, respectively. T represents the temperature in Kelvin and R
the gas constant.
k = Ae−
Ea
RT (4.2)
In a previous study addressed to the encapsulation of acridin-based 1,2-
dioxetanes inside silica particles [see Ref. 107, 109, 110], we noticed a quite
strong dependence of both the activation energy (Ea) and preexponential coeffi-
cient (A) of 1 from the surrounding environment. Thus, we investigated which
effect the polymeric shell of NPs might have upon the thermal decomposition of
1,2-dioxetane substrate. By acquiring the emission decay at different temperatures,
we obtained the kinetic constants k (i.e. the inverse of the decay time in seconds)
of TCL process and then, we calculated both Ea and lnA of 1 from the Arrhenius
plot (see Figure 4.3 a).
We found the Ea and lnA of substrate 1 to be 21.12 ± 2.4 kcal mol−1 K−1
and 21.42 ± 3.11 respectively, which were lower than the activation parameters
of 1,2-dioxetane 1 in its dry state [see Ref. 111]. However, using these results to
extrapolate the life-time of TCL substrate at different temperatures, we calculated
a remarkable delay in thermal decomposition of 1 occuring for high values of
T (◦C), which was confirmed by kinetic experiments. For instance, as shown in
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Figure 4.3 b, extintion of TCL signal at 110 ◦C fully occurred in a period of time
longer than 30 minutes, suggesting a shielding effect of the polymeric matrix
towards the increase in temperature.
Figure 4.3: a) Arrhenius plot obtained from thermal decomposition studies of dioxetane
1, displaying the logarithm of kinetic constants at different temperatures against the
inverse of temperature; b) TCL emission decay of substrate 1, occurring at 110 ◦C; c)
TCL signal acquired to assess the stability of TCL-Pdots-SA over time, showing the
emission of nanoparticles solution kept at 4 ◦C (solid line) or 37 ◦C (dashed line).
In order to be suitable for immunoassay applications, TCL-Pdots-SA should
demonstrate a good stability throughout all the operational steps. We therefore
monitored the TCL signal over the storage conditions (in refrigerator at 4 ◦C)
as well as during incubation at 37 ◦C. In Figure 4.3 c, we show the plots TCL
signal vs time of different aliquots of NP solutions kept at 4 (solid line) or 37 ◦C
(dashed line). It can be clearly seen how TCL-Pdots-SA were particularly stable
over time, giving a loss in TCL signal lower than 30%, at storage conditions, or
20% at 4 ◦C. Comparing these results with the stability of a previously reported
silica-based TCL nanoparticles [see Ref. 109], we concluded that 1,2-dioxetane
1 was much more stable when encapsulated into a polymeric matrix rather than
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in presence of silica atoms. This evidence could be explained considering the
high light-harvesting capacity of CN-PPV-based Pdots, which might act as filter
for the external ambient light. In fact, it has been already demonstrated how
benzoate-based 1,2-dioxetanes, bearing an aromatic ring as chromophore unit,
can undergo a light-induced decomposition under normal room illumination [see
Ref. 350]. This photo-catalyzed degradation would be even more evident for
compound 1, due to the higher molar extinction coefficient of acridin unit. We
therefore hypothesize that polymeric shell could prevent substrate 1 to absorb the
light from the outside very efficiently.
4.2.4 Development of a TCL-Pdot-SA based immunoassay for IgG
detection
The applicability of TCL-Pdots-SA was tested in a proof-of-concept im-
munoassay for determination of Immunoglobuline G (IgG) (Scheme 4.2 a). In
particular, we combined the biofunctionalized magnetic bead (MB) technology
with TCL-based detection method to build up a non-competitive sandwich-type
assay for detection of Biotinylated targets (Scheme 4.2a). In details, equal vol-
umes of Anti-IgG magnetic beads (Anti-IgG MBs) were incubated with a solution
of Biotinylated IgG (Biotin-IgG) at different concentrations. After the washing
steps, same volumes of Streptavidinated TCL nanoprobes were added to the
solutions to selectively interact only with the bounded Biotin-IgG. An additional
washing step followed by eluition of Pdots from MBs allowed us to effectively
recover TCL-Pdots-SA/Biotin-IgG complex in basic aqueous solutions, which
were analyzed by a CCD camera in a classical TCL experiment. The entire
immunoassay analysis was performed in less than 5 hours, which is a quite short
time, in comparison with classical CL- or BL-based assays.
The sandwich-like immunossay developed for detection of IgG has shown
a good sensibility and a TCL signal proportional to the analyte concentration
(Scheme 4.2 b) in the nanomolar range. Furthermore, although it was just a
proof of the applicability of TCL-Pdots-SA nanoprobes as labeling agents in
(bio)analyses, the TCL immunoassay allowed us to reach a quite low limit of
detection (LOD), namely 13 nM of Biotin-IgG.
4.2.5 Conclusion
Herein, we described the synthesis of the first thermochemiluminescent Pdot-
based (TCL-Pdots-SA) nanoprobe suitable for immunoassay applications. Fol-
lowing a nanoprecipitation method, we easily obtained quite monodisperse TCL-
Pdots, employing CN-PPV as the polymer matrix and 1,2-dioxetane 1 as TCL
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Scheme 4.2: a) Representation of the proof-of-concept non-competitive sandwich-
type immunoassay for detection of IgG, b) Calibration curve obtained from the TCL-
Pdots based immunoassay. TCL signal was calculated as mean of three independent
measurements
substrate. The NPs were successfully functionalized with Streptavidin to gen-
erate TCL nanolabels specific for Biotinylated-target detection. Furthermore,
TCL-Pdots-SA have shown a remarkable stability over time, giving a minimal
loss in TCL signal under storage conditions as well as during the immunoassay
incubation phase. Exploiting a highly efficient (φFRET = 90%) FRET mechanism
occurring between dioxetane 1 and the surrounding polymer matrix, we were able
to shift the emission of TCL substrates from blue to yellow wavelengths. Besides,
TCL signal from Pdots was further amplified thanks to the higher fluorescence of
CN-PPV polymer. Lastly, we tested our TCL-nanoprobes in a proof-of-concept
non-competitive immunoassay for detection of IgG, which showed a good sensibil-
ity in the nanomolar range and a LOD for IgG of about 10 nM. We firmly believe
TCL-Pdots based systems to represent a new valid alternative to the classical
luminescent probes used so far in (bio)analytical analyses. In fact, combining the
advantages of Pdots (i.e. high φF and light-harvesting capacity, biocompatibility,
tunability etc.) with the inherent charactheristics of TCL-based detection methods
(no further reagents required for luminescent reaction, thermally-triggered light
generation etc.) a broad panel of ultrabright TCL nanoprobes could be designed
for development of high sensitive ultra-fast immunoassays.
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Chapter5
Realization of a portable device for
(bio)analytical analyses, combining the
smartphone technology with TCL-based detection
methods
5.1 Introduction
In recent years, smartphone technologies have been gaining several attentions
by the scientific community, expecially among researchers actively involved in
development of new (bio)analytical methods suitable for implementation in Point-
of-Care (POC) test [see Ref. 351–357]. In fact, the inherent characteristics of a
smartphone-based detection methodology perfectly match some crucial require-
ments that a robust and user-friendly diagnostic device should posses for POC
applications, namely a reduced dimensions and weight of detector (smartphone’s
camera) and autonomous power supply system (phone’s battery) which make
it portable and easy-to-handle, even by unskilled operators. Furthermore, the
increasing computing capabilities of latest smartphones, the multitude of built-in
applications (apps) available and the possibility to quickly diffuse a lot of data
into the worldwide network through direct internet connection, have made smarth-
phones almost self-sufficient in development of analytical portable devices. In
principle, using a smartphone-based detection method it can be possible to acquire
the analytical signal in situ, to perform data analyses and to communicate the
results to a specialized laboratory or a physician all at once, for almost real-time
diagnosis.
Herein, we describe the realization of an home-made portable device to
combine TCL-based detection techniques with smartphone technology. All the
different items constituting the apparatus (Figure 5.1) have been fabricated ex-
ploiting a 3D printing process [see Ref. 358] and acrylonitrile-butadiene-styrene
(ABS) as starting material. The device was tailored to the 41-megapixel camera
of a Nokia Lumia 1020 (used as detector) and 1,2-dioxetane 1 was chosen as
TCL substrate because of its good TCL stability and high fluorescence quantum
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Figure 5.1: Different 3D-printed items which constitute the TCL-based portable device.
yield [see Ref. 111]. Preliminary experiments have been conducted to evaluate
the performances of our portable TCL-based device for future immunoassay
applications. In particular, we obtained a calibration curve for thermal decom-
position of 1, which has shown a good linearity of TCL signal along with quite
low limit of detections. In addition, we tested the feasibility of FRET mechanism
occurring between our TCL substrate and two different energy acceptors, in order
to modulate the emission signal towards longer wavelengths.
5.2 Materials and Methods
5.2.1 Device fabrication
The analytical device (Figure 5.1) was designed using an open-source soft-
ware for 3D images (Schetckup 2016) first, then it was easily obtained employing
a low-cost commercial 3D printer (Replicator 2X Desktop 3D Printer, Maker-
Bot Industries, New York, NY). The project files were exported as .stl les and
MakerWare v.2.4 so ware, an algorithm that slices digital into thin layers for 3D
printing, was used to define printing options and settings. As shown in Figure 5.1,
the device consists of three main components:
• a disposable analytical cartridge, in which a defined area (0.6 x 0.4 cm)
for sample loading was created exploiting the wax printing method [see
Ref. 359]. Specifically, the rectangular-shape region for solution spotting
(white region) was obtained through a negative printing approach, injecting
a wax-based solid ink all around the selected area and heating the paper
cartridge up to 120◦C for a few minutes, in order to let the wax ink penetrate
in between cellulose fibers. The surrounding hydrophobic walls, thus, can
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prevent the spotted solutions from leaking out during acquisition of TCL
emission.
• a cubic-like dark box (2 x 2 x 1.5 cm), comprising both a 0.2 cm thick
channel, for cartridge insertion and holding, and a mini-heater element (0.8
x 1.2 cm) for TCL signal generation. The latter was obtained encasing a
serpentine nickel/chrome thin-film resistance between two kapton layers.
Besides, the dark box is encapsulate within an additional round-shape unit
to better fit the smartphone adapter. A USB wire and a on-off type switch
were used to connect the mini-heater to the power supply, represented by a
common portable power bank.
• an external smartphone adapter, specific for Nokia Lumia 1020 model,
required for the correct positioning of sample under the phone’s camera.
Moreover, the adapter includes a plano-convex plastic lens (diameter 0.6
cm, focus 0.12 cm), which focuses the image of the analyzed area directly
onto the camera’s sensor.
5.2.2 Nokia Lumia 1020 for image capturing and processing
We chose the Nokia Lumia 1020, as smartphone to be integrated in our
portable device, since it posseses a 41-mexapixel camera which can ensure out-
standing high-resolution images acquisition. Moreover, the 1020’s dual-core
Snapdragon processor and 2GB of RAM alllows to both capture and process
pictures in very short times. As for the majority of shamrtphones, Lumia 1020’s
camera exploits the complementary metal-oxide semiconductor (CMOS) technol-
ogy [see Ref. 360].
A CMOS circuit consists of an array of identical photo sensors organized
within a grid. Once the light reaches the photo sensor, it is transformed into a
digital signal [see Ref. 361] which is proportonial to the incident light intensity.
A three colour (red, green and blue) filter array (CFA) with a Bayer pattern is
placed over the CMOS grid [see Ref. 360], causing each photo sensor to detect
only one colour band of the UV-vis spectrum. Thus, images are represented by
the sum of distinct signals according to a RGB pattern.
In order to decide what delay in time acquisition would have ensured the
highest intensity for TCL signal, we followed the thermal decomposition of
compound 1 over time (5 µL of 1 4 mM in ACN), acquiring 10s images through
a CCD camera (see Figure 5.2b). To obtain the calibration curve (Figure 5.3),
10 µL of 1 in ACN at different concentrations (ranging from 21 µM to 2 mM )
were spotted onto the paper-based cartridge, and the solutions were heated up
using the embedded mini-heater element. After a 90s time delay, we took a photo
65
CHAPTER 5. REALIZATION OF A PORTABLE DEVICE FOR (BIO)ANALYTICAL ANALYSES, COMBINING THE
SMARTPHONE TECHNOLOGY WITH TCL-BASED DETECTION METHODS
using the Nokia Lumia’s camera with the following default parameters for image
acquisition: a 4s shutter opening, ISO value of 4000 and brightnesse of 14. The
on-paper FRET experiments (Figure 5.4 a) were performed spotting a solution
of 1 (10 µL, 0.1 mM) together with 9,10-Bis(phenylethynyl)anthracene (BPEA,
10 µL, 4 mM) or BPEA and Kiton red-620 dye (10 µL, 4 mM), and following
the above-reported setting for images acquisition. For evaluation of the signal-
to-noise (S/N) ratios of the images, signals (S) were calculated by averaging the
pixel intensity over the analyzed area, while noise (N) was taken as the standard
deviation of the mean pixel intensity in a dark image area.
5.3 Results and discussion
In order to ensure fast and easy-to-perform analyses, we designed our portable
device in such a way that it could employ cartridges made of simple cellulose.
In fact, paper-based sensors have recently gained increasingly attentions since
they represent a new alternative technology in the fabrication of simple, low-cost,
user-friendly disposable apparatuses for (bio)analyses. Cellulose material have
been largely used in sensors fabrication, to develop analytical devices for food
quality control, environmental monitoring and assessment and clinical diagnosis
[see Ref. 362–364].
Despite its versatility and low cost, a paper-based platform usually requires
specific chemical or physical treatments to make it suitable for bio-applications.
In addition to surface functionalization and derivatization, great efforts have been
made trying to confine the liquid to a specific region of paper cartridge, such as
photolithography [see Ref. 365], analogue plotting [see Ref. 366], inkjet printing
[see Ref. 367] and etching [see Ref. 368], plasma treatment [see Ref. 369], paper
cutting [see Ref. 370], flexography printing [see Ref. 371], screen printing [see
Ref. 372], and laser treatment [see Ref. 373]. Here, we employed the wax-printing
technology [see Ref. 359] to create a well-defined spot for sample loading on
the cellulose cartridge, avoiding the potential diffusion of solution out from the
analyzed area. Furthermore, since the fabbrication of our paper-based cartridges
required the use of a normal inkjet printer, it can be accomplished with simplicity
even by unskilled operators.
TCL-based detection methods should be able to ensure high light detectability
per se, due to the inherent reagentless nature and thermally-triggered signal of
TCL process, which can prevent, in principle, any background interferences from
the matrix. The use of a dark box (Figure 5.1) to hold both the mini-heater
element and the cartridge, allowed us to further enhance the device’s sensibility
avoiding the external environmental light to be detect by the phone’s camera, thus,
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Figure 5.2: a) Thermal response of the resistance employed for the mini-heater fabri-
cation; b) TCL signal generated by different concentrations of dioxetane 1 in ACN over
time, using a CCD camera as detector and our portable device for sample heating.
lowering the background noise.
We designed and created the mini-heater element to perfectly fit into the dark
box, ensuring a quick and homogeneous heating of cartridge (i. e. the loaded
sample). However, we needed to assess the performance of our mini-heater
first, in order to use it for reproducible analyses. We therefore measured the
thermal response of the resistance, using a Type K thermocouple to detect the
increase in temperature of the mini-heater surface, over time (Figure 5.2 a). We
noticed the thermal profile of the resistance to be very reproducible over several
heating experiments, giving a fast increase in temperatures up to 100 - 110 ◦C
within 3 minutes. In addition, using a CCD camera as detector and our portable
device for sample heating, we measured the TCL signal generated by different
concentrations of dioxetane 1 in ACN, over time. As shown in Figure 5.2 b,
TCL signal has followed a Gaussian-shape distribution for each concentration
analyzed, with a maximum emission pick centered around 120 seconds. The
atypical decomposition profile of 1 showed in Figure 5.2 b could be explained
considering it as the overlap of two different knetic processes: from one hand,
decomposition of 1 keep speeding up along with the increase in temperature upon
the heater’s surface, then, once the temperature stays constant, decomposition of
substrate 1 follows the usual first-order decay.
Aiming our portable device to allow very fast analyses, still ensuring high
sensitivity, we decided to reduce the initial time delay (before each acquisitions)
of about 30 sec. Thus, we started acquiring TCL emission after 90 sec from the
device switching-on, rather than 2 minutes. Doing so, we were able to remarkably
shorten the total time acquisition of TCL signal, saving about 30 sec for each
image, versus a minimal loss in emission intensity (less than 10%).
Figure 5.3 shows the calibration curve we obtained from TCL experiments,
using our portable device and the smartphone’s camera. We found TCL signal
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Figure 5.3: a) Calibration curve obtained measuring the TCL signal generated by
solutions of 1 at different concentration; b) Linear response of TCL-based portable device
for lower concentrations of 1.
Figure 5.4: a) TCL images of solutions containing dioxetane 1 alone or together with
energy acceptors BPEA (green light) and Kiton red-620 (red light); b) Spectral response
for a CMOS-based camera.
to be proportional to the amount of substrate 1 within the entire concentrations
range explored. Specifically, TCL signal has shown a different trend for low and
higher concentrations of 1, giving a linear or exponential tendency, respectively.
We, then, measured the lowest amount of dioxetane 1 detectable by our device,
which corresponded to a LOD of 2.6 picomol mm−2.
Finally, we tested the feasibility of employing our TCL-based portable device
in multiplex biosensing systems based on FRET mechanism. Thus, we analyzed
solutions of substrate 1 in presence of two different energy acceptors, namely
BPEA and Kiton red-620. The first one emits around 500 nm, while Kiton red-620
produces a photon in the red region of Uv-vis spectrum. As shown in Figure 5.4
a, FRET process occurred even for the solid state-like sample (mixed solution
absorbed onto the paper-based cartridge), generating images of different colours.
The possibility to shift the TCL emission towards longer wavelengths represents a
great advantage of our system, since it could further increase both the performance
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(CMOS are more sensible to red light, see Figure 5.4 b) and applications range
(e.g. for immunoassay and in vivo experiments) of our portable device.
5.4 Conclusion
Here we described the fabrication of an homemade portable device for TCL-
based (bio)analyses, exploiting the low-cost 3D printing technology and the
performance of a CMOS camera, integrated in Nokia Lumia 1020 smartphone.
Although the development of our analytical device is still in its early stage,
we conducted some preliminary experiments which supported the suitability
of our system for applications in the (bio)analytical field. Our portable device
has shown a remarkable sensibility in detection of TCL signal along with a
great reproducibility of experiments. Exploiting the thermal decomposition of
dioxetane 1, we have been able to reach a very low limit of detection, with the
lowest detectable concentration of analyte in the picomolar range. Furthermore,
our system potentially leads itself to simple or ”cascade” type FRET experiments,
usually necessary for immunoassay or in vivo applications, in which the red-
shifted emission signal is required to reduce the background noise as well as
matrix interference.
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6.1 General Remarks
All of the commercial chemicals were purchased from Sigma Aldrich, Alfa
Aesar or TCI Chemicals, and used without additional purifications.
• The 1H and 13C NMR spectra were recorded on a 200 or 400 NMR instru-
ment with a 5 mm probe. All chemical shifts have been quoted relative to
deuterated solvent signals; chemical shifts (δ) are reported in ppm, and cou-
pling constants (J) are reported in hertz. Protons and carbons are assigned
as follows: (Ar) for aromatic protons, (Ad) for protons and carbons of the
adamantyl portion, (H1, H2, H3. . . ) for protons expressly labeled in the
molecule picture, (Hα) for allylic protons of the adamantyl moiety in the
alkenes (the same notation was used for the corresponding 1,2-dioxetanes),
(CO) for carbonyl carbons, (COO) for carboxyl carbons, (CF) for carbons
bearing a fluorine atom, (CHAr) for aromatic tertiary carbons, (Cq) for qua-
ternary alkenyl and aromatic carbons, (C*) for carbons of the 1,2-dioxetane
and (C1, C2, C3. . . ) for carbons expressly labeled in the molecule picture.
• HPLC-MS analyses were performed on an Agilent Technologies HP1100 in-
strument coupled with an Agilent Technologies MSD1100 single-quadrupole
mass spectrometer. A Phenomenex Gemini C18 3 µm (100 x 3 mm) col-
umn was employed for the chromatographic separation and two different
analytical methods were used: method A: mobile phase H2O/CH3CN, gra-
dient from 30% to 80% of CH3CN in 8 min, 80% of CH3CN until 22 min,
then up to 90% of CH3CN in 2 min, stop time at 25 min; flow rate 0.4 mL
min−1; method B: gradient analogous to method A employing a mobile
phase (H2O/CH3CN) containing 0.2% of formic acid. Mass spectrometric
detection was performed in full-scan mode from m/z 50 to 2500, scan time
0.1 s in positive ion mode, ESI spray voltage 4500 V, nitrogen gas 35 psi,
drying gas flow rate 11.5 mL min−1, fragmentor voltage 30 V. Almost all the
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synthesized compounds were analyzed employing method A; compounds
analyzed with method B are specified.
• High-resolution MS (HRMS) ESI analyses were performed on a LTQ
Orbitrap XL (Thermo Scientific) mass spectrometer.
• Melting point (mp) measurements were performed on a Bibby Stuart Scien-
tific SMP3 apparatus.
• Flash chromatography purifications were carried out using VWR silica gel
(40-63 µm particle size). Thin-layer chromatography was performed on
Merck 60 F254 plates.
• Spectroscopic properties, in terms of maxima absorption and emission
wavelengths (λabs and λem) and fluorescence quantum yields (φF ) were
recorded using a UV-Vis spectrophotometer (Varian Cary 50) and a Uv-Vis
spectrofluorimeter (Carian Cary Eclipse). Fluorescent quantum yields were
measured in acetonitrile, using quinine sulfate as standard (φF = 0.53 in
H2SO4 0.05 mol L−1) [see Ref. 374].
6.2 Optimization Study
We selected the ketone 2a as model compound for the optimization of the
reaction conditions (Table 6.1) regarding the two key steps leading to the corre-
sponding 1,2-dioxetane 4a (Scheme 6.1).
Scheme 6.1
Concerning the McMurry coupling, we originally employed equimolar amounts
of the two ketones (1 and 2a) and of the couple Zn/TiCl3, using three equivalents
of the metal species with respect to the carbonyl substrates (entry 1) [see Ref.
107]. Although we obtained a good yield (87%), we tried to improve it and
simultaneously to reduce the reaction time. Inspired by the work of other authors
[see Ref. 375–380], we increased the excess of the metal species and replaced
TiCl3 x 3THF with the cheaper and easier to handle TiCl4 (entry 2). Under these
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Table 6.1: Optimization of the reaction conditions for the synthesis of the acridan-
derived 1,2-dioxetane 4a.
Entry Substrate (eq.) Reagents (eq.) and conditions Time Product Yield (%)c
1a 2a (1)
TiCl3 3THF (3),
Zn (3) 4 h 3a 87
2a 2a (1)
TiCl4 (6.1)
, Zn (13.5) 45 min 3a 94
3a 2a (3.2)
TiCl4 (6.1),
Zn (13.5) 30 min 3a 90
4b 3a (1)
P-BR (0.05 g), -78◦C,
UV cutoff filter (400 nm) 8 h 4a 64d
5b 3a (1)
MB (6.5 mol%), 0◦C
UV cutoff filter (400 nm) 1.5 h 4a 81d
6b 3a (1)
MB (6.5 mol%), -20 ◦C
UV cutoff filter (550 nm) 2 h 4a 92
aReaction conditions: adamantanone 1 (0.28 mmol), tetrahydrofuran (THF, 7 mL),
reflux.bReaction conditions: dichloromethane (DCM, 1 mL for 10 mg of 3a), 500 W halo-
gen lamp, O2 (1 atm, balloon).cDetermined after purification by flash chromatography.dA partial
decomposition of 1,2-dioxetane 4a was observed. Eq. = equivalents, h = hours, min = minutes,
P-BR = Polymer-bound Bengal Rose, MB = Methylene blue.
conditions the best yield (94%) of olefin 3a was achieved after only 45 minutes.
Increasing the amount of aromatic ketone 2a we did not obtain further improve-
ments (entry 3), therefore the subsequent McMurry couplings were carried out
employing an equimolar amount of the two ketones (unless otherwise specified).
The photooxygenation reaction was originally carried out at -78 ◦C with polymer-
bound Bengal Rose as sensitizer and a 400 nm UV cutoff filter (entry 4). However,
we found that, using Methylene Blue as sensitizer and increasing the temperature,
better yields and shortened reaction times were achieved (entries 5 and 6).
6.3 Synthetic Procedures and Characterizations
6.3.1 General procedure for the synthesis of ketones 2h-l, 2y
Ketones 2h-l, 2y were synthesized following a previously reported three-
steps synthetic pathway [see Ref. 110] (Scheme 6.2): i) Ullmann-type reaction
between a substituted aniline (5) and a substituted 2-bromo benzoic acid (6) gave
the intermediates 7a-d; ii) intramolecular cyclization of intermediates 7a-d to
compounds 8h-l, 8y; iii) alkylation of the endocyclic nitrogen atom provided the
desired ketones 2h-l, 2y.
Step i): A solution of substituted aniline 5 (1.4 eq.), substituted 2-bromobenzoic
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Scheme 6.2
acid 6 (1 eq.), anhydrous K2CO3 (1.4 eq.), and copper (0.19 eq.) in anhydrous
1-pentanol (1 mL/1 mmol of 6) was heated under reflux for 3 h. The solvent was
evaporated under reduced pressure, and the residue was dissolved in hot H2O and
then filtered through Celite. The Celite was washed with H2O and the filtrate was
acidified with concentrated HCl to pH 6. The precipitate was isolated by filtration
and washed with H2O. The solid was purified by flash chromatography to give
compounds 7a-d.
Figure 6.1
4-fluoro-2-((3-fluorophenyl)amino)benzoic acid (7a): 3-fluoroaniline (625
µL, 6.5 mmol) was coupled with 2-bromo-4-fluorobenzoic acid (1.03 g, 4.7
mmol), following the procedure described above (step i, Scheme 6.2). The
chromatographic purification (eluent: cyclohexane/EtOAc = 80:20) provided
product 7a (710 mg, 61%) as pale yellow crystals (mp = 185 - 187 ◦C). 1H NMR
(400 MHz, CD3OD) δ 8.04 (dd, J = 8.9, 6.9 Hz, 1H, Ar), 7.39 - 7.33 (m, 1H, Ar),
7.05 (d, J = 8.8, Hz, 1H, Ar), 6.98 ( dd, J = 10.6, 2.4 Hz, 1H, Ar), 6.91, (dd, J
= 11.9, 2.4 Hz, 1H, Ar), 6.84 (dt, J = 9.2, 2.4 Hz, 1H, Ar), 6.51 (dt, J = 8.0, 2.4
Hz,1H, Ar). 13C NMR (100 MHz, CD3OD) δ 170.9 (COO), 167.9 (d, J = 248.5
Hz, CF), 164.9 (d, J = 242.8 Hz, CF), 150.7 (d, J = 12.2 Hz, Cq), 143.4 (d, J
=10.1 Hz, Cq), 136.1 (d, J = 11.4 Hz, CHAr), 132.0 (d, J = 9.8 Hz, CHAr), 118.7
(d, J = 2.9 Hz, CHAr), 111.4 (d, J = 21.7 Hz, CHAr), 110.6 (Cq), 109.7 (d, J =
23.8 Hz, CHAr), 106.1 (d, J =22.7 Hz, CHAr), 100.9 (d, J = 26.5 Hz, CHAr).
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HPLC-MS (ESI, method B) tr = 10.0 min; [M+H]+ = 250. 0 m/z. HRMS (ESI)
[M+H]+calcd for C13H10F2NO2 250.0680 found 250.0683.
Figure 6.2
5-fluoro-2-((4-fluorophenyl)amino)benzoic acid (7b): 4-fluoroaniline (606
µL, 6.39 mmol) was coupled with 2-bromo-5-fluorobenzoic acid (1 g, 4.57 mmol)
following the procedure described above (step i, Scheme 6.2). The chromato-
graphic purification (eluent: cyclohexane/EtOAc = 80:20) provided product 7b
(609 mg, 54%) as a pale yellow solid (mp = 222 - 224 ◦C). 1H NMR (400 MHz,
CD3OD) δ 7.63 (dd, J = 12.5, 3.0 Hz, 1H, H1), 7.21 - 7.16 (m, 2H, Ar), 7.13 - 7.04
(m, 4H, Ar). 13C NMR (100 MHz, CD3OD) δ 170.7 (COO), 160.7 (d, J =239.4
Hz, CF), 155.5 (d, J = 233.4 Hz, CF), 146.5 (Cq), 138.6 (Cq), 125.5 (d, J = 8.0
Hz, CHAr), 122.5 (d, J = 18.0 Hz, CHAr), 118.1 (d, J = 23.3 Hz, CHAr), 117.0
(d, J = 22.7 Hz, CHAr), 116.2 (d, J = 6.9 Hz, CHAr), 113.9 (Cq). HPLC-MS
(ESI, method B) tr = 9.3 min; [M+H]+ = 250.0 m/z. HRMS (ESI) [M+H]+calcd
for C13H10F2NO2 250.0680 found 250.0684.
Figure 6.3
2-((3,4-difluorophenyl)amino)-4,5-difluorobenzoic acid (7c): 3,4-difluoro-
aniline (1.17 mL, 11.81 mmol) was coupled with 2-bromo-4,5-difluorobenzoic
acid (2 g, 8.44 mmol) following the procedure described above (step i, Scheme 6.2).
The crude product 7c (1.7 g) was directly used in the next step without additional
purification. 1H NMR (400 MHz, DMSO-d6) δ 7.83 (dd, J = 11.2, 9.2 Hz, 1H,
Ar), 7.44 - 7.36 (m, 2H, Ar), 7.12 - 7.06 (m, 2H, Ar). HPLC-MS (ESI, method
B) tr = 10.1 min; [M+]+ = 286.0 m/z.
4-fluoro-2-(m-tolylamino)benzoic acid (7d): m-toluidine (697 µL, 6.5 mmol)
was coupled with 2- bromo-4-fluorobenzoic acid (1.03 g, 4.7 mmol) following the
procedure described above (step i, Scheme 6.2). The chromatographic purification
(eluent: cyclohexane/EtOAc = 70:30) provided product 7d (615 mg, 53%) as pale
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Figure 6.4
brown crystals (mp = 153 - 155 ◦C). 1H NMR (400 MHz, CDCl3) δ 9.42 (br s,
1H, NH), 8.06 (dd, J = 9.2, 6.8 Hz, 1H, Ar), 7.29 (t, J = 8.0 Hz, 1H, Ar) 7.09 -
7.08 (m, 2H, Ar), 7.02 (d, J = 7.6 Hz, 1H, Ar), 6.82 (dd, J = 12.4, 2.4 Hz, 1H, Ar),
6.44 (dt, J = 9.0, 2.4 Hz, 1H, Ar), 2.39 (s, 3H, H1). 13C NMR (100 MHz, CDCl3)
δ 172.9 (COO), 167.6 ( d, J = 251.0 Hz, CF), 151.6 (d, J = 13.2 Hz, Cq), 139.6
(Cq), 139.4 (Cq), 135.3 (d, J = 12.0 Hz, CHAr), 129.4 (CHAr), 125.8 (CHAr),
124.5 (CHAr), 120.8 (CHAr), 106.5 (Cq), 104.9 (d, J = 23.4 Hz, CHAr), 99.9
(d, J = 26.1 Hz, CHAr), 21.4 (C2). HPLC-MS (ESI, method B) tr = 10.6 min;
[M+H]+ = 246.2 m/z. HRMS (ESI) [M+H]+calcd for C14H13FNO2 246.0930
found 246.0929.
Step ii): Compounds 8h-l, 8y were synthesized by adapting previously re-
ported procedure.([see Ref. 110]) Typically, the starting material (7a-d) (1 eq.)
was dissolved in CH3CN (2.25 mL/1 mmol of limiting reagent) and heated to
reflux. Phosphorus (V) oxychloride (2.2 eq.) was added over 1 h. The solution
was refluxed for further 2 h and then cooled to 10-15 ◦C. H2O (1.25 mL/1 mmol
of limiting reagent) was added, and the mixture was heated to reflux for 2.5 h.
The suspension was cooled to 10 ◦C and filtered. The solid was washed with H2O
and CH3CN and then dried under vacuum to obtain compounds 8h-l, 8y. The
crude product was purified by flash chromatography on silica gel or directly used
in the next step, without additional purifications.
Figure 6.5
3,6-difluoroacridin-9(10H)-one (8h) and 1,6-difluoroacridin-9(10H)-one
(8i): compound 7a (498 mg, 2 mmol) was cyclized following the procedure
described above (step ii, Scheme 6.2), to give a mixture of products 8h and 8i
(326 mg of a mixture 8h/8i = 60/40, calculated from the 1H NMR spectrum in
DMSO-d6). The mixture was used without additional purification in the step iii
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(Scheme 6.2).
Ketone 8h: 1H NMR (400 MHz, DMSO-d6) δ 11.89 (NH), 8.26 (dd, J = 8.8,
6.4 Hz, 2H, H1), 7.21 (dd, J = 10.4, 2.4 Hz, 2H, H3), 7.12 (dt, J = 8.8, 2.4 Hz, 2H,
H2). HPLC-MS (ESI) tr = 7.1 min; [M+H]+ = 232.1 m/z, [2M+Na]+ = 485.0
m/z.
Ketone 8i: 1H NMR (400 MHz, DMSO-d6) δ 11.87 (NH), 8.21 (dd, J = 9.2,
6.8 Hz, 1H, Ar), 7.69 - 7.64 (m, 1H, Ar), 7.28 (d, J = 8.4 Hz, 1H, Ar), 7.17 - 7.06
(m, 2H, Ar), 6.94 (dd, J = 12.4, 8.4 Hz, 1H, Ar). HPLC-MS (ESI) tr = 6.2 min;
[M+H]+ = 232.1 m/z, [2M+Na]+ = 485.0 m/z.
Figure 6.6
2,7-difluoroacridin-9(10H)-one (8j): compound 7b (550 mg, 2.21 mmol)
was cyclized following the procedure described above (step ii, Scheme 6.2).
The crude product was purified by flash chromatography on silica gel (eluent:
cyclohexane/EtOAc = 85:15) providing product 8j (299 mg, 59%). The obtained
spectroscopic data were in agreement with the literature data [see Ref. 381].
Figure 6.7
2,3,6,7-tetrafluoroacridin-9(10H)-one (8k): compound 7c (1.5 g, 5.26 mmol)
was cyclized following the procedure described above (step ii, Scheme 6.2), to give
a mixture of products 8k and its constitutional isomer 1,2,6,7-tetrafluoroacridin-
9(10H)-one (901 mg of a mixture 8k/constitutional isomer = 50/50, calculated
from the 1H NMR spectrum in CDCl3). The mixture was used without additional
purification in the following step iii (Scheme 6.2).
Ketone 8k: 1H NMR (400 MHz, CDCl3) δ 8.09 (dd, J = 10.4, 8.8 Hz, 2H, Ar),
7.15 (dd, J = 10.8, 6.4 Hz, 2H, Ar). HPLC-MS (ESI) tr = 8.7 min; [M+H]+ =
268.0 m/z.
1,2,6,7-tetrafluoroacridin-9(10H)-one: 1H NMR (400 MHz, CDCl3) δ 7.78
(dd, J = 11.2, 9.2 Hz, 1H, Ar), 7.02 - 6.97 (m, 1H, Ar), 6.89 - 6.87 (m, 1H, Ar),
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6.81 (dd, J = 13.2, 6.5 Hz, 1H, Ar). HPLC-MS (ESI) tr = 7.9 min; [M+H]+ =
268.0 m/z, [2M+Na]+ = 557.0 m/z.
Figure 6.8
3-fluoro-6-methylacridin-9(10H)-one (8l) and 6-fluoro-1-methylacridin-
9(10H)-one (8y): compound 7d (490 mg, 2 mmol) was cyclized following the
procedure described above (step ii, Scheme 6.2), to give a mixture of products
8l and 8y (536 mg of a mixture 8l/8y = 40/60, calculated from the 1H NMR
spectrum in DMSO-d6). The mixture was used without additional purification in
the following step iii (Scheme 6.2).
Ketone 8l: 1H NMR (400 MHz, DMSO-d6) δ 11.78 (NH), 8.26 (dd, J = 8.8,
6.4 Hz, 1H, Ar), 8.10 (d, J = 8.4 Hz, 1H, Ar), 7.32 (d, J = 8.0 Hz, 1H, Ar), 7.28 (s,
1H, H1), 7.23 (dd, J = 10.0, 2.8 Hz, 1H, Ar), 7.12 - 7.08 (m, 1H, Ar), 2.50 (s, 3H,
H2). HPLC-MS (ESI) tr = 7.1 min; [M+H]+ = 228.1 m/z, [2M+Na]+ = 477.0
m/z.
Ketone 8y: 1H NMR (400 MHz, DMSO-d6) δ 11.66 (NH), 8.21 (dd, J = 8.8,
6.8 Hz, 1H, Ar), 7.54 (t, J = 8.0 Hz, 1H, Ar), 7.16 (dd, J = 10.8, 2.4 Hz, 1H, Ar),
7.07 - 7.02 (m, 2H, Ar), 6.98 (d, J = 6.8 Hz, 1H, Ar), 2.50 (s, 3H, H1). HPLC-MS
(ESI) tr = 8.2 min; [M+H]+ = 228.1 m/z, [2M+Na]+ = 477.0 m/z.
Step iii): According to the reported procedure,(. . . ) a solution of the cyclic
intermediate 8 (1 eq.) in anhydrous DMF (5 mL/1 mmol 8) was added to a
suspension of NaH (1.2 eq.) in anhydrous DMF (1.6 mL/1 mmol 8). The mixture
was stirred for 30 min at room temperature, and then, after the mixture was cooled
to 0 ◦C, ethyl 2-bromoacetate (1.5 eq.) and tetrabutylammonium iodide (0.01
eq.) were added. The solution was stirred for further 24 h at room temperature
and then poured into cold water. The precipitate was collected by filtration, dried
under vacuum, and purified by flash chromatography on silica gel.
Ethyl 2-(3,6-difluoro-9-oxoacridin-10(9H)-yl)acetate (2h) and ethyl 2-(1,6-
difluoro-9-oxoacridin-10(9H)-yl)acetate (2i): the mixture of compounds 8h
and 8i (358 mg, 1.55 mmol) was alkylated following the procedure described
above (step iii, Scheme 6.2) to give an overall 92% yield. The chromatographic
purification (eluent: cyclohexane/EtOAc = 80:20) provided products 2h (370 mg)
and 2i (83 mg).
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Figure 6.9
Ketone 2h: white solid, mp = 198 - 200 ◦C ; λabs = 355, 371 nm, λem = 386,
403 nm, φF = 0.01; 1H NMR (400 MHz, CDCl3) δ 8.58 (dd, J = 8.9, 6.8 Hz,
2H, H1), 7.05 (dt, J = 10.1, 2.4 Hz, 2H, H2), 6.97 (dd, J = 11.5, 2.4 Hz, 2H,
H3), 4.94 (s, 2H, H4), 4.36 (q, J = 7.1 Hz, 2H, H5), 1.35 (t, J= 7.1 Hz, 3H, H6).
13C NMR (100 MHz, CDCl3) δ 176.2 (CO), 167.4 (COO), 166.4 (d, J = 251.5
Hz, CF), 144.1 (d, J = 11.5 Hz, Cq), 131.1 (d, J = 11.1 Hz, C1), 119.4 (d, J =
1.6 Hz, Cq), 110.9 (d, J = 22.6 Hz, CHAr), 100.9 (d, J = 27.1 Hz, CHAr), 62.5
(C5), 48.7 (C4), 14.1 (C6). HPLC-MS (ESI) tr = 9.0 min; [M+H]+ = 318.0 m/z,
[2M+Na]+ = 657.0 m/z. HRMS (ESI) [M+H]+calcd for C17H14F2NO3 318.0942
found 318.0943.
Ketone 2i: white solid, mp = 176 - 178 ◦C; λabs = 363, 378 nm, λem = 395
nm, φF = 4x10−3; 1H NMR (400 MHz, CDCl3) δ 8.51 (dd, J = 8.8, 6.8 Hz, 1H,
Ar), 7.64 - 7.59 (m, 1H, Ar), 7.04 (d, J = 8.6 Hz, 2H, Ar), 7.01 - 6.90 (m, 2H, Ar),
4.95 (s, 2H, H1), 4.35 (q, J = 7.1 Hz, 2H, H2), 1.34 (t, J = 7.1 Hz, 3H, H3). 13C
NMR (100 MHz, CDCl3) δ 175.7 (CO), 167.7 (COO), 166.4 (d, J = 251.3 Hz,
CF), 162.8 (d, J = 263.3 Hz, CF), 144.3 (d, J = 2.7 Hz, Cq), 143.5 (d, J = 11.4 Hz,
Cq), 134.2 (d, J = 11.7 Hz, CHAr), 130.9 (d, J = 11.1 Hz, CHAr), 120.4 (d, J =
1.4 Hz, Cq), 112.7 (d, J = 8.1 Hz, Cq), 110.7 (d, J = 22.6 Hz, CHAr), 110.0 (d, J =
4.2 Hz, CHAr), 109.3 (d, J = 21.5 Hz, CHAr), 100.7 (d, J = 27.0 Hz, CHAr), 62.4
(C2), 49.5 (C1), 14.1 (C3). HPLC-MS (ESI) tr = 8.2 min; [M+H]+ = 318.0 m/z,
[2M+Na]+ = 657.0 m/z. HRMS (ESI) [M+H]+calcd for C17H14F2NO3 318.0942
found 318.0944.
Figure 6.10
Ethyl 2-(2,7-difluoro-9-oxoacridin-10(9H)-yl)acetate (2j): compound 8j
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(98 mg, 0.42 mmol) was alkylated following the procedure described above (step
iii, Scheme 6.2). The crude product was purified by flash chromatography on
silica gel (eluent: cyclohexane/EtOAc = 80:20) providing compound 2j (82 mg,
62%) as a yellow solid, mp = 221 - 223 ◦C; λabs = 387, 408 nm, λem = 421,
444 nm, φF = 0.65; 1H NMR (400 MHz, CDCl3) δ 8.17 (dd, J = 8.6, 3.0 Hz,
2H, Ar), 7.50 - 7.45 (m, 2H, Ar), 7.32 (dd, J = 9.2, 3.9 Hz, 2H, Ar), 5.06 (s,
2H, H1), 4.33 (q, J = 7.1 Hz, 2H, H2), 1.32 (t, J = 7.2 Hz, 3H, H3). 13C NMR
(100 MHz, CDCl3) δ 176.6 (CO), 167.9 (COO), 157.9 (d, J = 242.4 Hz, CF),
138.7 (d, J = 1.4 Hz, Cq), 122.9 (Cq), 122.7 (d, J = 24.8 Hz, CHAr), 116.4 (d,
J = 7.4 Hz, CHAr), 112.3 (d, J = 22.5 Hz, CHAr), 62.4 (C2), 49.0 (C1), 14.2
(C3). HPLC-MS (ESI) tr = 9.1 min; [M+H]+ = 318.0 m/z, [M+K]+ = 356.0 m/z.
HRMS (ESI) [M+H]+calcd for C17H14F2NO3 318.0942 found 318.0942.
Figure 6.11
Ethyl 2-(2,3,6,7-tetrafluoro-9-oxoacridin-10(9H)-yl)acetate (2k): the mix-
ture of compounds 8k and its constitutional isomer 1,2,6,7-tetrafluoroacridin-
9(10H)-one (800 mg, 2.99 mmol) was alkylated following the procedure described
above (step iii, Scheme 6.2). From the chromatographic purification (eluent: cy-
clohexane/EtOAc = 90:10) only compound 2k was isolated as brown crystals
(633 mg, 60%), mp = 211 - 213 ◦C; λabs = 368, 386 nm, λem = 399, 419 nm, φF
= 0.11; 1H NMR (400 MHz, DMSO-d6) δ 8.13 (dd, J = 10.0, 9.2 Hz, 2H, Ar),
7.87 (dd, J = 13.6, 6.4 Hz, 2H, Ar), 5.42 (s, 2H, H1), 4.21 (q, J = 7.2 Hz, 2H,
H2), 1.24 (t, J = 7.2 Hz, 3H, H3). 13C NMR (100 MHz, DMSO-d6) δ 173.7 (CO),
167.8 (COO), 153.7 (dd, J = 250.7, 14.5 Hz, CF), 145.7 (d, J = 243.8, 14.0 Hz,
CF), 139.8 (d, J = 10.3 Hz, Cq), 117.7 (d, J = 5.1 Hz, Cq), 113.8 (dd, J = 17.6,
2.6 Hz, CHAr), 105.5 (d, J = 23.3 Hz, CHAr), 61.5 (C2), 48.4 (C1), 13.9 (C3).
HPLC-MS (ESI) tr = 10.6 min; [M+H]+ = 354.0 m/z, [2M+Na]+ = 729.0 m/z.
HRMS (ESI) [M+H]+calcd for C17H12F4NO3 354.0753 found 354.0752.
Ethyl 2-(3-fluoro-6-methyl-9-oxoacridin-10(9H)-yl)acetate (2l) and ethyl
2-(6-fluoro-1-methyl-9-oxoacridin-10(9H)-yl)acetate (2y): the mixture of com-
pounds 8l and 8y (485 mg, 2.14 mmol, 8l/8y = 40/60) was alkylated following
the procedure described above (step iii, Scheme 6.2) to give an overall 59% yield.
The chromatographic purification (eluent: cyclohexane/EtOAc = 80:20) provided
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Figure 6.12
products 2l (173 mg) and 2y (219 mg).
Ketone 2l: pale yellow solid, mp = 138 - 140 ◦C; λabs = 361, 378 nm, λem =
394 nm, φF = 0.04; 1H NMR (400 MHz, CDCl3) δ 8.47 (dd, J = 8.80, 6.76 Hz,
1H, Ar), 8.33 (d, J = 8.12 Hz, 1H, Ar), 7.11 (d, J = 8.12 Hz, 1H, Ar), 7.03 (s, 1H,
H1), 6.98 (dt, J = 9.2, 2.1 Hz, 1H, Ar), 6.93 (dd, J = 11.4, 1.9 Hz, 1H, Ar), 4.96 (s,
2H, H3), 4.29 (q, J = 7.08 Hz, 2H, H4), 2.47 (s, 3H, H2), 1.28 (t, J = 7.12 Hz, 3H,
H5). 13C NMR (100 MHz, CDCl3 with a few drops of CD3OD to enhance the
solubility) δ 177.3 (CO), 168.0 (COO), 166.4 (d, J = 251.0 Hz, CF), 145.6 (Cq),
143.9 (d, J = 11.8 Hz, Cq), 130.8 (d, J = 11.1 Hz, CHAr), 127.7 (CHAr), 124.3
(Cq), 124.1 (CHAr), 120.3 (Cq), 119.1 (Cq), 114.1 (CHAr), 110.5 (d, J = 22.8
Hz, CHAr), 100.7 (d, J = 26.9 Hz, CHAr), 62.3 (C4), 48.4 (C3), 22.4 (C2), 14.0
(C5). HPLC-MS (ESI) tr = 9.2 min; [M+H]+ = 314.2 m/z, [2M+Na]+ = 649.2
m/z. HRMS (ESI) [M+H]+calcd for C18H17FNO3 314.1192 found 314.1191.
Ketone 2y: pale brown crystals, mp = 166 - 168 ◦C; 1H NMR (400 MHz,
CDCl3) δ 8.50 (dd, J = 8.80, 6.72 Hz, 1H, Ar), 7.54 (dd, J = 8.5, 7.3 Hz, 1H, Ar),
7.12 - 7.10 (m, 2H, Ar), 7.00 (dt, J = 8.9, 2.0 Hz, 1H, Ar), 6.90 (dd, J = 11.24,
2.20 Hz, 1H, Ar), 4.94 (s, 2H, H2), 4.35 (q, J = 7.12 Hz, 2H, H3), 2.99 (s, 3H,
H1), 1.34 (t, J = 7.12 Hz, 3H, H4). 13C NMR (100 MHz, CDCl3) δ 179.0 (CO),
168.05 (COO), 166.0 (d, J = 249.9 Hz, CF), 143.9 (Cq), 143.3 (d, J = 11.3 Hz,
Cq), 142.9 (Cq), 132.8 (CHAr), 130.8 (d, J = 10.8 Hz, CHAr), 125.6 (CHAr),
121.2 (Cq), 120.6 (Cq), 112.3 (CHAr), 110.0 (d, J = 22.7 Hz, CHAr), 100.3 (d,
J = 26.9 Hz, CHAr), 62.2 (C2), 49.3 (C3), 24.4 (C1), 14.1 (C4). HPLC-MS
(ESI) tr = 10.2 min; [M+H]+ = 314.2 m/z, [2M+Na]+ = 649.2 m/z. HRMS (ESI)
[M+H]+calcd for C18H17FNO3 314.1192 found 314.1195.
Figure 6.13
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10-methylacridin-9(10H)-one (2m) was synthesized by adapting a reported
procedure [see Ref. 382]: to a suspension of NaH (60% oil dispersion, 316 mg,
7.9 mmol) in anhydrous DMF (20 mL) was added 9(10H)-acridone (500 mg,
2.56 mmol) at 0 ◦C. The reaction mixture was stirred at 60 ◦C for 30 min, then
iodomethane (560 µL, 8.96 mmol) was added, and stirring was continued at 60 ◦C
for 14 h. The reaction mixture was quenched with H2O. The resulting solid was
collected by filtration and thoroughly washed with ethanol to give product 2m as
light-yellow solid. A further amount of product was recovered by extracting the
filtered water phase with CH2Cl2. Then, the combined organic layers were washed
with brine, dried over sodium sulfate, and concentrated. 508 mg of compound 2m
was obtained (95% yield). The obtained spectroscopic data were in agreement
with the literature data [see Ref. 382].
Figure 6.14
Ethyl 5-(9-oxoacridin-10(9H)-yl)pentanoate (2n) was synthesized follow-
ing the reported procedure [see Ref. 110]: a solution of 9(10H)-acridone (500
mg, 2.56 mmol) in anhydrous DMF (10 mL) was added to a suspension of NaH
(123 mg, 3.07 mmol) in anhydrous DMF (5 mL). The mixture was stirred for
30 min at room temperature, and then, after the mixture was cooled to 0 ◦C,
ethyl 5-bromovalerate (610 µL, 3.84 mmol) and tetrabutylammonium iodide (10
mg, 0.027 mmol) were added. The solution was stirred for further 24 h at room
temperature and then poured into cold water. The precipitate was collected by
filtration, dried under vacuum, and purified by flash chromatography on silica gel
(eluent: cyclohexane/EtOAc = 90:10) providing compound 2n (323 mg, 40%), as
pale yellow solid; mp = 92 - 94 ◦C; λabs = 399 nm, λem = 413 nm, φF = 0.44; 1H
NMR (400 MHz, CDCl3) δ 8.60 (dd, J = 8.0, 1.2 Hz, 2H, Ar), 7.76 (t, J = 7.4 Hz,
2H, Ar), 7.51 (d, J = 8.7 Hz, 2H, Ar), 7.31 (t, J = 7.4 Hz, 2H, Ar), 4.39 (t, J = 7.6
Hz, 2H, H1), 4.17 (q, J = 7.1 Hz, 2H, H5), 2.47 (t, J = 6.8 Hz, 2H, H4), 2.05 - 1.88
(m, 4H, H2 and H3), 1.27 (t, J = 7.1 Hz, 3H, H6). 13C NMR (100 MHz, CDCl3)
δ 177.9 (CO), 173.0 (COO), 141.7 (Cq), 133.9 (CHAr), 128.0 (CHAr), 122.5
(Cq), 121.3 (CHAr), 114.4 (CHAr), 60.6 (C5), 45.8 (C1), 33.7 (C4), 26.6 and
22.2 (C2 and C3), 14.2 (C6). HPLC-MS (ESI) tr = 9.6 min; [M+H]+ = 324.2
m/z, [M+Na]+ = 346.3 m/z. HRMS (ESI) [M+H]+calcd for C20H22NO3 324.1600
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found 324.160.
6.3.2 General procedure for the synthesis of compounds 2o-q
Scheme 6.3
Compounds 2o-q were synthesized by adapting a previously reported pro-
cedure (Scheme 6.3) [see Ref. 383]: 1-bromobenzene derivative 10 (1.1 eq.),
acridin-9(10H)-one (9) (1 eq.), K2CO3 (1.1 eq.), CuI (0.1 eq.), 2,2,6,6-tetramethyl-
3,5-heptanedione (0.19 eq.) were dissolved in anhydrous DMF (6 mL/1 mmol
of 9), into a three-necked round flask. The mixture was degassed and refluxed
under nitrogen atmosphere for 24 h. After cooling to room temperature, the
reaction mixture was quenched with H2O and extracted with ethyl acetate (3 X
10 mL). The combined organic layers were collected, dried over sodium sulfate
and evaporated under vacuum. Then, the crude product was purified by flash
chromatography on silica gel.
Figure 6.15
10-phenylacridin-9(10H)-one (2o): compound 9 (300 mg, 1.54 mmol) was
coupled with bromobenzene (180 µL, 1.71 mmol) following the above-mentioned
procedure (Scheme 6.3). The chromatographic purification (eluent: cyclohex-
ane/EtOAc = 95:5) provided compound 2o (362 mg, 87%). The obtained spectro-
scopic data were in agreement with the literature data [see Ref. 384].
10-(p-tolyl)acridin-9(10H)-one (2p): compound 9 (300 mg, 1.54 mmol)
was coupled with 1- bromo-4-methylbenzene (210 µL, 1.71 mmol) following
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Figure 6.16
the above-mentioned procedure (Scheme 6.3). The chromatographic purification
(eluent: cyclohexane) provided compound 2p (89 mg, 20%). The obtained
spectroscopic data were in agreement with the literature data [see Ref. 385].
Figure 6.17
10-(4-fluorophenyl)acridin-9(10H)-one (2q): compound 9 (300 mg, 1.54
mmol) was coupled with 1-bromo-4-fluorobenzene (253 µL, 2.31 mmol) fol-
lowing the above- mentioned procedure (Scheme 6.3). The chromatographic
purification (eluent: cyclohexane/EtOAc = 80:20) provided compound 2q (107
mg, 24%). The obtained spectroscopic data were in agreement with the literature
data [see Ref. 384].
Procedure for the synthesis of compound 2s: a previously reported two-
steps synthetic pathway (Scheme 6.4) [see Ref. 386], was followed to synthesize
ketone2s: i) intramolecular cyclization of 2,2’,4,4’-tetrahydroxybenzophenone
(11) gave the intermediate 12; ii) di-methylation of compound 12 yielded the
desired product 2s.
Step i): 2,2’,4,4’-Tetrahydroxybenzophenone (11) (1 g, 4.07 mmol) was
heated at 210-220 ◦C (sand bath) for 4 h. The yellow powder in the reaction
mixture changed to a brown solid. The crude product was purified by flash
chromatography on silica gel (eluent: cyclohexane/EtOAc = 50:50) to give ketone
84
CHAPTER 6. SUPPORTING INFORMATION OF CHAPTER 2
Scheme 6.4
12 (790 mg, 85%). The obtained spectroscopic data were in agreement with the
literature data [see Ref. 386].
Step ii): ketone 12 (250 mg, 1.10 mmol), K2CO3 (227 mg, 1.64 mmol), MeI
(273 µL, 4.39 mmol) and acetone (15 mL) were mixed, and the reaction mixture
was stirred under reflux for 3 h. The reaction mixture was then filtered and washed
with ethyl acetate (3 X 10 mL). The organic layer was evaporated under vacuum
and purified by flash chromatography on silica gel (eluent: cyclohexane/EtOAc =
80:20) to give compound 2s (126 mg, 45% yield). The obtained spectroscopic
data were in agreement with the literature data [see Ref. 386].
Procedure for the synthesis of ketones 2A and 2B:
Scheme 6.5
9H-thioxanthen-9-one 10-oxide (2A) and 9H-thioxanthen-9-one 10,10- di-
oxide (2B) were synthesized by adapting a reported procedure (Scheme 6.5) [see
Ref. 387]: 11 9H-thioxanthen-9-one (2z) (400 mg, 1.88 mmol) was dissolved in
MeOH (8 mL). Then, H2O2 (30% in H2O, 563 µL, 4.97 mmol) and ZrCl4 (1.1
g, 4.7 mmol) were added and the mixture was stirred at room temperature for
10 minutes. After that, the solution was evaporated under vacuum and the crude
product was purified by flash chromatography on silica gel (eluent: cyclohex-
ane/EtOAc = 90:10) to give compounds 2A (135 mg, 31%) and 2B (59 mg, 13%).
The obtained spectroscopic data were in agreement with the literature data [see
Ref. 388].
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Scheme 6.6
6.3.3 General procedure for the synthesis of alkenes 3h-t, 3y-z, 3C-E,
3G-I:
All the synthesized olefins (except for 3A and 3B) were obtained by a reduc-
tive coupling under McMurry conditions (Scheme 6.6). Three different synthetic
methods were followed:
Method A: Under a nitrogen atmosphere, TiCl4 (1M in dichloromethane, 6.1
eq.) was added to a suspension of zinc powder (13.5 eq.) in anhydrous THF
(8mL/0.5 mmol of 1) at 0 ◦C, and the suspension was stirred for 10 min under
reflux. A solution of ketone 2 (1 eq.) and 2-adamantanone 1 (1 eq.) in dry THF
(2 mL/0.5 mmol of 1) was added dropwise over a period of 30 min. The reaction
mixture was refluxed for 45 minutes. Then, it was cooled to room temperature,
quenched with water and extracted with AcOEt (3 x 10 mL). The combined
organic layers were dried over sodium sulfate and evaporated under vacuum. The
crude product was purified by flash chromatography on silica gel.
Method B: the same experimental procedure of method A was followed,
except for the ratio between the starting materials 1 and 2 and the reaction time.
In particular, 1 eq. of 2-adamantanone 1 and 3.2 eq. of aromatic ketone 2 were
employed, and the reaction was stirred under reflux for 1.5 h.
Method C: compound 3I was synthesized by adapting a reported procedure
[see Ref. 389]: under a nitrogen atmosphere, LiAlH4 (598 mg, 15.75 mmol) was
added to a suspension of TiCl4 2THF (4.57 g, 13.70 mmol) in anhydrous THF (18
mL) at 0 ◦C, and the mixture was stirred for 10 min. After addition of triethyl-
amine (4.1 mL, 30 mmol) at room temperature, the reaction mixture was refluxed
for 1 h. A solution of lactone 2I (100 mg, 0.68 mmol) and 2-adamantanone 1
(1.54 g, 10.27 mmol) in dry THF (11 mL) was added dropwise over a period of
30 min. The reaction mixture was refluxed for 2 h and then, it was cooled to room
temperature, quenched with water and extracted with AcOEt (3 x 12 mL). The
combined organic layers were dried over sodium sulfate and evaporated under
vacuum. The crude product was purified by flash chromatography on silica gel.
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Figure 6.18
Compound 3h: 2-adamantanone 1 (18 mg, 0.12 mmol) and ketone 2h were
coupled following the above-mentioned procedure (method B, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane/EtOAc = 95:5) provided com-
pound 3h (45 mg, 86%) as a yellow solid (mp = 213 - 215 ◦C). 1H NMR (400
MHz, CDCl3) δ 7.14 (dd, J = 8.4, 6.6 Hz, 2H, H1), 6.76 (dt, J = 8.4, 2.4 Hz, 2H,
H2), 6.50 (dd, J = 10.9, 2.4 Hz, 2H, H3), 4.57 (s, 2H, H4), 4.32 (q, J = 7.1 Hz, 2H,
H5), 3.36 (br s, 2H, Hα), 2.28 - 1.57 (m, 12H, Ad), 1.33 (t, J = 7.1 Hz, 3H, H6).
13C NMR (100 MHz, CDCl3) δ 168.9 (COO), 161.6 (d, J = 241.2 Hz, CF), 144.9
(Cq), 144.3 (d, J = 9.9 Hz, Cq), 128.3 (d, J = 26.9 Hz, CHAr), 121.9 (d, J = 2.7
Hz, Cq), 118.3 (Cq), 107.5 (d, J = 21.4 Hz, CHAr), 100.3 (d, J = 26.9 Hz, CHAr),
61.7 (C5), 48.9 (C4), 36.9 (Ad), 32.2 (Ad), 14.2 (C6). HPLC-MS (ESI) tr= 21.1
min; [M+H]+ = 436.1. HRMS (ESI) [M+H]+calcd for C27H28F2NO2 436.2088
found 436.2091.
Figure 6.19
Compound 3i: 2-adamantanone 1 (20.4 mg, 0.14 mmol) and ketone 2i were
coupled following the above-mentionedprocedure (method A, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane/EtOAc = 95:5) provided com-
pound 3i (52 mg, 88%) as a sticky solid. 1H NMR (400 MHz, CDCl3) δ 7.18
(dd, J = 8.3, 6.5 Hz, 1H, Ar), 7.15 - 7.09 (m,1H, Ar), 6.80 - 6.72 (m, 2H, Ar),
6.56 (d, J = 8.2 Hz, 1H, Ar), 6.51 (dd, J = 10.9, 2.3 Hz, 1H, Ar), 4.64 (d, J = 18.2
Hz, 1H, H1a), 4.58 (d, J = 18.2 Hz, 1H, H1b), 4.30 (q, J = 7.1 Hz, 2H, H2), 3.34
(s, 1H, Hα), 2.73 (s, 1H, Hα), 2.22 - 2.03 (m, 5H, Ad), 1.85 (m, 3H, Ad), 1.76
- 1.66 (m, 2H, Ad), 1.60 - 1.53 (m, 2H, Ad), 1.30 (t, J = 7.1 Hz, 3H, H3). 13C
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NMR (100 MHz, CDCl3) δ 169.0 (COO), 161.6 (d, J = 241.0 Hz, CF), 157.8 (d,
J = 241.7 Hz, CF) 147.9 (Cq), 145.3 (d, J = 7.1 Hz, Cq), 144. 6 (d, J = 10.0 Hz,
Cq), 128.5 (d, J = 9.4 Hz, CHAr), 126.9 (d, J = 9.6 Hz, CHAr), 122.1 (d, J = 2.7
Hz, Cq), 114.4 (d, J = 21.1 Hz, Cq), 113.0 (Cq), 108.8 (d, J = 23.5 Hz, CHAr),
108.1 (d, J = 2.7 Hz, CHAr), 107.5 (d, J = 21.5 Hz, CHAr), 100.4 (d, J = 26.0
Hz, CHAr), 61.6 (C2), 49.1 (C1), 39.8 (Ad), 39.4 (Ad), 39.1 (Ad), 38.7 (Ad),
38.66 (Ad), 36.9 (Ad), 34.8 (Ad), 34.3 (Ad), 32.6 (Ad), 28.2 (Ad), 27.6 (Ad),
14.2 (C3). HPLC-MS (ESI) tr= 18.2 min; [M+H]+ = 436.1 m/z. HRMS (ESI)
[M+H]+calcd for C27H28F2NO2 436.2088 found 436.2088.
Figure 6.20
Compound 3j: 2-adamantanone1 (42 mg, 0.27 mmol) and ketone 2j were
coupled following the above-mentioned procedure (method A, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane) provided compound 3j (91
mg, 76%) as pale yellow crystals (mp = 209 - 211 ◦C). 1H NMR (400 MHz,
CDCl3) δ 6.95 - 6.86 (m, 4H, Ar), 6.69 (dd, J = 8.9, 4.6 Hz, 2H, Ar), 4.60 (s,
2H, C1), 4.29 (q, J = 7.1 Hz, 2H, C2), 3.43 (br s, 2H, Hα), 2.25 - 1.61 (m, 12H,
Ad), 1.30 (t, J = 7.1 Hz, 3H, C3). 13C NMR (100 MHz, CDCl3) δ 169.5 (COO),
157.7 (d, J = 236.5 Hz, CF), 146.9 (Cq), 139.7 (d, J = 1.9 Hz, Cq), 127.1 (d, J
= 7.6 Hz, Cq), 118.9 (Cq), 113. 9 (d, J = 22.8 Hz, CHAr), 113.0 (d, J = 8.4 Hz,
CHAr), 112.7 (d, J =22.7 Hz, CHAr), 61.4 (C2), 49.1 (C1), 36.9 (Ad), 32.3 (Ad),
14.2 (C3). HPLC-MS (ESI) tr= 19.4 min; [M+H]+ = 436.2 m/z. HRMS (ESI)
[M+H]+calcd for C27H28F2NO2 436.2088 found 436.2089.
Figure 6.21
Compound 3k: 2-adamantanone 1 (61 mg, 0.41 mmol) and ketone 2k were
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coupled following the abovementioned procedure (method A, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane) provided compound 3k (93
mg, Y = 48%) as pink solid (mp = 175 - 177 ◦C). 1H NMR (400 MHz, CDCl3) δ
6.98 (dd, J = 10.7, 8.6 Hz, 2H, Ar), 6.57 (dd, J = 12.0, 6.8 Hz, 2H, Ar), 4.51 (s,
2H, C1), 4.33 (q, J = 7.1 Hz, 2H, C2), 3.33 (br s, 2H, Hα), 2.20 - 1.59 (m, 12H,
Ad), 1.34 (t, J = 7.1 Hz, 3H, C3). 13C NMR (100 MHz, CDCl3) δ 168.7 (COO),
148.6 (dd, J = 243.7, 13.6 Hz, CF), 146.8 (Cq), 145.2 (dd, J = 239.3, 12.9 Hz,
CF), 139.6 (dd, J = 7.7, 2.1 Hz, Cq), 121.5 (dd, J = 5.5, 3.2 Hz, Cq), 117.1 (Cq),
115.6 (dd, J = 18.8, 1.3 Hz, CHAr), 102.1 (d, J = 21.4 Hz CHAr), 61.9 (C2), 49.2
(C1), 36.8 (Ad), 32.3 (Ad), 14.2 (C3). HPLC-MS (ESI) tr= 19.9 min; [M+H]+ =
472.1 m/z, [M+Na]+ = 494.0 m/z. HRMS (ESI) [M+H]+calcd for C27H26F4NO2
472.1900 found 472.1899.
Figure 6.22
Compound 3l: 2-adamantanone 1 (63 mg, 0.42 mmol) and ketone 2l were
coupled following the above-mentioned procedure (method A, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane) provided compound 3l (161
mg, 89%) as a yellow solid (mp = 195 - 197 ◦C). 1H NMR (400 MHz, CDCl3) δ
7.15 - 7.10 (m, 2H, Ar), 6.84 (d, J = 7.6 Hz, 1H, Ar), 6.70 (dt, J = 8.4, 2.2 Hz, 1H,
H3), 6.58 (s, 1H, H1), 6.49 (dd, J = 11.1, 2.2 Hz, 1H, H2), 4.59 (s, 2H, H5), 4.30
(q, J = 7.1 Hz, 2H, H6), 3.42 (s, 1H, Hα), 3.36 (s, 1H, Hα), 2.34 (s, 3H, H4), 2.21
- 1.61 (m, 12H, Ad), 1.31 (t, J = 7.1 Hz, 3H, H7). 13C NMR (100 MHz, CDCl3)
δ 169.5 (COO), 161.6 (d, J = 240.7 Hz, CF), 144.7 (d, J = 10.0 Hz, Cq), 144.1
(Cq), 142.7 (Cq), 135.9 (Cq), 128.2 (d, J = 9.4 Hz, CHAr), 127.2 (CHAr), 123.5
(Cq), 122.1 (d, J = 2.6 Hz, Cq), 121.7 (CHAr), 118.9 (Cq), 113.2 (CHAr), 106.8
(d, J = 21.4 Hz, CHAr), 100.1 (d, J = 25.9 Hz, CHAr), 61.4 (C6), 48.8 (C5), 37.1
(Ad), 32.2 (Ad), 21.6 (C4), 14.2 (C7). HPLC-MS (ESI) tr= 20.9 min; [M+H]+ =
432.2 m/z, [M+Na]+ = 454.2 m/z. HRMS (ESI) [M+H]+calcd for C28H31FNO2
432.2339 found 432.2342.
Compound 3m: 2-adamantanone 1 (45 mg, 0.3 mmol) and ketone 2m were
coupled following the above-mentioned procedure (method B, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane/EtOAc = 95:5) provided com-
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Figure 6.23
pound 3m (93 mg, 95%). The obtained spectroscopic data were in agreement
with the literature data [see Ref. 390].
Figure 6.24
Compound 3n: 2-adamantanone 1 (69 mg, 0.46 mmol) and ketone 2n were
coupled following the above-mentioned procedure (method A, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane/EtOAc = 90:10) provided
compound 3n (193 mg, 95%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.21
- 7.15 (m, 4H, Ar), 7.01 (d, J = 8.0 Hz, 2H, Ar), 6.96 (t, J = 7.4 Hz, 2H, Ar), 4.08
(q, J = 7.1 Hz, 2H, C3), 3.99 (t, J = 6.8 Hz, 2H, C1), 3.41 (s, 2H, Hα), 2.30 (t, J =
7.4 Hz, 2H, C2), 2.21 - 1.84 (m, 12H), 1.74 - 1.66 (m, 4H), 1.21 (t, J = 7.1 Hz, 3H,
C4). 13C NMR (100 MHz, CDCl3) δ 173.3 (COO), 143.9 (Cq), 143.4 (Cq), 127.3
(CHAr), 126.8 (Cq), 126.0 (CHAr), 120.5 (Cq), 119.9 (CHAr), 112.9 (CHAr),
60.2 (C3), 44.8 (C1), 37.1, 33.9, 32.1, 25.7, 22.2, 14.1 (C4). HPLC-MS (ESI)
tr= 28.5 min; [M+H]+ = 442.3 m/z. HRMS (ESI) [M+H]+calcd for C30H36NO2
442.2746 found 442.2748.
Figure 6.25
Compound 3o: 2-adamantanone 1 (14.7 mg, 0.1 mmol) and ketone 2o were
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coupled following the above-mentioned procedure (method B, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane/EtOAc = 95:5) provided com-
pound 3o (35 mg, 92%). The obtained spectroscopic data were in agreement with
the literature data [see Ref. 390].
Figure 6.26
compound 3p: 2-adamantanone 1 (14 mg, 0.095 mmol) and ketone 2p were
coupled following the above-mentioned procedure (method B, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane/EtOAc = 90:10) provided
compound 3p (35.6 mg, 93%) as a sticky solid. 1H NMR (400 MHz, CDCl3) δ
7.42 (d, J = 8.0 Hz, 2H, Ar), 7.28 - 7.25 (m, 4H, Ar), 7.02 - 6.93 (m, 4H, Ar),
6.48 (dd, J = 8.1, 1.3 Hz, 2H, Ar), 3.51 (s, 2H, Hα), 2.50 (s, 3H, H1), 2.04 - 1.89
(m, 12H, Ad). 13C NMR (100 MHz, CDCl3) δ 144.7 (Cq), 144.5 (Cq), 138.0
(Cq), 137.9 (Cq), 131.0 (CHAr), 130.9 (CHAr), 127.2 (CHAr), 125.8 (CHAr),
124.0 (Cq), 119.9 (CHAr), 119.8 (Cq), 113.7 (CHAr), 39.7 (Ad), 37.2 (Ad), 32.1
(Ad), 28.2 (Ad), 21.3 (C1). HPLC-MS (ESI) tr= 37.1 min; [M+H]+ = 404.1 m/z.
HRMS (ESI) [M+H]+calcd for C30H30N 404.2378 found 404.2381.
Figure 6.27
Compound 3q: 2-adamantanone 1 (18 mg, 0.12 mmol) and ketone 2q were
coupled following the above-mentioned procedure (method B, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane) provided compound 3q (45
mg, 91%) as a sticky solid. 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.34 (m, 2H,
Ar), 7.31 - 7.24 (m, 4H, Ar), 7.03 - 6.95 (m, 4H, Ar), 6.43 (d, J = 7.7 Hz, 2H,
Ar), 3.49 (s, 2H, Hα), 2.04 - 1.89 (m, 12H, Ad). 13C NMR (100 MHz, CDCl3) δ
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162.1 (d, J = 245.9 Hz, CF), 145.0 (Cq), 144.4 (Cq), 136.6 (d, J = 3.3 Hz, Cq),
133.0 (d, J = 8.5 Hz, CHAr), 127.3 (CHAr), 125.9 (CHAr), 124.2 (Cq), 120.2
(CHAr), 119.6 (Cq), 117.3 (d, J = 22.3 Hz, CHAr), 113.6 (CHAr), 39.7 (Ad), 37.1
(Ad), 32.2 (Ad), 28.1 (Ad). HPLC-MS (ESI) tr= 34.2 min; [M+H]+ = 408.2 m/z.
HRMS (ESI) [M+H]+calcd for C29H27FN 408.2128 found 408.2126.
Figure 6.28
Compound 3r: 2-adamantanone 1 (230 mg, 1.53 mmol) and ketone 2r were
coupled following the above-mentioned procedure (method A, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane) provided compound 3r (434
mg, 90%) as a yellow solid (mp = 217 - 219 ◦C). 1H NMR (400 MHz, CDCl3) δ
7.29 (d, J = 8.0 Hz, 2H, Ar), 7.23 - 7.18 (m, 4H, Ar), 7.12 - 7.08 (m, 2H, Ar), 3.53
(br s, 2H, Hα), 2.04 (br s, 2H, Ad), 1.97 - 1.90 (m, 10H, Ad). 13C NMR (100
MHz, CDCl3) δ 155.0 (Cq), 146.6 (Cq), 127.5 (CHAr), 126.9 (CHAr), 126.7 (Cq),
122.6 (CHAr), 116.4 (CHAr), 116.38 (Cq), 39.5 (Ad), 37.0 (Ad), 32.5 (Ad), 27.9
(Ad). HPLC-MS (ESI, method B) tr= 22.5 min; [M+H]+ = 315.2 m/z. HRMS
(ESI) [M+H]+calcd for C23H23O 315.1749 found 315.1749.
Figure 6.29
Compound 3s: 2-adamantanone 1 (46.3 mg, 0.31 mmol) and ketone 2s
were coupled following the above-mentioned procedure (method A, Scheme 6.6).
The chromatographic purification (eluent: cyclohexane/EtOAc = 95:5) provided
compound 3s (89 mg, 77%) as orange crystals (mp = 182 - 184 ◦C). 1H NMR
(400 MHz, CDCl3) δ 7.19 (d, J = 8.5 Hz, 2H, H3), 6.76 (d, J = 2.4 Hz, 2H, H1),
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6.68 (dd, J = 8.5, 2.4 Hz, 2H, H2), 3.83 (s, 6H, H4), 3.48 (s, 2H, Hα), 2.03 (s,
2H, Ad), 1.96 - 1.91 (m, 10H, Ad). 13C NMR (100 MHz, CDCl3) δ 158.6 (Cq),
155.9 (Cq), 144.0 (Cq), 127.9 (CHAr), 119.5 (Cq), 115.4 (Cq), 109.0 (CHAr),
101.7 (CHAr), 55.4 (C4), 39.4 (Ad), 37.1 (Ad), 32.5 (Ad), 27.9 (Ad). HPLC-MS
(ESI) tr= 20.6 min; [M+H]+ = 375.2 m/z, [M+Na]+ = 397.1 m/z. HRMS (ESI)
[M+H]+calcd for C25H27O3 375.1960 found 375.1959.
Figure 6.30
Compound 3t: 2-adamantanone 1 (166.5 mg, 1.11 mmol) and ketone 2t were
coupled following the above-mentioned procedure (method A, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane) provided compound 3t (191
mg, 58%). The obtained spectroscopic data were in agreement with the literature
data [see Ref. 390].
Figure 6.31
Compound 3y: 2-adamantanone 1 (28.5 mg, 0.19 mmol) and ketone 2y
were coupled following the above-mentioned procedure (method B, Scheme 6.6).
The chromatographic purification (eluent: cyclohexane/EtOAc = 95:5) provided
compound 3y (75 mg, 91%) as yellow crystals (mp = 134 - 136 ◦C). 1H NMR
(400 MHz, CDCl3) δ 7.16 (dd, J = 8.4, 6.6 Hz, 1H, H3), 7.09 (t, J = 7.8 Hz, 1H,
H4), 6.94 (d, J = 7.5 Hz, 1H, Ar), 6.73 (dt, J = 8.4, 2.2 Hz, 1H, H2), 6.65 (d, J =
8.1 Hz, 1H, Ar), 6.55 (dd, J = 11.1, 2.2 Hz, 1H, H1), 4.65 (d, J = 17.6 Hz, 1H,
H6a), 4.59 (d, J = 17.6 Hz,1H, H6b), 4.29 (q, J = 7.1 Hz, 2H, H7), 3.26 (s, 1H,
Hα), 2.63 (s, 1H, Hα), 2.38 (s, 3H, H5), 2.20 - 1.97 (m, 5H, Ad), 1.83 (br s, 3H,
Ad), 1.69 - 1.59 (m, 2H, Ad), 1.45 (m, 2H, Ad), 1.30 (t, J = 7.1 Hz, 3H, H8). 13C
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NMR (100 MHz, CDCl3) δ 169.3 (COO), 161.5 (d, J = 240.0 Hz, CF), 146.1 (Cq),
144.5 (d, J = 10.2 Hz, Cq), 143.2 (Cq), 134.7 (Cq), 127.8 (d, J = 9.4 Hz, CHAr),
125.7 (Cq), 125.5 (CHAr), 123.5 (CHAr), 123.2 (d, J = 2.6 Hz, Cq), 118.9 (Cq),
109.4 (CHAr), 106.9 (d, J = 21.6 Hz, CHAr), 100.0 (d, J = 25.9 Hz, CHAr), 61.4
(C7), 48.9 (C6), 40.0 (Ad), 39.6 (Ad), 39.0 (Ad), 37.3 (Ad), 36.8 (Ad), 33.4 (Ad),
32.6 (Ad), 27.9 (Ad), 27.7 (Ad), 20.2 (C5), 14.2 (C8). HPLC-MS (ESI) tr = 23.1
min; [M+H]+ = 432.2 m/z, [M+Na]+ = 454.1 m/z. HRMS (ESI) [M+H]+calcd
for C28H31FNO2 432.2339 found 432.2338.
Figure 6.32
Compound 3z: 2-adamantanone 1 (60 mg, 0.4 mmol) and ketone 2z were
coupled following the above-mentioned procedure (method B, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane/EtOAc = 98:2) provided com-
pound 3z (119 mg, 90%) as a white solid (mp = 220 - 222 ◦C). 1H NMR (400
MHz, CDCl3) δ 7.50 (dd, J = 7.6, 1.1 Hz, 2H, Ar), 7.30 (dd, J = 7.6, 1.4 Hz, 2H,
Ar), 7.23 (dt, J = 7.3, 1.2 Hz, 2H, Ar), 7.16 (dt, J = 7.5, 1.7 Hz, 2H, Ar), 3.25 (s,
2H, Hα), 2.18 - 2.10 (m, 5H, Ad), 1.87 (s, 3H, Ad), 1.75 - 1.59 (m, 4H, Ad). 13C
NMR (100 MHz, CDCl3) δ 147.2 (Cq), 137.6 (Cq), 135.6 (Cq), 128.1 (CHAr),
127.3 (CHAr), 125.8 (CHAr), 125.7 (CHAr), 39.9 (Ad), 39.4 (Ad), 37.0 (Ad),
33.0 (Ad), 28.4 (Ad), 27.6 (Ad). HPLC-MS (ESI) tr= 24.4 min; [M+H]+ = 331.2
m/z. HRMS (ESI) [M+H]+calcd for C23H23S 331.1520 found 331.1522.
Procedure for the synthesis of alkenes 3A and 3B:
Scheme 6.7
Compound 3A and 3B were synthetized by the direct oxidation of alkene 3z
(Scheme 6.7), by adapting a reported synthetic procedure [see Ref. 387]. Alkene
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3z (40.3 mg, 0.122 mmol) was dissolved in 1-butanol (4.5 mL). Then, H2O2
(30% in H2O, 122 µL, 1.08 mmol) and ZrCl4 (71.1 mg, 0.31 mmol) were added
and the mixture was stirred at room temperature for 15 minutes. After that, the
solution was evaporated under vacuum and the crude product was purified by flash
chromatography on silica gel (eluent: cyclohexane/EtOAc = 90:10). However,
it was not possible to isolate compounds 3A and 3B from the starting material
3z. Both the 1H NMR spectrum and the HPLC-MS analysis showed a 78%
conversion of alkene 3z to a mixture of alkenes 3A and 3B (3A/3B = 85/15). The
mixture of the three olefins (3z, 3A and 3B) was subjected to photooxygenation
reaction, but no traces of the corresponding 1,2-dioxetanes were observed.
Alkene 3A: 1H NMR (400 MHz, CDCl3) δ 7.93 - 7.90 (m, 2H, Ar), 7.42 -
7.36 (m, 6H, Ar), 3.30 (br s, 2H, Hα), 2.18 - 2.09 (m, 5H, Ad), 1.90 (br s, 3H,
Ad), 1.80 (d, J = 11.2 Hz, 2H, Ad), 1.61 (d, J = 11.6 Hz, 2H, Ad). HPLC-MS
(ESI) tr= 14.0 min; [M+H]+ = 347.0 m/z, [M+Na]+ = 369.0 m/z, [2M+Na]+ =
715.1 m/z.
Alkene 3B: 1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 7.6 Hz, 2H, Ar), 7.45
- 7.36 (m, 6H, Ar), 3.30 (br s, 2H, Hα), 2.18 - 2.09 (m, 5H, Ad), 1.90 (br s, 3H,
Ad), 1.80 (d, J = 11.2 Hz, 2H, Ad), 1.61 (d, J = 11.6 Hz, 2H, Ad). HPLC-MS
(ESI) tr= 13.5 min; [M+H]+ = 363.0 m/z, [M+Na]+ = 385.0 m/z, [2M+Na]+ =
747.0 m/z.
Figure 6.33
Compound 3C: 2-adamantanone 1 (45 mg, 0.3 mmol) and ketone 2C were
coupled following the above-mentioned procedure (method B, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane) provided compound 3C (72
mg, 77%). The obtained spectroscopic data were in agreement with the literature
data [see Ref. 390].
Compound 3D: 2-adamantanone 1 (90 mg, 0.6 mmol) and ketone 2D were
coupled following the above-mentioned procedure (method B, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane) provided compound 3D (142
mg, 68%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 7.2
Hz, 1H, Ar), 7.90 (d, J = 7.6 Hz, 1H, Ar), 7.79 (d, J = 8.4 Hz, 1H, Ar), 7.70
(dd, J = 7.2, 1.6 Hz, 1H, Ar), 7.56 (t, J = 7.6 Hz, 1H, Ar), 7.49 - 7.43 (m, 3H,
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Figure 6.34
Ar), 7.34 (dt, J = 7.6, 1.6 Hz, 1H, Ar), 7.27 (dt, J = 7.4, 1.2 Hz, 1H, Ar), 3.63
(s, 1H, Hα), 3.58 (s, 1H, Hα), 2.00 - 1.82 (m, 12H, Ad). 13C NMR (100 MHz,
CDCl3) δ 148.5 (Cq), 135.3 (Cq), 134.3 (Cq), 133.6 (Cq), 132.9 (Cq), 132.0 (Cq),
130.0 (Cq), 128.2 (CHAr), 127.2 (CHAr), 126.3 (CHAr), 125.9 (CHAr), 125.7
(CHAr), 125.5 (CHAr), 124.9 (CHAr), 124.9 (CHAr), 124.5 (CHAr), 123.7 (Cq),
119.1 (CHAr), 39.7 (Ad), 39.6 (Ad), 37.0 (Ad), 33.5 (Ad), 31.2 (Ad), 30.3 (Ad),
27.9 (Ad). HPLC-MS (ESI) tr= 29.7 min; [M+H]+ = 349.1 m/z. HRMS (ESI)
[M+H]+calcd for C27H25 349.1956 found 349.1955.
Figure 6.35
Compound 3E: 2-adamantanone 1 (70 mg, 0.46 mmol) and ketone 2E were
coupled following the above-mentioned procedure (method A, Scheme 6.6). The
crude was purified by flash chromatography on silica gel (eluent: cyclohexane),
however, it was not possible to perfectly purify compound 3E (24 mg, 12% yield,
calculated from the 1H NMR spectrum). Because of the small amount of not
perfectly purified alkene 3E, 13C NMR spectrum was not acquired. Both the
1H NMR spectrum and the HPLC-MS analysis confirmed the presence of 3E.
The photooxygenation was carried out on the contaminated sample of 3E and
we observed no traces of the corresponding 1,2-dioxetane. 1H NMR (400 MHz,
CDCl3) δ 7.69, (d, J = 8.8 Hz, 2H, Ar), 7.37 - 7.32 (m, 4H, Ar), 7.25 - 7.13 (m,
4H, Ar), 6.92 (s, 1H, H1), 6.45 (d, J = 8.8 Hz, 2H, Ar), 3.59 (br s, 1H, Hα), 3.44
(br s, 1H, Hα), 2.97 (s, 6H, H2), 2.51 (d, J = 12.8 Hz, 2H, Ad), 2.24 - 2.13 (m,
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10H, Ad). HPLC-MS (ESI) tr= 35.4 min; [M+H]+ = 444.2 m/z.
Figure 6.36
Compound 3G: 2-adamantanone 1 (146 mg, 0.97 mmol) and ketone 2G were
coupled following the above-mentioned procedure (method A, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane) provided compound 3G (10
mg, 3%) as a sticky solid. 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.30 (m, 4H,
Ar), 7.24 - 7.02 (m, 4H, Ar), 6.92 (s, 2H, H1 and H2), 2.65 (br s, 2H, Hα), 2.09 -
1.93 (m, 6H, Ad), 1.82 - 1.80 (m, 3H, Ad), 1.65 - 1.62 (m, 3H, Ad). 13C NMR
(100 MHz, CDCl3) δ 146.6 (Cq), 139.6 (Cq), 134.9 (Cq), 131.0 (CHAr), 128.2
(Cq), 121.1 (CHAr), 127.9 (CHAr), 127.7 (CHAr), 125.9 (CHAr), 39.5 (Ad),
39.3 (Ad), 37.1 (Ad), 32.8 (Ad), 28.4 (Ad), 27.9 (Ad). HPLC-MS (ESI) tr= 25.6
min; [M+H]+ =325.1 m/z, [M+Na]+ = 347.1 m/z. HRMS (ESI) [M+H]+calcd
for C25H25 325.1956 found 325.1956.
Figure 6.37
Compound 3H: 2-adamantanone 1 (45 mg, 0.3 mmol) and ketone 2H were
coupled following the above-mentioned procedure (method B, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane) provided compound 3H (68
mg, 67%) as a pale yellow solid (mp = 124 -126 ◦C). 1H NMR (400 MHz, CDCl3)
δ 7.74 (d, J = 7.2 Hz, 2H, Ar), 7.42 - 7.36 (m, 4H, Ar), 7.34 - 7.30 (m, 2H, Ar),
7.07 (t, J = 8.4 Hz, 1H, H2), 6.62 (s, 1H, H1), 3.55 (s, 1H, Hα), 3.19 (s, 1H, Hα),
2.05 - 1.88 (m, 12H, Ad). 13C NMR (100 MHz, CDCl3) δ 154.3 (Cq), 148.9
(Cq), 141.2 (Cq), 134.1 (Cq), 128.3 (CHAr), 128.1 (CHAr), 127.41 (CHAr),
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127.40 (CHAr), 124.4 (CHAr), 124.1 (Cq), 122.8 (CHAr), 116.9 (CHAr), 115.9
(Cq), 102.6 (C1), 39.4 (Ad), 39.2 (Ad), 37.1 (Ad), 33.5 (Ad), 28.2 (Ad). HPLC-
MS (ESI) tr= 35.3 min; [M+H]+ = 341.3 m/z. HRMS (ESI) [M+H]+calcd for
C25H25O 341.1905 found 341.1908.
Figure 6.38
Compound 3I: 2-adamantanone 1 (1.54 g, 10.27 mmol) and lactone 2I were
coupled following the above-mentioned procedure (method C, Scheme 6.6). The
chromatographic purification (eluent: cyclohexane/EtOAc = 90:10) provided
compound 3I (33 mg, 18%) as a yellow sticky solid. 1H NMR(400 MHz, CDCl3)
δ 7.05 (dt, J = 9.2, 1.6 Hz, 1H, Ar), 6.87 (dd, J = 7.3, 1.5 Hz, 1H, Ar), 6.80 (t, J =
7.2 Hz, 1H, Ar), 6.71 (d, J = 8.1 Hz, 1H, Ar), 6.37 (d, J = 10.1 Hz, 1H), 6.17 (d, J
= 10.1 Hz, 1H), 3.30 (s, 1H, Hα), 2.23 (s, 1H, Hα), 1.99 (br s, 2H, Ad), 1.9 - 1.74
(m. 10H, Ad). 13C NMR (100 MHz, CDCl3) δ 154.5 (Cq), 138.2 (Cq), 128.9
(CHAr), 125.7 (CHAr), 124.1 (Cq), 121.8 (Cq), 121.77 (CHAr), 121.5 (CHAr),
119.2 (CHAr), 114.5 (CHAr), 39.3 (Ad), 38.6 (Ad), 37.2 (Ad), 31.2 (Ad), 29.2
(Ad), 28.4 (Ad). HPLC-MS (ESI) tr = 21.8 min; [M+H]+ = 265.1 m/z. HRMS
(ESI) [M+H]+calcd for C19H21O 265.1592 found 265.1596.
6.3.4 General procedure for the synthesis of 1,2-dioxetanes 4h-t, 4H-
I:
Scheme 6.8
The 1,2-dioxetane derivatives 4 were synthesized by photooxygenation of the
corresponding olefin 3 (Scheme 6.8): Alkene 3 (16 eq.) and Methylene Blue (1
eq.) were dissolved in CH2Cl2 (1 mL/10 mg of alkene 3). The solution was cooled
(usually at -20 ◦C) and subjected to an oxygen atmosphere (1 atm, balloon). The
solution was stirred at the same temperature under irradiation using a 500 W
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halogen lamp equipped with an UV cut-off filter (0.5% transmission at 550 nm).
The irradiation was continued until the starting material disappeared (usually 2
h of irradiation), and the conversion was monitored by 1H NMR. The product 4
was purified by a rapid filtration on a 5 mm layer of silica gel, using cooled (-40
◦C) CH2Cl2 as eluent, and the filtered solution was evaporated under vacuum at 0
◦C. The 1H NMR spectrum was acquired immediately after stopping the reaction,
whereas the 13C NMR spectrum acquisition was carried out overnight. During
the 13C NMR spectrum acquisition, some 1,2-dioxetanes 4 partially decomposed
into the corresponding ketones 1 and 2. For this reason, the peaks referring to
the dioxetane 4 are marked with a star in the 13C NMR spectra. Due to the
thermo-lability of the synthesized 1,2-dioxetanes 4, it was not possible to obtain
the corresponding HRMS analyses.
Figure 6.39
Compound 4h: alkene 3h (21 mg, 0.048 mmol) was photooxygenated fol-
lowing the above-mentioned procedure (Scheme 6.8). The solution was irradiated
at -20 ◦Cfor 2h to give compound 4h (21.3 mg, 95%), as a yellow sticky solid.
1H NMR (400 MHz, CDCl3) δ 8.18 (dd, J = 8.6, 6.4 Hz, 2H, H1), 6.94 (dt, J =
8.6, 2.4 Hz, 2H, H2), 6.55 (dd, J = 10.8, 2.4 Hz, 2H, H3), 4.57 (s, 2H, H4), 4.32
(q, J = 7.2 Hz, 2H, H5), 2.25 (s, 2H, Hα), 1.81 (d. J = 13.8 Hz, 2H, Ad), 1.66 (br
s, 1H, Ad), 1.49 - 1.42 (m, 5H, Ad), 1.32, (t, J = 7.2 Hz, 3H, H6), 1.21 (d, J =
12.3 Hz, 2H, Ad), 0.59 (d, J = 15.0 Hz, 2H, Ad). 13C NMR(100 MHz, CDCl3) δ
168.3 (COO), 163.4 (d, J = 244.4 Hz, CF), 140.5 (d, J = 10.6 Hz, Cq), 130.2 (d, J
= 9.8 Hz, CHAr), 117.5 (d, J = 2.5 Hz, Cq), 108.4 (d, J = 21.6 Hz, CHAr), 99.7
(d, J = 26.7 Hz, CHAr), 97.7 (C*), 86.3 (C*), 62.0 (C5), 48.6 (C4), 36.0 (Ad),
32.9 (Ad), 32.8 (Ad), 31.6 (Ad), 25.6 (Ad), 25.4 (Ad), 14.2 (C6). HPLC-MS
(ESI) tr = 15.3 min; [M+H]+ = 468.2 m/z.
Compound 4i: alkene 3i (18 mg, 0.041 mmol) was photooxygenated follow-
ing the above-mentioned procedure (Scheme 6.8). The solution was irradiated
at -30 ◦C for 7h to give compound 4i (10.6 mg, 55%), as a yellow sticky solid.
1H NMR (400 MHz, CDCl3) δ 8.27 (dd, J = 8.8, 6.4 Hz, 1H, Ar), 7.37 - 7.31 (m,
1H, Ar), 6.97 - 6.90 (m, 2H, Ar), 6.61 (d, J = 8.4 Hz, 1H, Ar), 6.54 (dd, J = 10.8,
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Figure 6.40
2.4 Hz, 1H, Ar), 4.62 (d, J = 18.4 Hz, 1H, H1a), 4.56 (d, J = 18.4 Hz, 1H, H1b),
4.32 (q, J = 7.2 Hz, 2H, H2), 2.51 (br s, 1H, Hα), 2.14 (br s, 1H, Hα), 1.94 (br d, J
= 13.6 Hz, 1H, Ad), 1.83 (br d, J = 16.4 Hz, 1H, Ad), 1.66 (br s, 2H, Ad), 1.53 -
1.42 (m, 4H, Ad), 1.31 (t, J = 7.2 Hz, 3H, H3), 1.23 - 1.19 (m, 2H, Ad), 0.64 (br t,
J = 13.2 Hz, 2H, Ad). 13C NMR(100 MHz, CDCl3) δ 168.5 (COO), 164.5 (d, J
= 117.9 Hz, CF), 161.2 (d, J = 126.4 Hz, CF), 141.2 (d, = 7.5 Hz, Cq), 140.2 (d,
J = 13.9 Hz, Cq), 130.5 (d, J = 13.1 Hz, CHAr), 130.2 (d, J = 14.8 Hz, CHAr),
117.5 (Cq), 110.4 (d, J = 32.1 Hz, CHAr), 108.4 (d, J = 12.6 Hz, CHAr), 108.2
(d, J = 12.2 Hz, CHAr), 99.6 (d, J = 35.6 Hz, CHAr), 97.7 (C*), 91.2 (Cq), 86.9
(C*), 62.0 (C2), 49.4 (C1), 36.0 (Ad), 33.7 (Ad), 33.5 (Ad), 33.2 (Ad), 33.0 (Ad),
31.8 (Ad), 31.4 (Ad), 25.6 (Ad), 25.4 (Ad), 14.2 (C3). HPLC-MS (ESI) tr = 14.1
min; [M+H]+ = 468.0 m/z.
Figure 6.41
Compound 4j: alkene 3j (20 mg, 0.046 mmol) was photooxygenated follow-
ing the above-mentioned procedure (Scheme 6.8). The solution was irradiated
at -20 ◦C for 4h to give compound 4j (19 mg, 89%), as a yellow sticky solid. 1H
NMR (400 MHz, CDCl3) δ 7.92 (dd, J = 9.1, 2.9 Hz, 2H, Ar), 7.12 - 7.07 (m, 2H,
Ar), 6.76 (dd, J = 8.9, 4.1 Hz, 2H, Ar), 4.60 (s, 2H, H1), 4.30 (q, J = 7.1 Hz, 2H,
H2), 2.31 (s, 2H, Hα), 1.83 (d, J = 18.4 Hz, 2H, Ad), 1.67 (br s, 1H, Ad), 1.50 -
1.42 (m, 5H, Ad), 1.29 (t, J = 7.1 Hz, 3H, H3), 1.23 (d, J = 12.3 Hz, 2H, Ad), 0.63
(d, J = 13.1 Hz, 2H, Ad). 13C NMR(100 MHz, CDCl3) δ 168.9 (COO), 157.9 (d,
J = 238.4 Hz, CF), 135.8 (d, J = 2.1 Hz, Cq), 122.7 (d, J = 7.1 Hz, Cq), 116.2 (d,
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J = 23.1 Hz, CHAr), 114.8 (d, J = 24.2 Hz, CHAr), 113.0 (d, J = 7.8 Hz, CHAr),
97.8 (C*), 86.6 (C*), 61.8 (C2), 48.8 (C1), 36.0 (Ad), 32.9 (Ad), 32.9 (Ad), 31.6
(Ad), 25.6 (Ad), 25.4 (Ad), 14.2 (C3). HPLC-MS (ESI) tr = 16.2 min; [M+H]+
= 468.2 m/z.
Figure 6.42
Compound 4k: alkene 3k (25 mg, 0.053 mmol) was photooxygenated fol-
lowing the above-mentioned procedure (Scheme 6.8). The solution was irradiated
at -20 ◦C for 4h to give compound 4k (23.8 mg, 89%), as a yellow sticky solid.
1H NMR (400 MHz, CDCl3) δ 8.01 (dd, J =10.6, 8.7 Hz, 2H, Ar), 6.65 (dd, J
= 11.8, 6.3 Hz, 2H, Ar), 4.52 (s, 2H, H1), 4.33 (q, J = 7.1 Hz, 2H, H2), 2.26 (s,
2H, Hα), 1.82 (d, J = 13.8 Hz, 2H, Ad), 1.68 (br s, 1H, Ad), 1.51 - 1.44 (m, 5H,
Ad), 1.33 (t, J = 7.1 Hz, 3H, H3), 1.26 (d, J = 7.1 Hz, 2H, Ad), 0.59 (d, J = 12.9
Hz, 2H, Ad). 13C NMR (100 MHz, CDCl3) δ 168.0 (COO), 150.3 (dd, J = 247.3,
13.7 Hz, CF), 145.7 (dd, J = 241.7, 12.9 Hz, CF), 135.9 (m, Cq), 117.3 (m, Cq),
117.1 (dd, J = 21.2, 1.8 Hz, CHAr), 101.8 (d, J = 22.3 Hz, CHAr), 97.8 (C*), 85.8
(C*), 62.2 (C2), 49.0 (C1), 35.9 (Ad), 33.0 (Ad), 32.9 (Ad), 31.6 (Ad), 25.5 (Ad),
25.4 (Ad), 14.2 (C3). HPLC-MS (ESI) tr = 17.5 min; [M+H]+ = 504.0 m/z.
Figure 6.43
Compound 4l: alkene 3l (20 mg, 0.046 mmol) was photooxygenated follow-
ing the above-mentioned procedure (Scheme 6.8). The solution was irradiated
at -20 ◦C for 2h to give compound 4l (17 mg, 80%), as a sticky solid. 1H NMR
(400 MHz, CDCl3) δ 8.17 (dd, J = 8.2, 6.6 Hz, 1H, H1), 8.08 (d, J = 7.9 Hz, 1H,
Ar), 7.04 (d, J = 7.9 Hz, 1H, Ar), 6.89 (dt, J = 8.2, 2.3 Hz, 1H, H2), 6.62 (s, 1H,
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H4), 6.54 (dd, J = 11.0, 2.3 Hz, 1H, H3), 4.63 (d, J = 18.2 Hz, 1H, H6a), 4.56
(d, J = 18.2 Hz, 1H, H6b), 4.31 (q, J = 7.1 Hz, 2H, H7), 2.41 (s, 3H, H5), 2.31
(s, 1H, Hα), 2.24 (s, 1H, Hα), 1.84 - 1.77 (m, 2H, Ad), 1.65 (s, 1H, Ad), 1.48 -
1.40 (m, 5H, Ad), 1.30 (t, J = 7.1 Hz, 3H, H8), 1.22 - 1.16 (m, 2H, Ad), 0.65 -
0.60 (m, 2H, Ad). 13C NMR(100 MHz, CDCl3) δ 168.8 (COO), 163.4 (d, J =
243.8 Hz, CF), 140.9 (d, J = 10.5 Hz, Cq), 139.3 (Cq), 138.9 (Cq), 130.1 (d, J
= 10.0 Hz, CHAr), 128.3 (CHAr), 122.4 (CHAr), 118.9 (Cq), 117.7 (Cq), 112.6
(CHAr), 107.7 (d, J = 21.6 Hz, CHAr), 99.5 (d, J = 26.4 Hz, CHAr), 97.8 (C*),
86.6 (C*), 61.7 (C7), 48.5 (C6), 36.1 (Ad), 32.94 (Ad), 32.9 (Ad), 32.8 (Ad), 31.7
(Ad), 31.69 (Ad), 25.6 (Ad), 25.5 (Ad), 21.8 (C5), 14.2 (C8). HPLC-MS (ESI)
tr = 15.9 min; [M+H]+ = 464.2 m/z.
Figure 6.44
Compound 4m: alkene 3m (21.7 mg, 0.066 mmol) was photooxygenated
following the above-mentioned procedure (Scheme 6.8). The solution was irra-
diated at -40 ◦C for 12 h to give compound 4m (19 mg, 80%), as a sticky solid.
1H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 8.8 Hz, 2H, Ar), 7.41 (t, J = 8.4 Hz,
2H, Ar), 7.18 (t, J = 7.6 Hz, 2H, Ar), 7.02 (d, J = 8.4 Hz, 2H, Ar), 3.49 (s, 3H,
H1), 2.29 (br s, 2H, Hα), 1.84 (d, J = 15.2 Hz, 2H, Ad), 1.64 (br s, 1H, Ad), 1.47 -
1.38 (m, 5H, Ad), 1.18 (d, J = 15.2 Hz, 2H, Ad), 0.67 (d, J = 13.6 Hz, 2H, Ad).
13C NMR(100 MHz, CDCl3) δ 140.3 (Cq), 129.0 (CHAr), 127.9 (CHAr), 121.6
(Cq), 120.3 (CHAr), 111.7 (CHAr), 97.8 (C*), 87.0 (C*), 36.2, 33.1, 33.0, 32.9,
31.7, 29.7, 25.8, 25.5 (among the last unassigned 8 signals, 7 refer to adamantyl
carbons and 1 refers to C1). HPLC-MS (ESI) tr = 16.7 min; [M+H]+ = 360.0
m/z.
Figure 6.45
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Compound 4n: alkene 3n (12 mg, 0.027 mmol) was photooxygenated fol-
lowing the abovementioned procedure (Scheme 6.8). The solution was irradiated
at -40 ◦C for 2 h to give compound 4n (11.6 mg, 91%), as a sticky solid. The 1H
NMR spectrum showed a partial degradation of the product 4n into the corre-
sponding ketones 1 and 2n. It was not possible to obtain the 13C NMR spectrum
because the 1,2-dioxetane 4n totally decomposed during the overnight acquisition.
1H NMR (400 MHz, CDCl3) δ 8.22 (dd, J = 8.0, 1.6 Hz, 2H, Ar), 7.41 (dt, J =
7.6, 1.6 Hz, 2H, Ar), 7.16 (t, J = 7.6 Hz, 2H, Ar), 7.04 (d, J = 8.0 Hz, 2H, Ar),
4.17 (q, J = 7.2 Hz, 2H, H3), 4.01 - 3.98 (m, 2H, H1), 2.43 (t, J = 7.2 Hz, 2H, H2),
2.26 (br s, 2H, Hα), 1.92 - 1.79 (m, 6H), 1.63 (br s, 1H), 1.46 - 1.42 (m, 4H), 1.36
- 1.35 (m, 1H), 1.27 (t, J = 7.2 Hz, 3H, H4), 1.14 (br d, J =12.0 Hz, 2H, Ad), 0.59
(br d, J = 13.2 Hz, 2H, Ad). HPLC-MS (ESI) tr = 20.8 min; [M+H]+ = 474.2
m/z.
Figure 6.46
Compound 4o: alkene 3o (30 mg, 0.077 mmol) was photooxygenated fol-
lowing the above-mentioned procedure (Scheme 6.8). The solution was irradiated
at -20 ◦C for 2 h to give compound 4o (27.5 mg, 85%), as a brown sticky solid.
1H NMR (400 MHz, CDCl3) δ 8.27 (dd, J = 7.2, 2.2 Hz, 2H, Ar), 7.65 (t, J = 7.4
Hz, 2H, Ar), 7.57 - 7.53 (m, 1H, H1), 7.25 (d, J = 7.8, Hz, 2H, Ar), 7.21 - 7.13
(m, 4H, Ar), 6.42 (dd, J = 8.1, 1.6 Hz, 2H, Ar), 2.35 (br s, 2H, Hα), 1.86 (d, J =
12.5 Hz, 2H, Ad), 1.67 (br s, 1H, Ad), 1.53 - 1.47 (m, 5H, Ad), 1.26 - 1.24 (m,
2H, Ad), 0.88 (d, J = 13.7 Hz, 2H, Ad). 13C NMR (100 MHz, CDCl3) δ 140.5
(Cq), 139.9 (Cq), 130.9 (CHAr), 130.8 (CHAr), 128.8 (CHAr), 128.7 (CHAr),
128.4 (CHAr), 120.4 (CHAr), 119.0 (Cq), 113.4 (CHAr), 98.2 (C*), 86.7 (C*),
36.2 (Ad), 33.0 (Ad), 31.8 (Ad), 25.7 (Ad), 25.6 (Ad). HPLC-MS (ESI) tr = 22.5
min; [M+H]+ = 422.1 m/z.
Compound 4p: alkene 3p (17 mg, 0.042 mmol) was photooxygenated fol-
lowing the above-mentioned procedure (Scheme 6.8). The solution was irradiated
at -40 ◦C for 2 h to give compound 4p (16 mg, 87%), as a sticky solid. The 13C
NMR spectrum showed a partial degradation of the product 4p into the corre-
sponding ketones 1 and 2p. 1H NMR (400 MHz, CDCl3) δ 8.26 (dd, J = 7.2, 2.0
Hz, 2H, Ar), 7.43 (d, J = 8.2 Hz, 2H, Ar), 7.21 - 7.11 (m, 6H, Ar), 6.45 (dd, J =
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Figure 6.47
8.2, 1.3 Hz, 2H, Ar), 2.50 (s, 3H, H1), 2.35 (s, 2H, Hα), 1.85 (d, J = 13.6 Hz, 2H,
Ad), 1.67 (br s, 1H, Ad), 1.52 - 1.47 (m, 5H, Ad), 1.25 - 1.23 (m, 2H, Ad), 0.88
(br d, J = 11.0 Hz, 2H, Ad). 13C NMR (100 MHz, CDCl3) δ 140.6 (Cq), 138.7
(Cq), 137.2 (Cq), 131.5 (CHAr), 130.4 (CHAr), 128.7 (CHAr), 128.3 (CHAr),
120.3 (CHAr), 119.0 (Cq), 113.5 (CHAr), 98.2 (C*), 86.7 (C*), 36.2 (Ad), 33.02
(Ad), 33.0 (Ad), 31.8 (Ad), 25.7 (Ad), 25.6 (Ad), 21.3 (Ad). HPLC-MS (ESI) tr
= 26.9 min; [M+H]+ = 436.1 m/z.
Figure 6.48
Compound 4q: alkene 3q (19 mg, 0.047 mmol) was photooxygenated fol-
lowing the above-mentioned procedure (Scheme 6.8). The solution was irradiated
at -20 ◦C for 2 h to give compound 4q (19 mg, 92%), as a sticky solid. 1H NMR
(400 MHz, CDCl3) δ 8.27 (dd, J = 7.3, 1.9 Hz, 2H, Ar), 7.34 (t, J = 8.5 Hz, 2H,
Ar), 7.25 - 7.15 (m. 6H, Ar), 6.40 (dd, J = 7.8, 1.2 Hz, 2H, Ar), 2.34 (s, 2H, Hα),
1.85 (br d, J = 13.2 Hz, 2H, Ad), 1.67 (br s, 1H, Ad), 1.52 - 1.47 (m, 5H, Ad),
1.26 - 1.24 (m, 2H, Ad), 0.85 (br d, J = 12.8 Hz, 2H, Ad). 13C NMR (100 MHz,
CDCl3) δ 162.4 (d, J = 247.1 Hz, CF), 140.5 (Cq), 135.7 (Cq), 132.6 (d, J = 8.5
Hz, CHAr), 128.8 (CHAr), 128.5 (CHAr), 120.6 (CHAr), 119.2 (Cq), 118.0 (d, J
= 22.4 Hz, CHAr), 113.3 (CHAr), 98.1 (C*), 86.6 (C*), 36.2 (Ad), 33.04 (Ad),
33.0 (Ad), 31.7 (Ad), 25.6 (Ad), 25.57 (Ad). HPLC-MS (ESI) tr = 22.0 min;
[M+H]+ = 440.1 m/z, [M+Na]+ = 462.0 m/z.
Compound 4r: alkene 3r (25 mg, 0.08 mmol) was photooxygenated follow-
ing the above-mentioned procedure (Scheme 6.8). The solution was irradiated
at -20 ◦C for 5 h to give compound 4r (25 mg, 91%), as a white solid. 1H NMR
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Figure 6.49
(400 MHz, CDCl3) δ 8.18 (dd, J = 7.6, 1.6 Hz, 2H, Ar), 7.43 (dt, J = 8.0, 1.6 Hz,
2H, Ar), 7.30 (dt, J = 7.6, 1.2 Hz, 2H, Ar), 7.22 (dd, J =8.0, 1.2 Hz, 2H, Ar), 2.43
(br s, 2H, Hα), 1.85 (d, J = 16.8 Hz, 2H, Ad), 1.67 (br s, 1H, Ad), 1.50 - 1.45 (m,
5H, Ad), 1.22 (d, J = 12.7 Hz, 2H, Ad), 0.69 (d, J = 15.2 Hz, 2H, Ad). 13C NMR
(100 MHz, CDCl3) δ 151.2 (Cq), 129.8 (CHAr), 128.3 (CHAr), 123.1 (CHAr),
121.6 (Cq), 116.0 (CHAr), 97.0 (C*), 84.8 (C*), 36.0 (Ad), 33.1 (Ad), 32.8 (Ad),
31.7 (Ad), 25.5 (Ad), 25.3 (Ad). HPLC-MS (ESI) tr = 18.9 min; [M+H]+ =
347.2 m/z.
Figure 6.50
Compound 4s: alkene 3s (19 mg, 0.051 mmol) was photooxygenated follow-
ing the above-mentioned procedure (Scheme 6.8). The solution was irradiated
at -40 ◦C for 7 h to give compound 4s (17 mg, 82%), as a sticky solid. 1H NMR
(400 MHz, CDCl3) δ 8.05 (d, J = 8.6 Hz, 2H, H1), 6.86 (dd, J = 8.6, 2.5 Hz, 2H,
H2), 6.72 (d, J = 2.5 Hz, 2H, H3), 3.87 (s, 6H, H4), 2.44 (s, 2H, Hα), 1.84 (d, J =
12.8 Hz, 2H, Ad), 1.67 (s, 1H, Ad), 1.51 - 1.47 (m, 5H, Ad), 1.24 (d, J = 10.8 Hz,
2H, Ad), 0.70 (d, J = 13.7, 2H, Ad). 13C NMR (100 MHz, CDCl3) δ 160.9 (Cq),
152.3 (Cq), 129.2 (CHAr), 114.2 (Cq), 109.9 (CHAr), 100.7 (CHAr), 97.1 (C*),
84.6 (C*), 55.5 (C4), 36.1 (Ad), 33.17 (Ad), 32.83 (Ad), 31.8 (Ad), 25.55 (Ad),
25.43 (Ad). HPLC-MS (ESI) tr = 17.9 min; [M+H]+ = 407.1 m/z, [M+Na]+ =
429.0 m/z.
Compound 4t: alkene 3t (20 mg, 0.067 mmol) was photooxygenated follow-
ing the above-mentioned procedure (Scheme 6.8). The solution was irradiated at
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Figure 6.51
-20 ◦C for 10 h. During the irradiation the 1,2-dioxetane 4t partially decomposed
into the corresponding ketones 1 and 2t. Compound 4t was obtained with a 50%
yield (11 mg), calculated from the 1H NMR spectrum of the filtered mixture. 1H
NMR (400 MHz, CDCl3) δ 8.04 (d, J = 7.6 Hz, 2H, Ar), 7.59 (d, J = 7.6 Hz, 2H,
Ar), 7.42 (t, J = 7.6 Hz, 2H, Ar), 7.32 (t, J = 7.6 Hz, 2H, Ar), 3.06 (br s, 2H, Hα),
1.75 (br s, 1H, Ad), 1.61 (d, J = 13.6 Hz, 4H, Ad), 1.40 (br s, 1H, Ad), 1.34 -1.31
(m, 4H, Ad), 0.68 (d, J = 15.2 Hz, 2H, Ad). 13C NMR (100 MHz, CDCl3) δ 142.6
(Cq), 140.1 (Cq), 130.2 (CHAr), 127.2 (CHAr), 126.8 (CHAr), 120.1 (CHAr),
97.7 (C*), 94.5 (C*), 36.0 (Ad), 33.7 (Ad), 33.2 (Ad), 31.9 (Ad), 25.5 (Ad), 25.4
(Ad). HPLC-MS (ESI) tr = 15.8 min; [M+H]+ = 331.1 m/z, [M+K]+ = 369.0
m/z.
Figure 6.52
Compound 4H: alkene 3H (20 mg, 0.059 mmol) was photooxygenated fol-
lowing the above-mentioned procedure (Scheme 6.8). The solution was irradiated
at -20 ◦C for 4 h to give compound 4H (20.9 mg, 95%), as a sticky solid. 1H
NMR (400 MHz, CDCl3) δ 8.31 (dd, J = 7.9, 1.5 Hz, 1H, Ar), 7.81 (dd, J =8.0,
2.0 Hz, 2H, Ar), 7.49 - 7.43 (m, 4H, Ar), 7.32 (t, J = 8.0, 1H, Ar), 7.26 (m, 1H,
Ar), 6.30 (s, 1H, H1), 2.99 (s, 1H, Hα), 2.53 (s, 1H, Hα), 2.07 (br d, J = 14.0
Hz, 2H, Ad), 1.84 (br d, J = 13.4 Hz, 1H, Ad), 1.70 - 1.59 (m, 5H, Ad), 1.53 -
1.49 (m, 1H, Ad), 1.30 - 1.25 (m, 2H, Ad), 0.75 (br d, J = 19.9 Hz, 1H, Ad). 13C
NMR (100 MHz, CDCl3) δ 151.0 (Cq), 150.9 (Cq), 132.9 (Cq), 129.8 (CHAr),
129.7 (CHAr), 129.3 (CHAr), 128.7 (CHAr), 125.5 (CHAr), 123.5 (CHAr), 119.6
(Cq), 116.2 (CHAr), 98.3 (CHAr), 97.4 (C*), 83.4 (C*), 36.2 (Ad), 33.8 (Ad),
33.77 (Ad), 33.0 (Ad), 32.6 (Ad), 32.4 (Ad), 31.5 (Ad), 25.98 (Ad), 25.84 (Ad).
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HPLC-MS (ESI) tr = 20.1 min; [M+H]+ = 373.3 m/z.
Figure 6.53
Compound 4I: alkene 3I (25 mg, 0.095 mmol) was photooxygenated follow-
ing the above-mentioned procedure (Scheme 6.8). The solution was irradiated
at -40 ◦C for 3 h. The product 4I partially decomposed into the corresponding
ketones 1 and 2I during the photooxygenation. Compound 4I was obtained with
a 78% yield (21.9 mg), calculated from the 1H NMR spectrum of the filtered
mixture. The peaks of the 1,2-dioxetane 4I are marked with a star in both the 1H
NMR and 13C NMR spectra. 1H NMR (400 MHz, CDCl3) δ 7.29 (dt, J = 8.4, 1.6
Hz, 1H, Ar), 7.19 - 7.15 (m, 2H, Ar), 7.02 (dt, J = 7.2, 0.8 Hz, 1H, Ar), 6.87 (d, J
= 10.0 Hz, 1H), 6.24 (d, J = 10.0 Hz, 1H), 3.16 (s, 1H, Hα), 2.75 (s, 1H, Hα), 1.89
- 1.54 (m, 12H, Ad). 13C NMR (100 MHz, CDCl3) δ 151.2 (Cq), 130.2, 129.0,
127.0, 122.1, 118.4 (Cq), 116.5, 116.4 (among the last unassigned 6 signals, 4
refer to aromatic CH and 2 refer to alkenyl carbons), 107.2 (C*), 97.2 (C*), 36.2
(Ad), 34.6 (Ad), 33.7 (Ad), 33.0 (Ad), 32.2 (Ad), 31.7 (Ad), 31.1 (Ad), 26.1 (Ad),
26.0 (Ad). HPLC-MS (ESI) tr = 13.2 min; [M+H]+ = 297.2 m/z.
6.4 Thermochemiluminescence (TCL) Measurements
TCL imaging experiments were performed with a CCD camera as detector.
The heating support consisted of a resistance with a high-resistivity (70-100 Ω).
The temperature of the resistance was controlled by varying the applied current
and monitored by a copper/constantan thermocouple. Sample was dissolved in
acetonitrile and 2 µL of the solution was deposited on the supports. The spot
was allowed to dry before the TCL measurement. TCL images were acquired
upon heating the support to the desired temperature (70-130 ◦C, the range was
chose properly for each substrates 4) using different integration times, depending
on the compound analyzed and the experimental temperature. Images were then
analyzed to measure the TCL signals using the image analysis software provided
with the instrument. The kinetic and thermodynamic parameters of the TCL
process were obtained by measuring the TCL emission decay kinetics in the
temperature range between 70 and 130 ◦C. For each temperature, the kinetic
constant k of the TCL process (i.e., the inverse of the decay time in seconds) was
calculated by fitting the decay profile of the TCL emission with the first-order
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decay equation (see 6.1), in which I(t) is the intensity of TCL signal during
time-acquisition, I0 is the intensity of TCL signal at zero time.
I(t) = (I0)e
−kt (6.1)
Then, the activation energy (Ea) and the pre-exponential factor (A) of the
TCL process were calculated from the kinetic constants k measured at different
temperatures using the logarithmic form of the Arrhenius equation (see 6.2), in
which R is the universal gas constant and T is the temperature in Kelvin.
lnK = lnA− Ea
RT
(6.2)
The kinetic constants at different temperatures (70 - 100 ◦C) and the Arrhenius
plot for a model compound (4t) are reported in Figure 6.54. The values of kinetic
constants k are listed in Table 6.2.
Figure 6.54
Table 6.2: Values of kinetic constants k for compound 4t.
Tenperature (◦ Celsius) k(s−1)
70 (3.0 ± 2.1) x 10−4
80 (8.0 ± 4.1) x 10−4
90 (2.8 ± 1.6) x 10−3
100 (9.1 ± 3.7) x 10−3
The TCL emission spectrum for a model fluorinated 1,2-dioxetane (4j) and
the fluorescence emission spectrum of the corresponding ketone 2j are reported
in Figure 6.55. In particular, we chose the most fluorescent dioxetane 4j. The
good overlapping confirms that the light signal recorded during the TCL process
is mainly due to the electronic-excited state of the aromatic ketone, which is
generated during the thermal decomposition.
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Figure 6.55
6.5 Molecular Descriptors
Table 6.3: Molecular descriptors for alkenes 3a-q, 3u-y, and 3F.
Electronic
descriptors
Alkene HOMO (eV) LUMO (eV) Ca-Mul C9-Mul Ca-HOMO C9-HOMO Ca-LUMO C9-LUMO Active
3a -4.931 -0.592 0.160 -0.071 0.1341 0.0640 0.1969 0.0725 Y
3b -4.797 -0.489 0.159 -0.070 0.1253 0.0560 0.1977 0.0746 Y
3c -4.882 -0.551 0.159 -0.069 0.1383 0.0650 0.1956 0.0727 Y
3d -5.043 -0.515 0.158 -0.085 0.1395 0.0731 0.2107 0.0849 Y
3e -4.798 -0.549 0.159 -0.071 0.1177 0.0511 0.1963 0.0723 Y
3f -4.746 -0.490 0.158 -0.071 0.1239 0.0527 0.1967 0.0743 Y
3g -4.698 -0.433 0.156 -0.069 0.1302 0.0544 0.1974 0.0766 Y
3h -5.169 -0.712 0.161 -0.070 0.1592 0.0822 0.1939 0.0717 Y
3i -5.174 -0.687 0.169 -0.049 0.1457 0.0840 0.1841 0.0663 Y
3j -4.988 -0.839 0.164 -0.069 0.1074 0.0479 0.1925 0.0641 Y
3k -5.201 -0.925 0.165 -0.071 0.1310 0.0631 0.1901 0.0646 Y
3l -4.951 -0.550 0.156 -0.066 0.1527 0.0736 0.1945 0.0735 Y
3m -4.859 -0.527 0.159 -0.071 0.1280 0.0601 0.1973 0.0743 Y
3n -4.783 -0.436 0.165 -0.076 0.1227 0.0609 0.1897 0.0672 Y
3o -4.993 -0.753 0.163 -0.081 0.0491 0.0222 0.2046 0.0750 Y
3p -4.883 -0.717 0.163 -0.080 0.0431 0.0179 0.2033 0.0755 Y
3q -5.021 -0.810 0.164 -0.083 0.0457 0.0203 0.2036 0.0743 Y
3u -4.954 -0.473 0.177 -0.095 0.1084 0.0545 0.1926 0.0768 N
3v -5.041 -0.398 0.171 -0.104 0.1141 0.0609 0.2039 0.0889 N
3w -4.749 -0.350 0.175 -0.097 0.0944 0.0423 0.1915 0.0797 N
3x -4.772 -0.373 0.175 -0.097 0.0999 0.0450 0.1918 0.0799 N
3y -5.072 -0.530 0.177 -0.095 0.1203 0.0629 0.1871 0.0741 N
3F -5.050 -0.604 0.172 -0.073 0.1261 0.0734 0.1711 0.0596 Y
Mean -4.937 -0.578 0.165 -0.077 0.116 0.056 0.195 0.074
St Dev 0.147 0.155 0.007 0.013 0.032 0.018 0.008 0.007
Var 0.022 0.024 0.00005 0.0001 0.001 0.000 0.0003 0.0001
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Structural
descriptors
Alkene φ1 (◦) φ2 (◦) d1 (Å) d2 (Å) d3 (Å) d4 (Å) Active
3a 131.001 -131.511 3.064 3.065 2.783 2.782 Y
3b 131.397 -131.369 3.058 3.069 2.777 2.785 Y
3c 131.168 -131.770 3.083 3.053 2.794 2.777 Y
3d 131.512 -131.358 3.061 3.096 2.780 2.805 Y
3e 131.523 -131.104 3.056 3.059 2.774 2.776 Y
3f 131.700 -131.091 3.045 3.077 2.769 2.787 Y
3g 132.115 -131.529 3.059 3.064 2.780 2.783 Y
3h 131.812 -131.293 3.062 3.069 2.784 2.788 Y
3i 129.596 -128.890 3.087 3.162 2.786 2.924 Y
3j 131.090 -131.090 3.097 3.097 2.813 2.813 Y
3k 131.330 -131.330 3.097 3.097 2.815 2.815 Y
3l 132.527 -132.319 3.069 3.060 2.791 2.786 Y
3m 131.640 -131.640 3.072 3.072 2.787 2.793 Y
3n 130.868 -130.431 3.080 3.096 2.785 2.793 Y
3o 132.191 -132.191 3.109 3.109 2.803 2.803 Y
3p 131.621 -131.621 3.111 3.111 2.800 2.800 Y
3q 131.533 -131.533 3.113 3.113 2.802 2.802 Y
3u 124.115 -122.085 3.136 2.890 2.794 2.686 N
3v 124.985 -123.570 3.125 2.905 2.792 2.707 N
3w 124.585 -121.797 3.119 2.790 2.784 2.617 N
3x 124.333 -121.650 3.122 2.796 2.787 2.620 N
3y 124.321 -122.075 3.122 2.894 2.790 2.689 N
3F 128.113 -126.708 3.103 3.254 2.788 2.988 Y
Mean 129.786 -129.128 3.089 3.043 2.789 2.779
St Dev 3.002 3.902 0.027 0.113 0.011 0.081
Var 9.013 15.225 0.001 0.013 0.0001 0.007
Table 6.4: Molecular descriptors for alkenes 3a-z and 3A-G.
Electronic
descriptors
Olefin HOMO (eV) LUMO (eV) Ca-Mul C9-Mul Ca-HOMO C9-HOMO Ca-LUMO C9-LUMO Active
3a -4.931 -0.592 0.160 -0.071 0.1341 0.0640 0.1969 0.0725 Y
3b -4.797 -0.489 0.159 -0.070 0.1253 0.0560 0.1977 0.0746 Y
3c -4.882 -0.551 0.159 -0.069 0.1383 0.0650 0.1956 0.0727 Y
3d -5.043 -0.515 0.158 -0.085 0.1395 0.0731 0.2107 0.0849 Y
3e -4.798 -0.549 0.159 -0.071 0.1177 0.0511 0.1963 0.0723 Y
3f -4.746 -0.490 0.158 -0.071 0.1239 0.0527 0.1967 0.0743 Y
3g -4.698 -0.433 0.156 -0.069 0.1302 0.0544 0.1974 0.0766 Y
3h -5.169 -0.712 0.161 -0.070 0.1592 0.0822 0.1939 0.0717 Y
3i -5.174 -0.687 0.169 -0.049 0.1457 0.0840 0.1841 0.0663 Y
3j -4.988 -0.839 0.164 -0.069 0.1074 0.0479 0.1925 0.0641 Y
3k -5.201 -0.925 0.165 -0.071 0.1310 0.0631 0.1901 0.0646 Y
3l -4.951 -0.550 0.156 -0.066 0.1527 0.0736 0.1945 0.0735 Y
3m -4.859 -0.527 0.159 -0.071 0.1280 0.0601 0.1973 0.0743 Y
3n -4.783 -0.436 0.165 -0.076 0.1227 0.0609 0.1897 0.0672 Y
3o -4.993 -0.753 0.163 -0.081 0.0491 0.0222 0.2046 0.0750 Y
3p -4.883 -0.717 0.163 -0.080 0.0431 0.0179 0.2033 0.0755 Y
3q -5.021 -0.810 0.164 -0.083 0.0457 0.0203 0.2036 0.0743 Y
3r -5.365 -0.727 0.161 -0.069 0.1974 0.1272 0.2070 0.0761 Y
3s -5.052 -0.423 0.153 -0.063 0.2100 0.1132 0.2060 0.0871 Y
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3u -4.954 -0.473 0.177 -0.095 0.1084 0.0545 0.1926 0.0768 N
3v -5.041 -0.398 0.171 -0.104 0.1141 0.0609 0.2039 0.0889 N
3w -4.749 -0.350 0.175 -0.097 0.0944 0.0423 0.1915 0.0797 N
3x -4.772 -0.373 0.175 -0.097 0.0999 0.0450 0.1918 0.0799 N
3y -5.072 -0.530 0.177 -0.095 0.1203 0.0629 0.1871 0.0741 N
3z -5.474 -0.703 0.166 -0.146 0.0954 0.0622 0.2001 0.0754 N
3A -5.955 -1.019 0.168 -0.173 0.0482 0.0280 0.2066 0.0731 N
3B -6.241 -1.432 0.186 -0.178 0.2251 0.2480 0.1335 0.0331 N
3C -5.622 -0.603 0.156 -0.132 0.2443 0.1995 0.2127 0.0847 N
3D -5.141 -1.411 0.157 -0.106 0.1351 0.0730 0.0901 0.0151 N
3E -4.680 -1.074 0.152 -0.107 0.0298 0.0114 0.0481 0.0125 N
3F -5.050 -0.604 0.172 -0.073 0.1261 0.0734 0.1711 0.0596 Y
Mean -5.067 -0.668 0.164 -0.089 0.124 0.069 0.187 0.069
St Dev 0.354 0.271 0.008 0.031 0.051 0.048 0.035 0.018
Var 0.125 0.074 0.0001 0.001 0.003 0.002 0.001 0.0003
3t -5.643 -1.183 0.134 -0.053 0.2307 0.1670 0.2751 0.0705 SUPP
3G -5.516 -1.018 0.187 -0.165 0.0816 0.0618 0.0008 0.0001 SUPP
Structural
descriptors
Alkene φ1 (◦) φ2 (◦) d1 (Å) d2 (Å) d3 (Å) d4 (Å) Active
3a 131.001 -131.511 3.064 3.065 2.783 2.782 Y
3b 131.397 -131.369 3.058 3.069 2.777 2.785 Y
3c 131.168 -131.770 3.083 3.053 2.794 2.777 Y
3d 131.512 -131.358 3.061 3.096 2.780 2.805 Y
3e 131.523 -131.104 3.056 3.059 2.774 2.776 Y
3f 131.700 -131.091 3.045 3.077 2.769 2.787 Y
3g 132.115 -131.529 3.059 3.064 2.780 2.783 Y
3h 131.812 -131.293 3.062 3.069 2.784 2.788 Y
3i 129.596 -128.890 3.087 3.162 2.786 2.924 Y
3j 131.090 -131.090 3.097 3.097 2.813 2.813 Y
3k 131.330 -131.330 3.097 3.097 2.815 2.815 Y
3l 132.527 -132.319 3.069 3.060 2.791 2.786 Y
3m 131.640 -131.640 3.072 3.072 2.787 2.793 Y
3n 130.868 -130.431 3.080 3.096 2.785 2.793 Y
3o 132.191 -132.191 3.109 3.109 2.803 2.803 Y
3p 131.621 -131.621 3.111 3.111 2.800 2.800 Y
3q 131.533 -131.533 3.113 3.113 2.802 2.802 Y
3r 134.093 -134.093 3.104 3.104 2.827 2.827 Y
3s 135.287 -135.287 3.111 3.111 2.839 2.839 Y
3u 124.115 -122.085 3.136 2.890 2.794 2.686 N
3v 124.985 -123.570 3.125 2.905 2.792 2.707 N
3w 124.585 -121.797 3.119 2.790 2.784 2.617 N
3x 124.333 -121.650 3.122 2.796 2.787 2.620 N
3y 124.321 -122.075 3.122 2.894 2.790 2.689 N
3z 126.277 -126.277 3.078 3.078 2.763 2.763 N
3A 128.748 -128.748 3.105 3.105 2.788 2.788 N
3B 126.853 -126.853 3.096 3.096 2.777 2.777 N
3C 130.538 -130.538 3.088 3.088 2.793 2.793 N
3D 129.521 -132.028 3.064 3.014 2.791 2.761 N
3E 131.871 -131.136 3.057 3.063 2.780 2.777 N
3F 128.113 -126.708 3.103 3.254 2.788 2.988 Y
Mean 129.944 -129.513 3.089 3.053 2.791 2.782
St Dev 3.018 3.745 0.025 0.099 0.016 0.071
Var 9.110 14.027 0.001 0.010 0.0003 0.005
3t 159.802 -159.802 3.243 3.243 3.014 3.014 SUPP
3G 113.280 -113.280 3.111 3.111 2.708 2.708 SUPP
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6.6 Multivariate Analyses (PCA and LDA)
PCA analyses were made with the free R software environment for statistical
computing and graphics [see Ref. 391], using the FactoMineR package [see Ref.
392].
Figure 6.56: PCA results for the data matrix descriptors of olefins 3a-q, 3u-y, and 3F:
A) PCA score plot relative to the first and third PCs (blue triangles: reactive compounds;
red dots: unreactive compounds); B) PCA loading plot relative to the first and third PCs
(variables are colored according to their relative contribution).
As shown in Figure 6.56B, the orbital coefficients Ca-HOMO, C9-HOMO
and Ca-LUMO are the main parameters contributing to the third PC (cos2 =
0.621, 0.734 and 0.594, respectively). Plotting the data points along the first and
the third PCs (Figure 6.56A), it is clear that in this case the olefins 3F and 3i are
quite apart from the main cluster of the reactive alkenes along the third PC. Their
position derives from the presence of a heteroatom in position 1 of the acridan
moiety, which confers to these olefins smaller orbital coefficients of the LUMO
(Ca-LUMO and C9-LUMO), without distortion from planarity of the aromatic
system as much as the methyl substituent. Also, the N-aryl substituted olefins
3o-q are clustered together along the negative direction of the third PC, due to the
smaller orbital coefficients of the HOMO (Ca-HOMO and C9-HOMO).
In order to validate the PCA model and to verify its capability to predict
the reactivity with singlet oxygen of new compounds, the fluorenyl alkene 3t
(central five-membered ring) and the specially designed new olefin 3G (central
seven-membered ring) were projected in the space defined by the first two PCs
(Figure 6.57). The fluorenyl-derived alkene 3t is positioned in the top-right quad-
rant of the score plot, farther on the right along the first PC due to an almost
completely planar arrangement of the aromatic rings with respect to the plane
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Figure 6.57: Olefins 3t and 3G projected in the PCs space of the chemometric model
developed for alkenes 3a-s, 3u-z and 3A-F.
defined by the carbon-carbon double bond (φ1, φ2 = 159.8 ◦). 3t is located at the
same coordinate of the reactive alkenes along the PC2 axis, thus it is predicted to
be reactive in the photooxygenation process by virtue of both favourable steric and
electronic factors. As already mentioned in Table 2.1 (entry 14), when 3t was sub-
jected to the photooxygenation conditions the corresponding 1,2-dioxetane 4t was
obtained in 50% overall isolated yield. On the contrary, the 5-dibenzosuberenone-
derived alkene 3G is projected in the bottom-left quadrant of the score plot, in
a region where both the steric and the electronic factors are not favourable for
the reaction with singlet oxygen. Indeed, 3G has the same coordinates of the
not reactive acridan-based olefins along the PC1 axis, possessing significantly
smaller dihedral angles φ1 and φ2 (113.3 ◦) and, consequently, a much larger
deviation from planarity. As regards the electronic factors, the strongly negative
coordinate of 3G along the PC2 axis is due to the overall effect of: i) the lower
values of the HOMO (-5.52 eV vs -5.10 eV mean HOMO energy) and of the
LUMO (-1.02 eV vs -0.69 eV mean LUMO energy) energies; ii) the greater
negative Mulliken charge on C9 (-0.165 vs -0.09 mean C9-Mul charge); iii) the
particularly smaller LUMO orbital coefficients on both Ca (0.0008 vs 0.184 mean
Ca-LUMO coefficient) and C9 (0.0001 vs 0.067 mean C9-LUMO coefficient).
When subjected to the photooxygenation conditions, olefin 3G did not react, so
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that only the starting material was observed in the reaction mixture. Finally,
it should be noted that the fluorenyl-derived olefin 3t, simply considering the
energy values of the HOMO and LUMO orbitals, would have been projected
along the negative direction of the PC2 axis, due to the low values of both the
HOMO (-5.64 eV vs -5.10 eV mean HOMO energy) and the LUMO (-1.18
eV vs -0.69 eV mean LUMO energy) energies. On the other hand, the smaller
values of the Mulliken charges on both Ca (0.134 vs 0.164 mean Ca-Mul charge)
and C9 (-0.053 vs -0.09 mean C9-Mul charge), as well as a small but significant
contribution of the dihedral angles φ1 and φ2 also on the PC2 axis, overall balance
the frontier orbitals electronic effects and move olefin 3t in the top region of the
projection score plot. The experimental findings obtained for the supplementary
alkenes 3t and 3G validate the developed PCA model, which proves to be able to
anticipate the outcome of a photooxygenation reaction carried out on structurally
different tetrasubstituted olefins, characterized by the adamantyl unit coupled
with a tricyclic aromatic scaffold (regardless of the nature of the central ring).
LDA analyses were made with the free R software environment for statistical
computing and graphics [see Ref. 391], using the MASS package and the Deducer
plug-in [see Ref. 393].
6.7 Computational Details
MMFF conformational searches were performed with the Spartan suite of
programs, using the keywords SEARCHMETHOD=SYSTEMATC, FINDBOATS
and KEEPALL. All the conformers contained in a 8 kcal/mol window were
reoptimized at the B3LYP/6-31G(d) DFT level and confirmed as true minima by
frequency analysis. DFT calculations were performed with Gaussian 09 [see Ref.
394]. Structural and electronic descriptors were taken from the lowest energy
conformation obtained at the DFT level.
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7.1 General Remarks
All of the commercial chemicals were purchased from Sigma Aldrich, Alfa
Aesar or TCI Chemicals, and used without additional purifications.
• The 1H and 13C NMR spectra were recorded on a 200 or 400 NMR instru-
ment with a 5 mm probe. All chemical shifts have been quoted relative to
deuterated solvent signals; chemical shifts (δ) are reported in ppm, and cou-
pling constants (J) are reported in hertz. Protons and carbons are assigned
as follows: (Ar) for aromatic protons, (Ad) for protons and carbons of the
adamantyl portion, (H1, H2, H3. . . ) for protons expressly labeled in the
molecule picture, (Hα) for allylic protons of the adamantyl moiety in the
alkenes (the same notation was used for the corresponding 1,2-dioxetanes),
(CO) for carbonyl carbons, (COO) for carboxyl carbons, (CF) for carbons
bearing a fluorine atom, (CHAr) for aromatic tertiary carbons, (Cq) for qua-
ternary alkenyl and aromatic carbons, (C*) for carbons of the 1,2-dioxetane
and (C1, C2, C3. . . ) for carbons expressly labeled in the molecule picture.
• HPLC-MS analyses were performed on an Agilent Technologies HP1100 in-
strument coupled with an Agilent Technologies MSD1100 single-quadrupole
mass spectrometer. A Phenomenex Gemini C18 3 µm (100 x 3 mm) column
was employed for the chromatographic separation using the following ana-
lytical methods: mobile phase H2O/CH3CN, gradient from 30% to 80% of
CH3CN in 8 min, 80% of CH3CN until 22 min, then up to 90% of CH3CN
in 2 min, stop time at 25 min; flow rate 0.4 mL min−1. Mass spectrometric
detection was performed in full-scan mode from m/z 50 to 2500, scan time
0.1 s in positive ion mode, ESI spray voltage 4500 V, nitrogen gas 35 psi,
drying gas flow rate 11.5 mL min−1, fragmentor voltage 30 V.
• Flash chromatography purifications were carried out using VWR silica gel
(40-63 µm particle size). Thin-layer chromatography was performed on
Merck 60 F254 plates.
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7.2 Synthetic Procedures and Characterizations
Figure 7.1
Compound 1: Compound 1 was synthesized following the procedure in
literature [see Ref. 107]. The reaction was carried out under nitrogen atmosphere.
A suspension of 9(10)Acridanone (2g, 10.24 mmol) in dry DMF (9 mL) was
added dropwise to a suspension of NaH (492 mg, 12.29 mmol) in anhydrous
DMF (35 mL) at 0◦C. After 30 min of stirring at room temperature (rt), the
reaction was cooled down to 0◦C, and Ethyl bromoacetate (1.7 mL, 15.36 mmol)
and tetrabutylammonium iodide (Bu4NI, 40mg, 0.11 mmol) were added. The
reaction was stirred at rt overnight. Then, the crude was poured into cold water
and the precipitate was filtered through Büchner funnel and dried over MgSO4.
Compound 1 was obtained as pale yellow solid (2.82 g, 98%), and the obtained
1H NMR and 13C NMR were in agreement with the literature data. Product 1
was used directely in the next step, without further purifications.
Figure 7.2
Compound 2: Compound 2 was synthesized following the procedure in
literature [see Ref. 107]. Under a nitrogen atmosphere, a solution of TiCl4 (10.85
mL, 1 M in CH2Cl2) was added to a suspension of Zn powder (1.55 g, 24.02
mmol) in anhydrous THF (20 mL) at 0◦C, and the suspension was stirred for
10 min under reflux. Then, a solution of ketone 1 (500 mg, 1.78 mmol) and
2-adamantanone (267 mg, 1.78 mmol) in anhydrous THF (10 mL) was added
dropwise over a period of 30 min. The reaction mixture was refluxed for 45
minutes. Then, it was cooled to room temperature, quenched with water and
extracted with AcOEt (3 x 10 mL). The combined organic layers were dried over
sodium sulfate and evaporated under vacuum. The chromatographic purification
(eluent: cyclohexane/AcOEt = 80:20) provided compound 2 as white solid (642
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mg, 90%), and the obtained 1H NMR and 13C NMR were in agreement with the
literature data.
Figure 7.3
Compound 3: Compound 3 was synthesized following the procedure in
literature [see Ref. 395]. A solution of NaOH (6 mL, 0.5 M) was added dropwise
to a suspension of 2 (200 mg, 0.5 mmol) in EtOH (26 mL) at 0◦C. The solution
was stirred at 0◦C for 1 hour after which the reaction was stirred at rt for additional
58 hours. Then, it was poured into cold water (100 mL) and the acidity of the
aqueous solution was adjusted to 4 - 5 pH values, using HCl 6N. The water
solution was extracted with AcOEt (3 x 10 mL), and the combined organic layers
were dried over sodium sulfate and evaporated under vacuum. Compound 3 was
used directely in the next step, without further purifications.
Figure 7.4
Compound 4: Compound 4 was synthesized following the procedure in
literature [see Ref. 396]. Under nitrogen atmosphere, a solution of Di-tert-butyl
dicarbonate (Boc2O, 388 mg, 1.78 mmol) in CHCl3 (9 mL) was added dropwise
to a solution of 1,6-hexanediamine (1.03 g, 8.88 mmol) in CHCl3 (45 mL) at
0◦C. The reaction was stirred at rt overnight, after which it was concentrated
and purified through flash chromatography on silica gel. The chromatographic
purification (eluent: CH2Cl2/MeOH = 90:10 with 1% of TEA) provided compound
4 as sticky solid (254 mg, 44%), and the obtained 1H NMR and 13C NMR were
in agreement with the literature data [see Ref. 397]. HPLC-MS (ESI) tr= 10.3
min; [M+H]+ = 217.0, [M+Na]+ = 239.0, [M+K]+ = 255.0.
Compound 5: Compound 5 was synthesized following the procedure in liter-
ature [see Ref. 398]. Under nitrogen atmosphere, COMU coupling reagent (125
mg, 0.29 mmol) was added to a solution of 3 (108 mg, 0.29 mmol), diisopropy-
lamine (DIPEA, 0.1 mL, 0.58 mmol) and 4 (62.88 mg, 0.29 mmol) in anhydrous
DMF, at 0◦C. The solution was stirred at 0◦C for 1 hour after which the reaction
was stirred at rt overnight. The crude was washed with a solution of LiCl 5% (3 x
10 mL), and extracted with AcOEt (3x 20 mL). The combined organic layers were
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Figure 7.5
dried over sodium sulfate and evaporated under vacuum. The chromatographic
purification (eluent: cyclohexane/AcOEt = 95:5) provided compound 5 as pale
yellow solid (77.8 mg, 44%). 1H NMR (400 MHz, CDCl3) δ 7.28-7.25 (m, 2H),
7.19 (td, J = 7.6, 1.6 Hz, 2H), 7.05 (td, J = 7.2, 0.8 Hz, 2H), 6.93 (d, J = 8.4 Hz,
2H), 5.92 (bs, 1H), 4.57 (s, 2H), 4.45 (bs, 1H), 3.44 (s, 2H), 3.19 (q, J = 6.4 Hz,
2H), 3.03 (q, J = 6.4 Hz, 2H), 2.18-1.92 (m, 4H), 1.89 (s, 3H), 1.57 (s, 3H), 1.45
(s, 9H), 1.37 – 1.23 (m, 6H), 1.15 (m, 2H), 0.98-1.03 (m, 2H). 13C NMR (100
MHz, CDCl3) δ 168.5, 155.9, 145.6, 142.8, 127.5, 126.8, 126.5, 121.2, 119.8,
112.5, 79.0, 50.4, 39.1, 36.9, 32.2, 29.2, 28.4, 26.2, 26.2. HPLC-MS (ESI) tr=
18.3 min; [M+H]+ = 570.0, [M+Na]+ = 592.0, [M+K]+ = 608.0.
Figure 7.6
Compound 6: Compound 6 was obtained in two different ways: i) after
a deprotection step (according to the first strategy) or ii) through a McMurry
reductive coupling (following the second synthetic approach).
Approach i): Under nitrogen atmosphere, Trifluoroacetic acid (TFA, 48 µL,
0.63 mmol) was added to a solution of 5 (20 mg, 0.035 mmol) in anhydrous
CH2Cl2 (0.6 mL), at 0◦C. The reaction was stirret at rt for 2 hours; then, it was
neutralized adding a saturated solution of NaHCO3 at 0◦C (until pH = 8). The
basic aqueous solution was extracted with AcOEt (3 x 2 mL) and CH2Cl2 (3
x 2 mL), and the combined organic layers were dried over sodium sulfate and
evaporated under vacuum. Product 6 was obtained as yellow solid (12.3 mg, 79%).
Compound 6 was used directely in the next step, without further purifications.
Approach ii): Compound 6 was synthesized following the procedure in litera-
ture [see Ref. 111]. Under a nitrogen atmosphere, a solution of TiCl4 (2.9 mL, 1
M in CH2Cl2) was added to a suspension of Zn powder (409 mg, 0.47 mmol) in
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anhydrous THF (5.5 mL) at 0◦C, and the suspension was stirred for 10 min under
reflux. Then, a solution of ketone 11 (161 mg, 0.47 mmol) and 2-adamantanone
(71 mg, 0.47 mmol) in anhydrous THF (13 mL) was added dropwise over a
period of 30 min. The reaction mixture was refluxed for 45 minutes. Then, it
was cooled to room temperature, quenched with water and extracted with AcOEt
(3 x 10 mL). The aqueous phase was basified using a solution of NaOH (6 N),
and it was extracted, a second time, with CH2Cl2. The combined organic layers
were dried over sodium sulfate and evaporated under vacuum. Compound 6
was used directely in the next step, without further purifications. 1H NMR (400
MHz,CDCl3) δ 7.28-7.24 (m,2H), 7.19(td, 7.6, 1.2 Hz, 2H), 7.05 (td, J = 7.6,
1.2 Hz, 2H), 6.93 (d, J = 8.2, 2H), 5.93 (s, 1H), 4.57 (s, 2H), 3.44 (s, 2H), 3.19
(q, J = 6.8 Hz, 2H), 2.60 (t, J = 7.2 Hz, 2H), 2.29-1.94 (m, 4H), 1.89 (s, 3H),
1.55-1.37(m, 4H), 1.35-1.28 (m, 5H), 1.22-1.12 (m,2H), 1.08-0.98 (m,2H). 13C
NMR (100 MHz, CDCl3) δ168.5, 145.5, 142.7, 127.4, 126.7, 126.4, 121.1, 119.7,
112.4, 50.4, 41.9, 39.1, 36.9, 33.3, 32.2, 29.2, 26.3, 26.3. HPLC-MS (ESI) tr=
6.2 min; [M+H]+ = 470.0, [M+Na]+ = 492.0, [M+K]+ = 508.0.
Figure 7.7
Olefin precursor 7: Compound 7 was synthesized following the procedure
in literature [see Ref. 398]. Under nitrogen atmosphere, COMU coupling reagent
(137 mg, 0.32 mmol) was added to a solution of 6 (150 mg, 150 mmol), diiso-
propylamine (DIPEA, 0.11 mL, 0.64 mmol) and Biotin (78 mg, 0.32 mmol) in
anhydrous DMF (5 mL), at 0◦C. The solution was stirred at 0◦C for 1 hour after
which the reaction was stirred at rt for two more hours. The crude was concen-
trated under vacuum and the chromatographic purification (eluent: CH2Cl2/MeOH
= 99:1) provided compound 7 as yellow solid (63 mg, 28%). 1H NMR (400 MHz,
CDCl3) δ 7.25 (dd, J = 7.6, 1.6 Hz, 2H), 7.19 (td, J=7.6, 1.6, 2H), 7.04 (td, J =
7.2, 0.8 Hz, 2H), 6.92 (d, J = 8.0 Hz, 2H), 5.98 (s, 1H), 5.90 (s, 2H), 5.08 (s,
1H), 4.58 (s, 2H), 4.48 (dd, J = 8.0, 4.8 Hz, 1H), 4.31 (dd, J = 7.6, 4.4 Hz, 1H),
3.43 (s, 2H), 3.22-3.12 (m, 5H), 2.90 (dd, J = 12.8, 4.8 Hz, 1H), 2.72 (d, J =
12.8 Hz, 1H), 2.23-2.17 (m, 5H), 1.89 (s, 3H), 1.79-1.59 (m, 6H), 1.50 – 1.25 (m,
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10H), 1.23-1.04 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 172.9, 168.8, 163.3,
145.7, 142.8, 127.5, 126.8, 126.6, 121.2, 119.7, 112.5, 61.8, 60.1, 55.4, 53.4, 40.5,
39.2, 39.0, 36.9, 35.9, 32.3, 30.9, 29.7, 29.3, 29.2, 28.1, 28.0, 26.1, 26.0, 25.6.
HPLC-MS (ESI) tr= 11.6 min; [M+H]+ = 696.0, [M+K]+ = 734.0.
Figure 7.8
TCL-based molecular probe (8): Compound 8 was synthesized following
the procedure in literature [see Ref. 111]. Alkene 7 (17 mg, 0.025 mmol) and
Methylene Blue (0.60 mg, 0.0015 mmol) were dissolved in CH2Cl2 (2 mL). The
solution was cooled to - 40◦C and subjected to an oxygen atmosphere (1 atm,
balloon). The solution was stirred at the same temperature under irradiation using
a 500 W halogen lamp equipped with an UV cut-off filter (0.5% transmission at
550 nm). The conversion was monitored by 1H NMR and HPLC-MS. After 5
hours of irradiation, MeOH (0.1 mL) was added to better solubilize the starting
material textbf7, and the reaction was carried out for further 5 hours. After this
time, the irradiation was stopped and the 1H NMR of crude showed the formation
of several by-products (see 3).
Figure 7.9
Compound 9: Compound 9 was synthesized following the procedure in
literature [see Ref. 395]. A solution of NaOH (10mL, 0.5 M) was added to a
suspension of 1 (500 mg, 1.78 mmol) in EtOH (33 mL), at 0◦C. The solution
was stirred at rt for 4.3 hours and, then, it was poured into cold water (100 mL)
and the acidity of the aqueous solution was adjusted to 4 - 5 pH values, using
HCl 6N. The water solution was extracted with AcOEt (3 x 10 mL), and the
combined organic layers were dried over sodium sulfate and evaporated under
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vacuum. Compound 9 was obtained as yellow solid (444 mg, 98%) and and the
obtained 1H NMR and 13C NMR were in agreement with the literature data [see
Ref. 399].
Figure 7.10
Compound 10: Compound 10 was synthesized following the procedure in
literature [see Ref. 398]. Under nitrogen atmosphere, COMU coupling reagent
(350 mg, 0.82 mmol) was added to a solution of 9 (217 mg, 0.82 mmol), di-
isopropylamine (DIPEA, 0.29 mL, 1.65 mmol) and 4 (178 mg, 0.82 mmol) in
anhydrous DMF (13 mL), at 0◦C. The solution was stirred at 0◦C for 1 hour
after which the reaction was stirred at rt overnight. The crude was washed with
a solution of LiCl 5% (3 x 10 mL), and extracted with AcOEt (3x 20 mL). The
combined organic layers were dried over sodium sulfate and evaporated under
vacuum. The chromatographic purification (eluent: cyclohexane/AcOEt = 50:50)
provided compound 10 as yellow solid (332 mg, 91%). 1H NMR (400 MHz,
CDCl3) δ 8.38 (d,8.0 Hz, 2H), 7.75 (ddd, J = 8.8, 6.8, 1.6 Hz, 2H), 7.38 (d, J =
8.4 Hz, 2H), 7.29 (t, J = 8 Hz, 2H), 6.61 (s, 1H), 4.99 (s, 2H), 4.47 (s, 1H), 3.29
(q, J = 6.4 Hz, 2H), 2.94 (q, J = 6.4 Hz, 2H), 1.51 – 1.43 (m, 2H), 1.40-1.31 (m,
11H), 1.24-1.17 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 177.6, 167.1, 155.9,
142.1, 134.1, 127.2, 122.1, 121.9, 114.3, 78.9, 51.2, 40.0, 39.3, 29.9, 29.0, 28.3,
26.1, 25.9. HPLC-MS (ESI) tr= 9.0 min; [M+H]+ = 452.0, [M+Na]+ = 474.0,
[M+K]+ = 490.0, [2M+K]+ = 925.0.
Figure 7.11
N-(6-aminohexyl)-2-(9-oxoacridin-10(9H)-yl)acetamide (11): Under nitro-
gen atmosphere, Trifluoroacetic acid (TFA, 898 µL, 12 mmol) was added to a
solution of 10 (292 mg, 0.65 mmol) in anhydrous CH2Cl2 (12 mL), at 0◦C. The
reaction was stirret at rt for 3 hours; then, the solvent was evaporated under
vacuum. The crude was redissolved in H2O (5 mL) and the aqueous solution was
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acidified using HCl 6 N. Once compound 11 was completely dissolved, NaOH
6 N was added dropwise, adjusting the solution pH to 8 -9 values. The aqueous
phase was extracted with CH2Cl2 (3 x 10 mL) and the combined organic layers
were dried over sodium sulfate and evaporated under vacuum. Product 11 was
obtained as yellow solid (152 mg, 66%). Compound 11 was used directely in the
next step, without further purifications. 1H NMR (400 MHz, CD3OD) δ 8.51 (dd,
J = 8.4, 2.0 Hz, 2H), 7.77 (ddd, J = 8.4, 6.8, 1.6 Hz, 2H), 7.40-7.33 (m, 4H), 6.13
(s, 1H), 4.98 (s, 2H), 3.29 (q, J = 6.4 Hz, 2H), 2.60 (t, J = 6.8 Hz, 2H), 1.45 – 1.37
(m, 2H), 1.37-1.30 (m, 2H), 1.22- 1.15 (m, 4H). 13C NMR (50 MHz, CD3OD)
δ 180.1, 169.7, 144.1, 135.6, 128.1, 123.3, 123.0, 116.5, 54.8, 41.7, 40.4, 31.8,
30.2, 27.5, 27.3. HPLC-MS (ESI) tr= 1.8 min; [M+H]+ = 352.0, [M+Na]+ =
374.0, [2M+K]+ = 725.0.
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8.1 General Remarks
All of the commercial chemicals were purchased from Sigma Aldrich and
used without additional purifications. Cyano-Polyphenylene vinylene (CN-PPV,
MW= 20 - 100 kDa) was purchased fom American Dye Source, Inc. while
Polystyrene derivatives (PS-COOH, 50 kDa and PS-NH2, 6.5 kDa) was purchased
from Poymer Source, Inc. Biotinylated Mouse IgG (Biotin-IgG) was purchased
from abcam, while Anti-IgG magnetic beads were purchased from New England
BioLabs, Inc.
Purification of TCL-Pdots-SA was carried out through filtration over a 400 µm
cutoff filter and centrifugation, using a 100 K molecular weight cutoff centrifugal
membrane (Amicon Ultra-4, Ultracel - 100K). Then, nanoparticles were further
purified by size exclusion chromatography, using Sephacryl S-300 HR resin.
Spectroscopic properties, in terms of absorption and emission spectra were
recorded using a UV-Vis spectrophotometer (Varian Cary 50) and a Uv-Vis spec-
trofluorimeter (Carian Cary Eclipse). The 1H NMR spectrum of polystyrene
fuctionalized with ketone 2 (PS-NH2-2) was recorded on 400 NMR instrument
with a 5 mm probe. Dynamic light scattering (DLS) experiments were conducted
using a Malvern Zetasizer NanoZS while TEM images were acquired using a
Philips CM100 transmission electron microscope (Philips/FEI Corp., Eindhoven,
Holland). Fluorescence images of TCL-Pdots-SA conjugated with Biotin-IgG,
before and after the eluition step, were obtained using an epi-fluorescence micro-
scope with a 100x, 1.3 oil immersion objective and with a 532 nm diode laser,
while the efficiency of FRET mechanism was calculated by Fluorescence Lifetime
measurements, using a FluoTime 100 spectrometer (PicoQuant, PicoHarp 300).
TCL signal was acquired using a portable battery-operated CCD camera
(model MZ-2PRO, MagZero, Pordenone, Italy) equipped with a thermoelectrically
cooled monochrome CCD image sensor and an objective (low distortion wide
angle lenses 1/3 in. 1.28 mm, f1.8) obtained from Edmund Optics (Barrington,
NJ). TCL images were analyzed using an open source image processing program
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(ImageJ). For evaluation of the signal-to-noise (S/N) ratios of the images, signals
(S) were calculated by averaging the pixel intensity over the analyzed area, while
noise (N) was taken as the standard deviation of the mean pixel intensity in a dark
image area.
8.2 Synthesis of Thermochemiluminescent Semiconductive Polymer
dots (TCL-Pdots-SA)
1,2-dioxetane 1-doped Pdots were prepared following a nanoprecipitation
method. In a typical procedure a THF solution of CN-PPV (1 mg/mL), PS-COOH
(1 mg/mL) and substrate 1 (2 mg/mL) was prepared. Then, a 7 mL aliquot of
the mixture was quickly injected into 10 mL of water under vigorous sonication
for about 1 minute. For the optimization studies, we prepared different mixed
solutions keeping constant the CN-PPV amount and changing the volume of
PS-COOH, dioxetane 1 or THF injected. The extra THF was evaporated under
nitrogen flow at room temperature and THF-free Pdot solution were filtrated
through a 0.4 µm cellulose membrane filter.
TCL-Pdots were bioconjugated to Streptavidin (SA) following a EDC cata-
lyzed codensation reaction between the carboxylic units of polystyrene chains
and amino groups of SA enzyme. Specifically, 80 µL of polyethylene glycol
(5% w/v PEG, MW 3350) and 80 µL of concentrated HEPES buffer (1 M) were
added to a solution of TCL-Pdots (80 ppm in MilliQ water). Then, 120 µL of
Streptavidin (2 mg/mL) was added to the solution along with 80 µ of freshly-
prepared EDC solution (10 mg/mL in MilliQ water). After 3 hours of stirring
at room temperature, BSA (10% (w/v), 80 µL) was added to the Pdots solution
and the mixture was stirred for 30 minutes. Lastly, Triton X-100 (2.5% (w/v),
80 µL) was added to the mixture of TCL-Pdots-SA to stabilize the nanoparticles
solution. The resulting streptavidinated TCL-Pdots were centrifuged by a 100 K
molecular cutoff membrane first, then purified by size exclusion chromatography
using Sephacryl HR-300 gel media.
The fully encapsulation of 1,2-dioxetane 1 inside Pdots was confirmed by
both the TCL emission from Pdots after bioconjugation and the Uv-vis absorption
spectrum (Figure 8.1 b) of the filtrate, which has shown the absence of dioxetane1.
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Figure 8.1: a) Uv-vis absorption of 1,2-dioxetane 1 (323 nm) and ketone 2 (387 nm) in
THF solution b) Absorption spectrum of the filtrate solution, showing only the presence
of a very small amount of ketone 2 (probably generated during the synsthesis of TCL-
Pdots-SA) in water.
8.3 Photophysical properties of CN-PPV polymer and 1,2-dioxetane
1
Figure 8.2: Absorption (yellow line) and emission (orange line) of CN-PPV-based
Pdots in water solution. The blue line represents the emission of 1,2-dioxetane 1 in THF
after thermal decomposition.
8.4 Synthesis of PS-NH2-2 derivative and FRET experiments
PS-NH2-2 was obtained following a two-steps synthetic strategy. First, the es-
ter functionality of ketone 2 underwent a basic hydrolisis to restore the carboxylic
acid unit. Then, a EDC-catalyzed condensation reaction between PS-NH2 and
ketone 2-COOH yielded the functionalized polymer PS-NH2-2.
According to a previously reported procedure [see Ref. 395], ketone 2 (0.4
mmol) was dissolved in Ethanol (8mL), and the solution was cooled down to
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Figure 8.3: 1H NMR spectrum of the fraction containing the desired product PS-NH2-2.
0 ◦C. Then, a solution of NaOH (0.5 M) was added dropwise and the mixture
was stirred at room temperature. After 2 hours, the solution was poured into
cold water (30 mL) and the pH was adjusted to 4-5 value using HCl (8 M). The
precipitate was collected and used in the next step without further purifications.
The condensation reaction was carried out dissolving ketone 2 (0.135 mmol),
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 1 eq.) and N-Hydroxy-
succinimide (NHS, 1 eq.) in DMF (3 mL). After 30 minutes of stirring, PS-NH2
(011 eq.) was added and the mixture was further stirred at room temperature for16
hours. Then, the solution was poured into cold water (10 mL) and the precipitated
was filtered and purified by flash chromatography on silica gel. The fraction
containing the desired product (metti grammi e resa) was characterized by both
1H NMR and Uv-vis absorption spectra (Figure 8.2). The first has shown typical
signal of polystyrene hydrogens [see Ref. 400], while the absorption spectrum
has confirmed the presence of the ketone 2 (covalently bonded to PS chains).
In order to calculate the efficiency of FRET mechanism, we synthesized two
different PS-based nanoparticles, following the above-reported procedure. In
particular, PS-NH2-2 (6 mg/mL) and PS-COOH (1 mg/mL) were mixed together
in THF and then, 6 mL aliquot of mixture was dispersed in water under sonication.
In a second experiment, CN-PPV (1 mg/mL) was added to the previous THF
solution. Both nanopartcle solutions were filtered by a 400 µm cellulose filter,
centrifugated using a 100 K molecular weight cutoff centrifugal membrane and
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Figure 8.4: Uv-vis absorption spectrum of the fraction containing the desired product
PS-NH2-2.
purified by size exclusion chromatography.
FRET experiments were performed using a FluoTime 100 spectrometer, set-
ting the time resolution of correlated single photon counting system to 32 ps and
using a 375 nm laser for excitation of ketone 2. In order to prevent photons emit-
ted by excited CN-PPV from being collected, a band pass filter (centered at 425
± 25 nm) was positioned in between the sample and detector. The experimental
data were analyzed using the open source software DecayFit.
8.5 Influence of temperature upon the emission of CN-PPV polymer
Figure 8.5: Emission spectra of CN-PPV in DMSO, acquired at different temperatures.
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Table 8.1: Kinetic constants for the thermal decomposition of dioxetane 1, occurring at
different temperatures.
Temperature (◦C) lnk ± SDa
100 -7,11 ± 0,23
110 -6,18 ± 0,29
120 -5,81 ± 0,29
130 -4,88 ± 0,20
aMean ± SD of three independent mea-
surements.
8.6 TCL emission experiment and determination of activation pa-
rameters (Ea and lnA)
In order to prove the occurring of FRET process between electronically excited
ketone 2 and CN-PPV, a 200 µL solution of 1,2-dioxetane 1 (6 mM) and CN-PPV
(0.07 mM) in THF was prepared. The glass vial containing the mixture was
positioned onto a mini-heating element (ceramic resistance connected to a power
supply) and centered to the spectrofluorimeter’s detector. Then, the solution was
heated up to 110 ◦C while acquiring the TCL emission spectrum. Since the low
intensity of TCL signal, the emission spectrum was obtained as sum of multiple
scans.
Activation parameters of 1,2-dioxetane 1 inside Pdots were calculated measur-
ing the TCL emission decay kinetics at different temperatures. Specifically, 3 µL
of TCL-Pdots solution was spotted onto an alluminum foil covering a homemade
mini-heater (electrical resistance encapsulated in between two kapton layers) and
let evaporating. The spot was allowed to dry, then the foil was heated up to the
desired temperature (in the range between 100 and 130 ◦C), and a sequence of im-
ages of TCL emission was acquired, using a CCD camera. For each temperature,
the kinetic constant k was calculated by fitting the TCL emission decay profile
with the first-order decay equation shown in ??, in which ITCL is the TCL signal
at time t and (ITCL)0 is the TCL signal at time zero (t0).
ITCL = (ITCL)0e
−kt (8.1)
In Table 8.1 are reported the kinetic constants of TCL emission decay, calcu-
lated at different temperatures.
128
CHAPTER 8. SUPPORTING INFORMATION OF CHAPTER 4
Figure 8.6: Images of TCL-Pdots-SA-Biotin-IgG MBs a) before and b) after the eluition
step.
8.7 TCL-based non-competitive sandwich-type immunoassay for de-
tection of IgG
Fo the immunoassay experiments a solution of Goat Anti-Mouse IgG Mag-
netic Beads (Anti-IgG MBs, 20 mg/mL) and Biotinylated Immunoglobuline G
(Biotin-IgG, 0.5 mg/mL) were used. An increasing volume of Biotin-IgG (in the
range between 0 and 34 µL) was added to a 100 µL Anti-IgG MBs solution, and
the final volume was diluted to 500 µL using a PBS 1X buffer solution (pH = 7.4)
with BSA 5% (w/v). Each sample was incubated at 37 ◦C for 2 hours. Then, MBs
were washed three times (washing buffer = PBS 1X with Tween-20 0.1% (v/v)) to
remove all the free Biotin-IgG, and 200 µL of TCL-Pdots-SA solution was added
along with 300 µL of PBS 1X buffer solution (pH = 7.4) and BSA 5%. Biotin-IgG
MBs were let incubating with TCL-Pdots-SA at 37 ◦C for additional 2 hours, after
which MBs were washed three times and dispersed in the eluition buffer (50 µL)
for 15 minutes, at room temperature . The eluition buffer (solution of Glycine,
pH = 10) allowed us to effectively recover the TCL-Pdots-SA/Biotin-IgG MBs,
as shown in Figure 8.6. In fact, the image taken before the eluition step shows the
presence of micrometric aggregates (MBs), while after using Glycine buffer, we
obtained a well dispersed solution of TCL-Podts-SA/Biotin-IgG.
The calibration curve was obtained heating 10 µL of the eluited solution up to
110 ◦C and acquiring the TCL emission by a CCD camera.
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